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INTRODUCTION 
 
 
In recent years creatine has been used as a muscular performance 
enhancing substance in numerous studies. In this thesis we have 
investigated the effects of creatine administration to animals and patients 
with renal failure with respect to muscle metabolism and homocysteine 
metabolism. As an introduction to the original studies, three major topics, 
reflecting the 3 chapters in the experiments’ section will be elaborated. A 
general overview of creatine metabolism will be presented, together with 
the metabolic link to the homocysteine metabolism. Safety and analytical 
aspects are introduced in this section. General background information on 
muscular energetics and composition is presented, with a rationale for the 
use of creatine as a performance enhancing substance. 
 
 
 
1. Creatine and skeletal muscle energy 
metabolism 
 
1.1 Synthesis and tissue distribution of creatine 
 
(Wyss et al., 2000; Walker, 1979; Persky et al., 2001) 
 
Creatine is a non-proteogenic nitrogenous substance with a molecular 
mass of 131 Da, present in high amounts in the human body. A 70-kg 
person contains about 120 g creatine. About 95% is found in the skeletal 
muscles. Other creatine containing organs are brain, testes and heart. 
About 1-2 g/d of creatine is synthesised endogenously and 1-2 g/d is 
provided exogenously by the diet. Creatine is found mainly in fish and 
meat products in concentrations between 5-10 g creatine/kg meat. With 
normal intake, creatine is metabolised to creatinine and subsequently 
excreted by the kidney. The presence of creatine in the urine is rare and is 
usually encountered during muscle trauma (e.g. myocardial infarction, 
myositis) or creatine ingestion (Delanghe et al, 1995). In vegetarians, 
creatine intake by food is lower due to the absence of meat products in the 
diet and serum creatine concentrations are lower. (Delanghe et al, 1989).  
 
Creatine synthesis in vivo (Figure 1.1.) proceeds through two successive 
metabolic steps. First, guanidinoacetic acid is formed from arginine and 
glycine, with transfer of the guanidino (amidino) - group from arginine to 
glycine, catalysed by L-arginine:glycine amidinotransferase (AGAT; EC 
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2.1.4.1). Creatine is synthesised from guanidinoacetic acid by methylation 
through methyl donation from S-adenosylmethionine, catalysed by S-
adenosyl-L-methionine:N-guanidinoacetate methyltransferase (GAMT; EC 
2.1.1.2). In contrast to lower vertebrates (fish, birds, amphibiae) which 
have both the AGAT and GAMT enzyme present in the liver, creatine 
synthesis in humans exhibits a distinct compartmentalisation. In humans, 
the kidney exhibits high AGAT activity, whereas it contains almost no 
GAMT activity. Most of the GAMT activity is situated in the liver. Sites of 
creatine synthesis and creatine storage are separated. This 
compartmentalisation implies transport of guanidinoacetic acid and 
creatine in the bloodstream. Creatine is taken up by tissues with  high and 
fluctuating energy demand, such as striated muscle, heart muscle and 
spermatozoa, through a specific Na+-dependent creatine transporter.  
Figure 1.1. (next page) 
 
Overview of creatine and homocysteine metabolism. 
 
 
X Arginine:glycine amidinotransferase (AGAT) 
Y Methionine adenosyltransferase 
Z Guanidinoacetate methyltransferase (GAMT) 
[ S-Adenosyl homocysteine hydrolase 
\ Methionine synthase 
] 5,10-CH2-THF reductase 
^ Serine-hydroxy methyltransferase 
_ Cystathinine-β–synthase 
` Creatine kinase 
a Non-enzymatic degradation  
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1.2  Skeletal muscle composition and metabolism 
 
In mammals, skeletal muscles are a major source of energy consumption 
and heat generation with a large variation according to the activity of the 
skeletal muscles. At rest, overall energy consumption is relatively low. 
During activation, force generation and active shortening, there is a 
dramatic increase in energy demand. The mechanisms by which the 
muscles regulate the energy metabolism in conditions of changing energy 
demand are complex and remain only partially understood. This section will 
only briefly address this topic, as background for the presented studies in 
this thesis. The main focus will be on the myosin motor and associated 
energy metabolism. 
 
Skeletal muscle is composed of several fiber types that substantially differ 
in functional and metabolic characteristics (Schiaffino et al., 1996; Pette et 
al., 1990; Thomason et al., 1986; Pette et al., 2000; Schiaffino et al., 
1994). Mammalian skeletal muscle fibers have been characterized 
histochemically, functionally and biochemically into:  
 
• Red, slow-twitch fibers (type I) 
• White, fast-twitch, glycogenolytic (IIx, IIb) fibers and oxidative 
(IIa) fibers 
 
 
The terminology (Pette et al., 1999; Schiaffino et al., 1994), referring to 
the different types of muscle fibers is based on different properties of the 
muscle fibers, using different methods: (1) From a functional point of view, 
the terms slow- and fast-twitch have been attributed to the muscle fibers 
according to the contraction speed during unfused tetani, and fatigue 
properties during fused tetani. (2) Histochemically fiber typing is based on 
the different pH-sensitivity of the myofibril ATP-ase activity in fibers of 
slow- and fast-twitch muscle (Barrany, 1967). (3) Biochemically, slow-
twitch fibers contain high concentrations of myoglobin and thus appear red 
on inspection, together with a high activity of oxidative enzymes. The fast-
twitch muscles are called ‘white’ due to a lower myoglobin concentration 
and are mainly glycogenolytic in their energy metabolism. (4) Molecularly, 
the ATP-ase activity of the muscle fibers, and thus contractile 
characteristics, depend mainly on the myofibrillar protein composition and 
especially the myosin heavy chain isoforms. Based on the expression of the 
myosin isoforms (I, IIa, IIx, IIb in rats; I, IIa and IIx in humans), different 
metabolic activity and contractile characteristics are observed in skeletal 
muscles.  
 
Type I fibers are well adapted for aerobic energy production. These fibers 
exhibit a low myosin ATP-ase activity but have a high mitochondrial 
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density, high oxidative enzyme activity profile, high cytochrome c 
concentration and rich capillary supply. Type II fibers are subdivided in IIa, 
IIx and IIb-fibers, with increasing myosin ATP-ase activity levels. The type 
II fibers are suited to anaerobic energy production and are characterised 
by a low mitochondrial density, high glycolytic enzyme activity profile, high 
creatine kinase activity, low myoglobin concentration, poor capillary supply 
and a high myosin ATP-ase activity.  Due to the difference in myoglobin 
content between fiber types, muscles composed of predominantly type I 
fibers are designated as red muscles, whereas muscles predominantely 
composed of  type II fibers are referred to as white muscles (Schiaffino et 
al., 1996). The expression of the different MHC-isoforms is not fixed and 
can change under several conditions. Inactivity, metabolic factors,… 
influence the expression of the MHC-gene in the skeletal muscle and in 
conditions of disuse, a general slow-to-fast transition is observed (Baldwin 
et al., 2001; Schiaffino et al., 1996; Pette et al., 1990). 
 
1.3  Uraemic myopathy 
 
Patients with chronic renal failure experience muscle dysfunction for a 
variety of reasons (Ritz et al., 2001; Clyne et al., 1993; Campistol, 2002). 
The myopathy associated with renal failure can be a manifestation of the 
underlying disease, neuropathy or aggravated by drug toxicity. It is 
characterised by an increased protein catabolism, mainly due to a higher 
ubiquitin-proteasome activity (Mitch et al., 2002). Acidosis, 
hyperparathyroidism, inactivity and ischemia can influence this myopathy. 
A vitamin D-responsive myopathy is often found in patients with renal 
failure, though the aetiology is not fully understood and probably 
multifactorial. 
 
1.4 Role of creatine in muscle energy metabolism 
 
The intramuscular creatine concentrations range from 110 to 160 mmol/kg 
dry weight in humans, whereas the creatine concentration in animals can 
vary between species (Edström et al., 1982). In skeletal muscle, about 
60% of the creatine is present in its phosphorylated form: 
phosphocreatine. Phosphocreatine plays a pivotal role in the energetic 
balance during muscle contraction, especially during high-intensity 
exercise. Energy for muscle contraction and relaxation is uniquely provided 
by the dephosphorylation of ATP. The sustainability of muscle contraction 
depends on the availability of ATP. The ATP-concentration in the skeletal 
muscle is about 24 mmol/kg dry weight. Without energy replenishing 
systems, ATP would be depleted within 2 seconds after onset of contraction 
(Figure 1.2.). During the first seconds of muscular contraction, ATP is 
replenished by the anaerobic degradation of phosphocreatine and glycogen 
(Maughan, 1999). 
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These ATP-regenerating systems can maintain muscular ATP-
concentrations, sufficient for muscular contraction during both a single 
bout of exercise and repeated bouts of high-intensity exercise. This 
temporal energy buffer system of the creatine-phosphocreatine system is 
the best known function of creatine.  
A second function of the creatine-phosphocreatine system consists of a 
cellular energy transport system (creatine-phosphocreatine shuttle). Older 
scientific insights state that intracellular energy translocation is entirely 
dependent on the diffusion of ATP and ADP from sites of energy production 
to sites of energy utilisation and vice versa (Meyer et al., 1984). In 1966, 
the concept of the creatine-phosphocreatine shuttle was introduced 
(Bessman et al., 1966). This provided insight in the movement of cellular 
chemical energy between several compartments in the cell. In this model 
(Wallimann et al., 1992; Saks et al., 1996), creatine and phosphocreatine 
are considered as cellular energy carriers and this model is supported by 
the existence of different isoforms of creatine kinase in discrete cellular 
locations with different metabolic roles. As the outer mitochondrial 
membrane is relatively impermeable to adenine nucleotides, creatine and 
phosphocreatine are more plausible energy carriers. In this regard, the 
creatine-phosphocreatine system is supportive for the 'classical' ATP-ADP 
system. The relative importance of each of these systems to cellular spatial 
energy transfer remains a matter of debate.  
A third function of creatine-phosphocreatine is a low threshold ADP-sensor. 
This sensor maintains the ATP/ADP ratios in subcellular locations. In the 
mitochondrion, creatine can react with ATP, derived from mitochondrial 
respiration in a reaction catalysed by mitochondrial creatine kinase, 
increasing the local ADP-concentration and stimulating the mitochondrial 
respiration. In this regard, Walsh et al. demonstrated in human skeletal 
muscle that by addition of creatine to a mitochondrial incubation medium, 
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ADP-stimulated mitochondrial respiration was increased (Walsh et al., 
2001). When phosphocreatine was added to the medium however, ADP-
stimulated mitochondrial respiration was reduced, and the effect was 
greater than the opposite effect of creatine on respiration. Phosphocreatine 
is likely to be a more potent regulator of mitochondrial respiration than 
creatine. Cellular phoshocreatine/creatine ratios can direct mitochondrial 
respiration and the creatine-phosphocreatine system functions as a low 
threshold ADP-sensor which functionally couples ATP-consuming and -
producing pathways.  
During ATP-synthesis from phosphocreatine, protons are consumed and 
provide a pH-buffer against lactic acid formation during exercise (Sahlin, 
1978). 
        Creatine kinase 
Phosphocreatine + ADP + H+    ATP + Creatine 
 
1.5 Creatine supplementation 
 
As described in the previous paragraph, creatine plays a central role in the 
energy metabolism of the muscle cell, especially during the first phase of 
muscle contraction (Figure 1.2.). Hence the hypothesis was developed that 
muscular performance could be enhanced by increasing the cellular 
concentrations of creatine and phosphocreatine (Casey et al., 2000; 
Greenhaff et al., 1994; Francaux et al., 2000).  
 
 
Theoretically creatine can have several metabolic interactions and modes 
of action: 
(1) Maintaining a high ATP/ADP ratio during exercise. 
(2) Buffering of protons, accumulating in the acidic environment  
     of anaerobic exercise.  
(3) Enhancing the creatine/phosphocreatine energy shuttle with  
     a more efficient transfer of energy to sites of ATP use. 
(4) Stimulating protein synthesis in the muscle. 
 
Short-term creatine supplementation with increased intramuscular creatine 
stores was first described by Harris (Harris et al., 1992). Muscular creatine 
stores can increase 10-20% after ingestion of 20 g/d creatine during 5 
days. Following creatine supplementation, intramuscular creatine 
concentration seem to have a maximum of about 160 mmol/kg dry weight 
and the increase in muscular creatine depends on the initial creatine 
concentration (Harris et al., 1992; Greenhaff et al., 1994). Prolonged 
intake of creatine was found to elevate intramuscular creatine 
concentrations using lower dosages (Hultman et al., 1996; Vandenberghe 
et al., 1997). Creatine loading in muscle was found to increase when 
creatine was ingested with carbohydrate (Green et al., 1996). Creatine was 
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also found to increase muscle glycogen concentrations (Robinson et al., 
1999; Op 't Eijnde  (1) et al., 2001; Van Loon et al., 2004) and GLUT4-
expression (Op 't Eijnde (2) et al., 2001; Derave et al., 2003; Ju et al., 
2005). 
The effect of creatine on muscle protein synthesis is less studied. Early 
studies suggested an important role for creatine in promoting muscular 
protein synthesis (Ingwall, 1974; Ingwall 1974). Studies on muscular 
protein synthesis and breakdown in human volunteers could not 
demonstrate a beneficial effect of creatine on protein synthesis or 
breakdown (Louis et al (1), 2003; Louis (2), 2003).    
 
Countless studies in humans have examined the effects of creatine 
supplementation on exercise performance (Kreider et al., 1998; Kraemer 
et al., 1999; Engelhardt et al.,1998; Demant et al., 1999). Several reviews 
summarising the ergogenic effects of creatine have been published 
(Terjung et al., 2000; Williams et al., 1998; Sheppard et al., 2000; 
Bemben et al., 2005). Earlier studies focussed on exercise performance 
using laboratory tests (Greenhaff et al., 1993; Leemputte et al., 1999; 
Maganaris et al., 1998; Kreis et al., 1998, whereas more recent studies 
focus on the effects of creatine on sport-specific performance on field tests 
(Rossiter et al., 1996; Preen et al., 2001; Peyrebrune et al., 1998; Chrusch 
et al., 2001). In controlled laboratory tests, creatine was found to enhance 
exercise performance of short-term, high intensity exercise. The effect is 
even more pronounced in schedules with repeated bouts of exercise.  
After immobilisation, creatine was found to enhance muscular rehabilition 
by changes in MRF4 and myogenin expression and therefore promoting 
muscular hypertrophy (Hespel et al., 2001). 
There is less convincing evidence for the performance enhancing effects of 
creatine during endurance exercise. The creatine-phosphocreatine system 
has only a limited role in exercise tasks of 1.5-3 min. Therefore creatine 
supplementation may not prove ergogenic in exercises of longer duration. 
The effects of creatine on field tests are less consistent. Most of the 
evidence on the beneficial effect of creatine on muscular performance 
derives from short-term studies in healthy athletes, whereas the long-term 
effect of creatine in animal models of neuromuscular disorders and in 
patients with these disorders remains controversial (Derave et al., 2003).  
Considering the possible health risks of creatine supplementation, several 
aspects can be discussed. There are only anecdotal reports on side effects 
of creatine supplementation in humans (e.g., muscle cramping, muscle 
injury, thermoregulation and renal complications). The only side-effect, 
consistently reported in literature is an acute (over 3–6 days) gain in body 
mass of 0.5-2 kg. This gain in body weight appears to be primarily due to 
increased muscle water storage (Häussinger et al., 1993; Ziegenfuss et al., 
1998). Robinson (Robinson, 2000) described a case of a weight-lifter who 
developed an acute quadriceps compartment syndrome with 
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rhabdomyolysis and renal failure after high-dose creatine ingestion. Mendel 
(Mendel et al., 2005) investigated the effect of creatine on 
thermoregulatory responses while exercising and found no negative 
effects. With short-term supplementation (days to weeks), other adverse 
effects appear to be anecdotal and non-consistent or minimal (Benzi, 
2000; Graham et al., 1999; Poortmans et al., 1997; Poortmans et al., 
1999; Schilling et al., 2001; Volek et al., 2001). Safety of prolonged 
(months to years) use of creatine remains undetermined as only limited 
data are available.  The absence of adverse reports with prolonged creatine 
use does not guarantee that chronic use is without risk. In young healthy 
adults, creatine is generally considered as safe (Pline et al., 2005; 
Groeneveld et al., 2005), though in elderly and renal disease patients, only 
limited data is available. Though controlled studies failed to demonstrate 
major negative effects of creatine, concern is still warranted when 
evaluating the impact of creatine ingestion on the renal function and 
possible carcinogenic potential. Preliminary data in our lab (Taes et al., 
unpublished data) demonstrated altered global DNA-methylation patterns 
in creatine treated animals. In both control animals and animals with renal 
failure, creatine supplementation was associated with lower (21%, p=0.03; 
(unpublished data, Y. Taes)) hepatic 5-methylcytosine concentrations. This 
finding contrasts with the decreased tHcy-concentrations and the increase 
in folic acid concentrations observed in this animal model. These findings, 
let us hypothesise that creatine could increase DNA-methylation by 
desinhibiting transmethylation of DNA through lower Hcy-concentrations. 
However we have observed lower DNA-methylation in association with 
creatine supplementation. A direct effect of creatine on DNA could explain 
these paradoxal findings. However low DNA-methylation is described to be 
associated with carcinogenesis and diseases with imprinting disorders 
(Paulsen et al., 2005). The effects of creatine on DNA-methylation and 
carcinogenetic risk needs further research. 
 
Analytical aspects of creatine and creatinine determination 
 
Apart from the in vivo degradation of creatine to creatinine, creatine could 
also interfere analytically in the determination of serum creatinine. Serum 
creatinine is routinely measured colorimetrically using the Jaffé’s reaction. 
Originally described in 1886 this reaction suffers from interference of 
bilirubin and non-specific chromogens such as ketones… and has been 
modified extensively over the decades. Today, several assays exist with 
varying propensity to interference of non-specific chromogens. Rate 
blanked kinetic assays suffer less from non-specific interference then end-
point assays. However with the use of random access analysers, the 
deproteinisation step was omitted in the analysis and the protein error is 
substantial in this kind of assay. Creatine can interfere with the Jaffé 
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reaction as a non-specific chromogen with higher apparent creatinine 
concentrations (Taes et al., 2005) 
 
2.    Creatine, methylation demand and homocysteine 
metabolism 
 
As described previously in figure 1.1., creatine and homocysteine 
metabolism are metabolically linked (Stead et al., 2001; Steenge et al., 
2001). In this paragraph, homocysteine and folic acid metabolism will be 
briefly summarised in relation to creatine metabolism. 
 
Homocysteine (Hcy) (Selhub, 1999; Hoffer, 2004) is a sulphur-containing 
amino acid, formed by demethylation of methionine and plays an important 
role in the activated methyl and folate cycle (figure 1.1.). Methionine is 
converted intracellular to S-adenosylmethionine, a sulphonium compound 
with a highly reactive methyl group, which acts as a universal methyl 
donor in numerous transmethylation reactions in vivo. The demethylated 
product S-adenosyl homocysteine, a thioether, is readily hydrolyzed to Hcy 
and adenosine by S-adenosyl homocysteine hydrolase.  
Elevated concentrations of plasma Hcy (total plasma Hcy (tHcy) are 
described in several populations to be associated with an increased 
cardiovascular mortality and morbidity (Refsum et al., 1998; Homocysteine 
Studies Collaboration, 2002; Wald et al., 2002; Ridker et al., 2002). In 
renal failure patients, Hcy is thought to contribute to the high prevalence of 
cardiovascular disease (Selhub, 1999; Moat et al., 2004). 
Hyperhomocysteinemia can be caused by: (1) mutations of the genes 
encoding for key enzymes in the homocysteine metabolism, such as the 
Cystathionine β-synthase deficiency. Homozygosity for the 
methylenetetrahydrofolate reductase 677C[PI]T transition, leading to the 
unstable ‘thermolabile form’ of this enzyme, is particularly frequent and is 
responsible for mild hyperhomocysteinemia and increased cardiovascular 
risk (Klerk et al., 2002); (2) reduced intake or intestinal absorption of folic 
acid, vitamin B12, or vitamin B6 (rare); (3) the administration of certain 
drugs (L-DOPA, methotrexate, etc.) and (4) chronic renal failure. The 
mechanism of hyperhomocysteinemia in renal failure remains incompletely 
understood, but both a decreased renal metabolism of Hcy (Refsum et al., 
1985; Guttormsen et al., 1997; Van Guldener et al., 1998; Van Guldener 
et al., 1999) and an inhibition of the Hcy-metabolising enzymes by the 
uraemic environment are thought to play a role (Perna et al., 2003; Perna 
et al., 2001).  
 
Treatment of hyperhomocysteinemia mainly consists of alimentary folic 
acid and vitamin B6 and B12 supplements. An average reduction of about 
30% in tHcy is observed in uraemic patients treated with folic acid (De 
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Vriese et al., 2002). The effect of vitamin B6 and B12 is in general much 
less pronounced (Bostom et al., 1997). Supplementation with other 
methyl-donating molecules such as betaine can decrease post-methionine 
loading tHcy-concentrations by 18%, in patients already treated with folic 
acid supplementation (McGregor et al., 2002; Wald et al., 2001; Splaver et 
al., 2004). However, even combined high-dose folic acid and vitamin B6 or 
B12 supplementation cannot entirely normalize tHcy in renal failure 
patients.  
The importance of hyperhomocysteinemia in determining cardiovascular 
risk remains unknown. Though in vivo and in vitro evidence points out 
towards a role for homocysteine in atherogenesis by endothelial injury, 
platelet activation, smooth muscle proliferation, oxidation of lipoproteins 
and leukocyte-endothelial interactions (Thambyrajah (1) et al., 2000), not 
all epidemiological evidence supports a role for tHcy in the cardiovascular 
risk. Moreover, tHcy-lowering intervention trials with folic acid or 
multivitamin preparations demonstrate lower tHcy-concentrations, but fail 
to demonstrate a reduced cardiovascular risk with lower tHcy-
concentrations. Homocysteine lowering by folic acid treatment (Van 
Guldener et al., 2000; Thambyrajah (2) et al., 2000) failed to show a 
beneficial effect on endothelial function or large artery stiffness in uraemia, 
while others report decreased markers of lipid peroxidation with folic acid 
treatment but no association of tHcy-concentrations and cause of death 
(Bayes et al., 2001, Bayes et al., 2003). The relation tHcy-cardiovascular 
risk is still unclear and a ‘reverse epidemiology’ has been described in 
uraemic patients with higher cardiovascular risk associated with lower 
tHcy-concentrations (Kalantar-Zadeh et al., 2004; Suliman et al., 2005) in 
contrast to the positive association in the general population. Malnutrition, 
wasting, inflammation and underlying diseases are confounding factors in 
the relation cardiovascular risk and tHcy-concentrations in uraemia 
(Suliman et al., 2005).  
 
 
Creatine metabolism is linked to the Hcy-metabolism by the 
transmethylation of guanidinoacetic acid to creatine with formation of S-
adenosylhomocysteine as a side-product and is further hydrolysed to Hcy 
(Figure 1.1.). Quantitatively, methylation of guanidinoacetic acid accounts 
for the majority of the transmethylation reactions in the body (Mudd et al., 
1975; Mudd et al., 1980). In this thesis we have investigated the potential 
use of creatine as a Hcy-lowering compound in both uraemic animals and 
dialysis patients. The hypothesis behind these studies is that 
supraphysiological creatine administration can decrease Hcy-formation by 
lowering the methylation demand through inhibition of endogenous 
creatine synthesis. 
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3. Remnant kidney model 
 
3.1 General aspects 
 
Several models of renal failure in animals exist (Gagnon et al., 1983; 
Esposito et al., 1999; Terzi et al., 2000, Kren et al., 1999; O’Bryan et al., 
2000). The models can be divided into induced models and genetic models. 
In the induced models, renal failure is generally established by destruction 
of kidney tissue. This can be accomplished by (partial) nephrectomy by 
ligation of (several branches of) the renal artery, electrocoagulation or 
thermal ablation of kidney tissue or the administration of nephrotoxins, 
such as adriamycin or puromycin. The genetic models consist of animal 
models with spontaneous evolution to renal failure such as the Jck-mice 
(juvenile cystic kidney), polycystic kidney rats (Han: SPRD-cy), ICGN-mice 
(spontaneous nephrotic mice with idiopathic crescentic glomerulonephritis). 
Transgenic animal models with renal failure, such as the Tg26-mouse 
(oligosyndactyly mice with evolution to proteinuria, renal failure and focal 
segmental glomerulosclerosis) are classed within the genetic models of 
renal failure. All these models have different characteristics and large 
differences in experimental results can be obtained using different animal 
strains (Esposito et al., 1999). 
In this thesis we have used the remnant kidney model to study the effects 
of creatine supplementation on renal function, skeletal muscle and 
homocysteine metabolism. The remnant kidney model is an induced model 
of renal insufficiency by reduction of the renal mass, based on a unilateral 
nephrectomy and partial infarction of the contralateral kidney. The surgical 
method for inducing renal failure allows application in several animal 
species. The technique is moderately easy to perform and the model has 
been applied mainly in various strains of rats, but also in mice, cats, dogs, 
rabbits and baboons. Reduced glomerular filtration, glomerular sclerosis 
and proteinuria are the cardinal features of this model. 
 
3.2  Procedure 
 
In this thesis we have used a two-stage model with cryoablation of the 
upper and lower pole of the left kidney, followed one week later by a right 
nephrectomy. The general procedure is described in figures 1.3. and 1.4.  
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During the past decade, creatine has established itself as an ergogenic aid 
in sports and has gained increasing attention in medical and lay press as 
apossible therapeutic agent for various neuromuscular diseases. The 
available literature mainly covers the short-term effects of creatine 
supplementation on skeletal muscle function in health and disease [1], 
while little is known about the efficiency of long-term supplementation and 
possible side effects. This letter addresses briefly the analytical 
interference of creatine supplementation on common laboratory tests and 
examines possible side effects and health risks. 
Creatine is linked to the arginine, guanidino-compound, one-carbon and 
homocysteine metabolism, as well as muscular energy metabolism. 
 
1. Creatine ingestion and renal function parameters 
 
Increased intake of creatine can interfere with the determination of 
creatinine concentrations. First, the increased creatine load is converted to 
creatinine and increases the daily excretion of creatinine. Secondly, 
analytical interference of creatine on the different creatinine assays can 
increase creatinine concentrations due to the aspecificity of the assay. In 
this regard, the apparent increases in plasma creatinine after creatine 
administration can be attributed to the in vivo degradation of creatine to 
creatinine, but also to analytical interference of creatine with the plasma 
creatinine determinations. Depending on the assay used, creatine can 
substantially interfere with routine creatinine determination. In the 
colorimetric Jaffe´ reaction, creatine can act as pseudochromogen resulting 
in higher apparent creatinine concentrations. Enzymatic assays, using 
creatinine-to-creatine conversion in their reaction, are also prone to 
analytical interference with less predictable deviation from the true 
creatinine concentration. Using an uncompensated rate-blanked kinetic 
Jaffe´ assay [2], we investigated the in vitro interference of creatine on 
this routine creatinine assay. Serum was spiked with increasing 
concentrations of creatine (0–10 mg/dl). Fig. 1 illustrates the serum 
creatinine concentrations in function of the creatine concentration added. 
Creatine addition significantly increased serum creatinine concentrations 
between 2.5 and 10 mg/dl (p<0.05). Endpoint Jaffé-based methods 
without rate-blanked kinetic correction are prone to larger deviations from 
the true serum creatinine concentration. In animals with renal failure, 
serum creatinine concentrations were apparently found to increase upon 
creatine administration without evidence of deterioration of renal failure, 
whereas in animals with normal renal function similar creatinine 
concentrations were observed upon creatine feeding [2]. 
The safety of high-dose creatine supplementation has been questioned. 
Two case reports of deleterious effects of creatine on kidney function have 
been published. The first describes an interstitial nephritis in a previously 
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healthy young man after ingestion of creatine [3]. In the second, 
deterioration of renal function in a young man with underlying focal 
segmental glomerulosclerosis was observed [4]. Although renal function 
recovered after cessation of creatine, no causal relationship between 
creatine ingestion and renal failure can be established on the basis of these 
case reports. In humans, controlled studies did not reveal adverse effects 
of creatine supplementation. Poortmans et al. [5–7] investigated intensely 
renal function in young healthy subjects. No alterations in creatinine, urea 
or albumin clearance were observed during short-term (5 days) or long-
term supplementation (1 month to 5 years) with dosages from 1 to 80 g 
daily. Robinson [8] and Volek [9] reported only transient increases in 
apparent serum creatinine during creatine ingestion, without evidence of 
renal dysfunction. Six weeks after cessation of the creatine 
supplementation, serum creatinine had returned to baseline [8]. In 
contrast to humans, experiments in animals suggest progression of renal 
disease in an animal model of human polycystic kidney disease [10]. In a 
surgical partial nephrectomy animal model of chronic renal failure, no 
changes in inulin- or creatinine clearance rates nor in renal protein 
handling were observed [2]. No biochemical evidence is currently available 
to assume negative effects of creatine supplementation on liver- or 
gastroenterological functions. A possible health risk of creatine, which is 
insufficiently studied, is the formation of mutagenic compounds. Creatine 
and creatinine are described as precursors for amino-imidazo azaarenes, a 
class of food mutagens, found in meat and fish. By heating the meat, 
creatine can be converted to these mutagenic and carcinogenic 
compounds. Whether or not high-dose creatine administration is associated 
with formation of these compounds in vivo is currently unknown [11]. 
Creatine is classed as a nutritional supplement and is freely available over 
the counter. These different formulations are not subjected to adequate 
quality control as with pharmaceutical preparations. Commercially, creatine 
is synthesized from cyanamide and sarcosine. Toxic side products or 
contaminants such as dihydrotriazine and dicyanamide could be present in 
these formulations. As creatine is ingested in high doses, these 
contaminants could be ingested in sufficient amount to exert toxic side 
effects. Moreover, both amateur and professional sportsmen tend to use 
even higher doses then recommended (>20 g).  
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Fig. 1. Apparent serum creatinine concentrations after addition of creatine. 
* p<0.05; serum creatinine concentrations after addition vs. baseline 
concentrations. 
 
2. Methylation demand and homocysteine metabolism 
 
A more appealing aspect of creatine supplementation in uraemia is the 
ability to diminish the in vivo methylation demand. Dietary intake (1 g) 
and endogenous synthesis (1 g) in liver compensate for a daily loss as 
creatinine of about 2 g. In humans, creatine is synthesized through two 
successive metabolic steps. Guanidinoacetate is formed in the kidney from 
glycine and arginine by arginine:glycine aminidinotransferase. 
Secondly, guanidinoacetate is methylated in the mammalian liver to 
creatine by guanidinoacetate-methyltransferase with S-adenosylmethionine 
acting as methyl-donor. Creatine is transported to the muscle in the blood 
as free molecule and is actively transported into the muscle cell by a 
specific transporter [11,12]. Methylation of guanidinoacetate accounts for 
up to 70% of the transmethylation reactions in the body. 
Quantitatively, this exceeds all other methylation reactions. Stead et al. 
[12] demonstrated that downregulation of endogenous creatine synthesis 
by creatine supplementation could decrease methylation demand and 
homocysteine in animals with normal renal function. In animals with renal 
failure, creatine supplementation was associated with lower homocysteine 
concentrations and increased folic acid concentrations, despite similar 
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intakes [13]. However, in humans, a placebo-controlled, cross-over study 
could not demonstrate any homocysteine lowering potential of creatine 
supplementation, despite documented uptake of creatine [14]. The effect 
of creatine on labile methyl pool consumption seems therefore limited in 
humans. 
 
3. Conclusions 
 
Although creatine is widely used as a performance enhancing nutritional 
supplement, safety of creatine administration still remains open for 
discussion. No major effects on renal function have been described in 
humans; however, side effects of long-term administration are unknown. 
Analytical interference of creatine ingestion on creatinine determinations is 
described and should be taken into account when evaluating renal function. 
Creatine lowers homocysteine concentrations in animals with normal and 
diminished renal function, though this effect is not observed in humans. 
The hype around creatine supplementation is decreasing over the years 
due to several negative studies on creatine supplementation in various 
diseases. 
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                    HAPTER 2  
 
 
 
 
 
 
 
Aims and outline  
    of the studies 
 
 
What lies still is easy to grasp; 
What lies far off is easy to anticipate; 
What is brittle is easy to shatter; 
What is small is easy to disperse. 
 
Yet a tree broader than a man can embrace, is born of a tiny shoot; 
A dam greater than a river can overflow starts with a clod of earth; 
A journey of a thousand miles begins at the spot under one's feet. 
 
Therefore deal with things before they happen; 
Create order before there is confusion. 
 
Tao Te King 64a/81  
Lao Tse 
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AIMS AND OUTLINE OF THE STUDIES 
 
 
The general objective of this thesis is to investigate the influence of 
creatine supplementation on biochemical and contractile properties of the 
striated muscle and the influence on homocysteine metabolism in an 
animal model of uraemia and in patients. We hypothesised that creatine 
could beneficially act on muscular performance in renal failure patients as 
in young healthy subjects. Moreover creatine could lower plasma tHcy-
concentrations by lowering endogenous creatine synthesis and methylation 
demand.  
 
More specific aims can be defined as  
 
 
1. To examine the renal safety of prolonged creatine supplementation 
in our animal model of chronic uraemia and the effects on renal 
function in rats with pre-existing renal failure.  
(chapter 3.1) 
2. To characterize the effect of creatine supplementation on plasma 
and liver concentrations of homocysteine, folate and vitamin B12 in 
rats with normal and diminished kidney function. 
(chapter 3.2a) 
3. To characterize the effect of creatine supplementation on plasma 
homocysteine, folate and vitamin B12 concentrations in dialysis 
patients with hyperhomocysteinemia, already treated with folic 
acid, vitamin B12 and vitamin B6.   
(chapter 3.2b) 
4. To investigate the effect of creatine supplementation, together with 
exercise training on physical performance in aging men. 
(chapter 3.3a) 
5. To examine the effect of creatine on myosin heavy chain expression 
in the rat striated muscle in animals with normal and diminished 
kidney function. 
(chapter 3.3b) 
 
 
 
The series of experiments addressing the research questions are presented 
in this thesis in the form of 6 manuscripts, published in peer-reviewed 
journals in the field of nephrology, biochemistry and physiology. The 
studies encompass both animal and human experiments and are presented 
in three chapters.  
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                    HAPTER 3  
 
 
 
 
 
 
 
 
    Experiments 
 
 
 
 
 
 
 
Great perfection seems incomplete, 
But does not decay; 
Great abundance seems empty, 
But does not fail. 
 
Great truth seems contradictory; 
Great cleverness seems stupid; 
Great eloquence seems awkward. 
 
As spring overcomes the cold, 
And autumn overcomes the heat, 
So calm and quiet overcome the world. 
Tao Te King 45/81  
Lao Tse 
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CHAPTER 3.1   
 
 
 
 
 
 
 
 
Safety of creatine supplementation in 
an animal model of moderate chronic 
uraemia 
 
 
 
 
 
 
 
Creatine supplementation does not affect kidney function in an 
animal model with pre-existing renal failure 
 
Taes YE, et al. Nephrol Dial Transplant 2003;18: 258-264 
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Abstract 
 
Background. Creatine is widely used as an ergogenic substance among 
athletes. Safety of prolonged creatine intake has been questioned, based 
upon case reports and animal data. We investigated the effect of prolonged 
creatine ingestion on renal function in animals with normal kidney function 
or pre-existing kidney failure, respectively.  
Methods. Male Wistar rats were randomly allocated to four experimental 
groups: (i) sham-operated, control diet; (ii) sham-operated, creatine-
supplemented diet (2% w/w (0.9±0.2 g creatine/kg body weight/day)); 
(iii) two-thirds nephrectomized, control diet; and (iv) two-thirds  
nephrectomized, creatine supplemented diet. Glomerular filtration rate was 
determined using inulin and creatinine clearance, together with albumin 
excretion, urea clearance, muscle and serum creatine and 
serum cystatin C concentrations.  
Results. In contrast to previous reports, no detrimental effects of creatine 
supplementation on the renal function indices were observed in two-thirds 
nephrectomized or sham-operated animals. No differences were observed 
in inulin (0.28±0.08 vs 0.25±0.08 ml/min/100 g; P=NS) or creatinine 
clearance rates. Serum cystatin C concentration, urinary protein excretion, 
and albumin and urea clearance were comparable between creatine-
supplemented and control-diet fed animals in both sham-operated and 
two-thirds nephrectomized animals. Serum creatine and intramuscular 
total creatine concentrations were higher in creatine-supplemented groups 
(P<0.05). 
Conclusions. Creatine supplementation at a dosage of 2% w/w for 4 
weeks does not impair kidney function in animals with pre-existing renal 
failure or in control animals. 
 
Keywords: creatine supplementation; kidney function 
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Introduction 
 
In recent years creatine has received considerable attention in the medical 
and lay press and is widely used as an ergogenic substance. Numerous 
publications have reported the beneficial effect of creatine supplementation 
on exercise performance, in healthy subjects or animals as well as in 
patients or animal models of neurodegenerative diseases [1–3]. 
As early as 1926, Chanutin [4] reported increased creatinine excretion 
after creatine ingestion in humans. Several studies have described the 
non-enzymatic degradation of creatine to creatinine, without evidence 
of altering kidney function. Phosphocreatine is converted to creatinine at a 
rate of 2.6%/day and creatine at 1.1%/day in vivo [2,4]. Based upon two 
case reports, safety of prolonged high-dose creatine intake has recently 
been questioned [5–7], but no causal relationship between creatine 
ingestion and renal failure can be attributed on the basis of these case 
reports. Controlled studies [5,8–11] could not demonstrate major adverse 
effects or health risks of creatine supplementation in humans. Muscle 
cramps, stomach upset or diarrhoea were reported as sporadic complaints. 
No biochemical evidence is present on eventual impairment of kidney or 
liver function in humans. In contrast, in Han:SPRD-cy rats, an animal 
model of human polycystic kidney disease, creatinine clearance diminished 
and renal impairment was found to be accelerated upon creatine 
supplementation [12]. Exact determination of glomerular filtration rate 
(GFR) in small laboratory animals can be a cumbersome task [13]. 
Isotope-based methods and inulin clearance are still regarded as gold-
standard methods. Creatinine clearance is easier to perform; however, 
creatinine is partly secreted by the tubules and analytical interferences 
exist in serum creatinine determination. The Jaffé reaction is influenced by 
protein, bilirubin, glucose and other non-specific chromogens [14]. The 
magnitude of the interference varies from method to method. Moreover, 
creatinine production is dependent on body composition and increases 
upon creatine supplementation. Several low-molecular-weight proteins 
have been described as good alternatives to serum creatinine in 
determining kidney function, independent of body composition. Cystatin C 
is a 13.3 kDa cysteine-protease inhibitor present in plasma. It has 
been regarded as the product of a ‘housekeeping’ gene and therefore 
production is considered to be stable. Cystatin C is freely filtered and 
neither reabsorbed intact nor secreted. Using anti-human cystatin C 
antibodies, cystatin C concentrations have been measured in rat sera with 
good linearity [15]. This study investigates the effects of creatine 
supplementation on kidney function in rats with normal kidney function and 
in rats with pre-existing renal impairment. Glomerular filtration was 
investigated using inulin and creatinine clearances, together with serum 
cystatin C concentration, 24 h protein excretion, urea and albumin 
clearance. 
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Subjects and methods 
 
 
High-pressure liquid chromatography of the creatine formulation 
Creatine monohydrate (99% pure) was obtained from Sigma (St Louis, 
MO, USA). Possible creatinine contamination of this formulation was 
assessed by high-pressure liquid chromatography (HPLC) analysis as 
described previously [16]. 
 
Experimental model of moderate chronic renal failure 
Male Wistar rats weighing 200–230 g were obtained from Iffa Credo 
(Brussels, Belgium). The animals had free access to drinking water and 
were fed ad libitum. After acclimatization, animals were randomly allocated 
to four experimental groups: (i) sham-operated, normal diet (n=10); (ii) 
sham-operated, creatine fed (n=10); (iii) renal failure, control diet (n=12); 
and (iv) renal failure, creatine fed (n=11). All animal care was in 
accordance with local prescriptions and the NIH Guide for the Care and Use 
of Laboratory Animals. 
Moderate renal failure was induced using a standard procedure of tissue 
removal (two-thirds nephrectomy), as described previously [17]. In brief, 
rats were anaesthetized with halothane (Fluothane; AstraZeneca, 
Södertälje, Sweden) and a flank incision was made exposing the kidney. 
The upper and lower pole of the left kidney were cryoablated, followed 1 
week later by a right nephrectomy. Sham procedure consisted of flank 
incision and manipulation of the kidney without destruction of tissue. The 
cumulative mortality, including nephrectomy/sham procedure, was 14%, 
mostly due to post-operative bleeding or anaesthesia-associated deaths 
[17]. Renal failure was confirmed by a serum creatinine determination 1 
week after the last incision. Dietary manipulation was started 1 week after 
last surgery/incision. Control animals received a soy-based grounded 
maintenance chow (RM1; Special Diet Services, Witham, UK) containing 
14% protein. Creatine monohydrate (2% w/w) was added to this diet in 
the creatine-supplemented groups. Rats were housed in metabolic cages 
for 24 h during the study at two occasions: at the start and after 4 weeks 
of creatine supplementation. Urine and blood samples were collected and 
food intake noted on these occasions. Body weight was measured once a 
week. Creatine intake in the supplemented groups was calculated from 
food intake. Creatine intake in the control-diet groups is neglectible 
due to the absence of meat products in the diet. 
 
Measurement of glomerular filtration rate and proteinuria 
Creatinine clearance. Serum and urinary creatinine concentrations 
were determined using an enzymatic method (Roche Diagnostics, 
Mannheim, Germany) on a Hitachi 911 Autoanalyzer according to the 
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manufacturer’s procedures. Creatinine clearances were calculated based 
upon 24 h urine collections.  
Inulin clearance. After 4 weeks of creatine supplementation, animals 
(n=27) were anaesthetized using pentobarbital (5 mg/100 g) (Nembutal; 
Sanofi, Libourne, France) and placed on a temperature-controlled heating 
pad. The trachea was intubated, the left carotid artery was canulated using 
a PE50 catheter for repeated blood sampling and the left jugular vein was 
canulated for continuous saline administration at a rate matching diuresis. 
A single bolus (80 mg/kg) of fluorescein isothiocyanate (FITC)-inulin 
(Sigma) was administered intravenously and plasma samples were 
obtained at t=0, 3, 30, 120, 140, 160 and 180 min. The FITC-inulin 
concentration was determined using a 96-well fluorometer (Fluoroscan; 
Titertek, Huntsville, AL, 35805). Inulin clearance was calculated as 
described previously [13]. 
Cystatin C concentrations were measured using anti-human cystatin C 
antibodies (Dade Behring, Marburg, Germany) on a BN nephelometer 
(Dade Behring). Relative values are reported, expressed as mg/l of human 
cystatin C, as described previously [15]. Using this cystatin C assay, 
correlations between renal function indices were in accordance with 
published data (serum creatinine vs cystatin C: r=0.92, P<0.001; 
creatinine clearance vs 1/cystatin C: r=0.94, P<0.001; inulin clearance vs 
1/cystatin C: r=0.82, P<0.001). Using these animal samples, the 
coefficient of variance (CV) value for this assay was 5.0%. 
Serum and urine urea were determined enzymatically using Roche 
diagnostics kits on a modular autoanalyser. Urea clearances were 
calculated using 24 h urine collections. Serum albumin was determined 
using the bromocresol green method. Total urinary protein was measured 
by pyrogallol red. Urine albumin concentration was determined as 
described before using a Protur Hisi kit [18]. 
 
Tissue collection and processing 
After the inulin clearance determinations, the animals were killed by 
cervical dislocation under pentobarbital anaesthesia and hindlimb muscles 
(soleus and gastrocnemius) were quickly excised, trimmed of fat and 
connective tissue, washed in phosphate-buffered saline (pH 7.4, 0.075 M), 
blotted dry, weighed and stored at -70°C for further analysis. Serum 
creatine was determined enzymatically [19] and total muscle creatine 
concentrations were determined colorimetrically [20]. 
 
Statistical analysis 
Multiple-sample comparison was performed using Kruskal– Wallis testing. 
One-sample Kolmogorov–Smirnov test was used to pre-test normal 
distribution. Student’s t-test (means±SD) or Mann–Whitney U-test 
[median (interquartile range)] were used to compare separate groups 
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when appropriate. Differences were considered significant at P<0.05. 
Correlation between parameters was examined using regression analysis. 
 
Results 
 
High-pressure liquid chromatography of the creatine formulation 
The creatine monohydrate formulation (Sigma) used in this study for 
supplementation was found to contain 0.37% creatinine. No other side 
products were detected in the formulation. 
 
Effect of creatine supplementation on glomerular filtration rate 
No detrimental effect of creatine supplementation on kidney function could 
be observed during the study period. Table 1 summarizes serum and urine 
renal function indices. Serum creatinine concentrations were higher in 
two-thirds nephrectomized creatine-supplemented animals, compared with 
two-thirds nephrectomized control diet fed animals (0.72±0.19 vs. 
0.58±0.08 mg/dl; P<0.001). Sham-operated animals did not differ in 
serum creatinine concentrations upon creatine supplementation. No 
significant difference was observed in serum urea or cystatin C 
concentrations or in 24 h protein excretion between supplemented and 
control-diet fed animals. Two-thirds nephrectomized animals had 
significantly different serum creatinine, cystatin C (Figure 1) and serum 
urea concentrations (P<0.01) and exhibited higher 24 h proteinuria 
[19.3±7.5 vs 15.1±4.7 mg; P<0.05 (pooled data)] and 24 h albuminuria 
[5.5±4.5 vs 1.9±1.2 mg; P<0.01 (pooled data)]. 
 
 
Table 1. Serum and urine renal function indices after 4 weeks of creatine 
supplementation 
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Creatine-supplemented groups exhibited higher serum creatine 
concentrations [11.66±5.48 vs. 1.74±1.04 mg/dl; P<0.0001 (pooled 
data)]. No significant differences in creatine concentrations were observed 
between two-thirds nephrectomized and shamoperated animals for either 
creatine-supplemented or control-diet groups. Inulin and creatinine 
clearance rates, corrected for body weight and serum cystatin C 
concentrations, are illustrated in Figure 1. No differences were observed in 
either inulin, creatinine clearance [absolute values (data not shown) or 
relative to body weight] or serum cystatin C values (P=NS) between 
creatine-supplemented and control-diet fed animals. Glomerular filtration 
rate in two-thirds nephrectomized animals was significantly lower 
compared with sham-operated animals [inulin clearance: 0.21±0.04 vs 
0.33±0.07 ml/min/100 g, P<0.001; creatinine clearance: 0.30±0.07 vs. 
0.48±0.13 ml/min/100 g, P<0.001; cystatin C: 97±21 vs. 50±15 mg/l, 
P<0.001 (pooled data)]. Creatinine clearance rates at the start and after 
4 weeks of creatine supplementation are illustrated in Table 2. Creatinine 
clearance was comparable at the start and after 4 weeks of creatine 
supplementation between supplemented and control-diet fed rats in either 
sham-operated or two-thirds nephrectomized animals. Recuperation of 
kidney function after renal ablation/nephrectomy was comparable in the 
creatinesupplemented group vs control-diet fed rats (0.69±0.34 vs. 
0.61±0.30 ml/min; P=NS) in the renal failure group. 
 
 
 
Table 2. Creatinine clearance during study period 
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Fig. 1. Effect of 4 weeks of creatine supplementation on inulin, creatinine 
clearance and serum cystatin C concentrations. No significant differences 
in inulin, creatinine clearance and cystatin C concentrations were 
observed between supplemented animals and control-diet fed animals. 
Two-thirds nephrectomized animals had significantly different glomerular 
filtration indices compared with sham-operated animals. Cr-, control diet; 
Cr+, creatine-supplemented diet. *P<0.05, two-thirds nephrectomized 
supplemented animals, compared with supplemented sham-operated 
animals. **P<0.05, two-thirds nephrectomized control-diet fed animals, 
compared with control-diet fed sham-operated animals. 
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Effect of creatine supplementation on albumin and urea excretion 
Urea and albumin clearance rates are illustrated in Figure 2. No differences 
were observed in either urea or albumin clearance between creatine-
supplemented and control-diet fed animals [urea clearance: 0.21±0.06 vs. 
0.18±0.07 ml/min/100 g, P=NS; albumin clearance: 0.019 (0.013–0.036) 
vs. 0.018 (0.011–0.042) ml/min/100 g, P=NS (Mann–Whitney U-test) 
(pooled data)]. 
 
 
 
 
 
 
Fig. 2. Effect of 4 weeks of creatine supplementation on urea and albumin 
clearance rates. No significant differences in urea or albumin were observed 
between supplemented animals and control-diet fed animals. Two-thirds 
nephrectomized animals had significantly different urea and albumin 
clearance rates compared with sham-operated animals. Cr-, control diet; 
Cr+, creatine-supplemented diet. *P<0.05, two-thirds nephrectomized 
supplemented animals, compared with supplemented sham-operated 
animals. **P<0.05, two-thirds nephrectomized control-diet fed animals, 
compared with control-diet fed sham-operated animals. 
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Effect of creatine supplementation on body mass, food intake and muscular 
creatine concentrations Table 3 summarizes food intake and body mass in 
the four experimental groups. No difference in body weight or food intake 
was observed after 4 weeks of creatine supplementation in either sham-
operated or in the two-thirds nephrectomized group. Two-thirds 
nephrectomized animals exhibited lower body mass than sham-operated 
controls [387±22 vs. 421±21 g; P<0.001 (pooled data)]. Daily food was 
not different between sham-operated and two-thirds nephrectomized 
animals [17.5±2.6 vs. 17.4± 3.7 g; P=NS (pooled data)]. Creatine intake, 
expressed as absolute intake (353±69 vs. 333±85 mg; P=NS) or relative 
to body weight (853±173 vs. 870±242 mg/kg; P=NS) in supplemented 
animals did not differ between two-thirds nephrectomized and sham-
operated animals. 
 
Total creatine intramuscular concentrations are increased upon 
supplementation [soleus: 23.9±4.0 vs. 21.5±2.3 µmol/g, P=0.02; 
gastrocnemius: 35.8±2.9 vs 32.8±1.6 µmol/g, P<0.001 (pooled data)]. No 
difference in muscular creatine concentration was observed comparing 
two-thirds nephrectomized animals with sham-operated animals [soleus: 
24.0±4.2 vs 21.9±2.6 µmol/g, P=NS; gastrocnemius: 34.4±2.6 vs 
34.5±3.3 µmol/g, P=NS (pooled data)]. 
 
 
 
Table 3. Effect of 4 weeks of creatine supplementation on body mass, food intake 
and total creatine intramuscular concentration 
 
 
 
 
 
 
 47
Discussion 
 
The present study could not demonstrate any deleterious effect of creatine 
supplementation on kidney function. No changes in GFR or renal protein 
handling were observed. Creatine supplementation was shown to increase 
intramuscular total creatine concentrations in sham-operated and 
nephrectomized animals. 
Creatinine determinations are susceptible to analytical interferences. These 
in vitro interferences can make up a substantial fraction of the apparent 
creatinine concentrations. The Jaffe´ reaction is particularly susceptible 
to non-specific chromogens, such as bilirubin and cephalosporins [14]. 
Creatine supplementation can interfere with creatinine determinations by 
Jaffé method, with apparent increases in creatinine concentrations 
up to 8% (Y. Taes, unpublished data). No analytical interferences were 
found using the enzymatic assay with increased creatine concentrations, 
as found in animals or subjects who ingest creatine (Y. Taes, unpublished 
data). As creatine feeding could interfere with creatinine determination, we 
investigated GFR by means of the gold-standard procedure (inulin 
clearance), together with creatinine clearance and serum cystatin C. No 
significant alterations in any of the markers were observed upon creatine 
supplementation, indicating no effect on GFR. Urea clearance was 
comparable in creatine-supplemented and control-diet animals. No 
changes in 24 h proteinuria or albumin excretion were noted in both sham-
operated and two-thirds nephrectomized animals upon creatine 
supplementation, indicating absence of structural glomerular changes. 
Serum creatinine concentrations were found to be higher in 
nephrectomized supplemented animals but not in creatine-supplemented 
sham-operated animals. With declining kidney function, increased serum 
creatinine concentrations are attained in order to excrete the increased 
creatinine load, due to creatine– creatinine interconversion. However, care 
is warranted as creatinine has been described as a weak uraemic 
toxin. Inhibitory effects on metabolic processes have been described, 
however, at supraphysiological concentrations and not observed in vivo 
[21].Upon creatine supplementation, Edmunds et al. [12] demonstrated 
renal disease progression in Han:SPRD-cy rats. These authors described 
increases in serum creatinine concentrations in male (but not in female) 
rats. Unfortunately, no independent renal function measurements were 
performed. Creatinine clearances were diminished in both sexes. Creatinine 
was determined using an end point Jaffé-based method (alkaline picrate; 
Sigma Diagnostics). The Jaffé method is susceptible to interference from 
non-specific chromogens [14], varying from method to method. The 
creatinine values reported by Edmunds et al. [12] might have been 
influenced by creatine concentrations. Unfortunately, no creatine 
determinations were communicated in the former study. Creatine was 
supplemented as a mixture of creatine and glutamine in an over-the-
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counter formulation. This formulation could contain traces of contaminants 
or toxic products. Purity of this formulation has not been established. 
The Han:SPRD-cy rat is a well-established animal model of human 
polycystic kidney disease. Several interventional studies reported effects 
on kidney function in this animal. Dietary interventions have been shown 
to delay the progression of renal disease [22]. While this model mimics 
human polycystic disease well, it cannot be used as an animal model for 
general renal functional impairment. The remnant kidney model is a well-
established animal model for kidney function impairment, by means of 
kidney tissue ablation. Intrinsic renal disease is, however, absent in these 
animals and the kidney function can partly recover over time. These 
differences in animal model can account for the differences found between 
the present study and the study by Edmunds et al. [12]. In humans, no 
evidence from controlled studies is available describing adverse effects of 
creatine supplementation. Poortmans [5,8,9,11] investigated kidney 
function in young healthy subjects. No alterations in creatinine, urea or 
albumin clearance were reported in short-term (5 days, 20 g creatine daily 
[8]) or long-term studies (1 month to 5 years, with 1–80 g creatine daily 
[9]; 63 days with 21 g creatine daily [11]). Robinson et al. [10] reported 
only transient increases in serum creatinine during creatine ingestion. Six 
weeks after cessation of the creatine supplementation, serum creatinine 
had returned to baseline. No gold-standard procedures for determining 
GFR, such as inulin or isotope-based methods, have been performed 
in humans. Creatine is regarded as a nutritional supplement and 
available over-the-counter. The different industrially prepared formulations 
are not subjected to adequate quality control. Toxic side products or 
contaminants could be present in these formulations. No toxic side 
products were detected in the creatine monohydrate formulation by our 
HPLC method [16]. Creatinine contamination was found to be 0.37%. 
Intake of creatinine is therefore very low in comparison to creatine 
intake. This study demonstrates that creatine supplementation 
can increase intracellular creatine concentration in skeletal muscle of renal 
failure animals, as described in animals with normal kidney function [1]. 
Serum and muscle creatine concentrations were found to increase 
upon creatine supplementation in animals with kidney function impairment. 
Creatine supplementation in animals has been shown to increase 
intracellular creatine concentration (total, free and phosphocreatine) in 
both fast-twitch and slow-twitch skeletal muscles, together with an 
improved running performance [1]. Differences in creatine concentrations 
between the soleus and gastrocnemius are in accordance with 
reported values [1], reflecting differences in energy metabolism. No 
intramuscular phosphocreatine or high energy nucleotides are reported in 
the present study as the prolonged anaesthesia during inulin clearance 
determination could have influenced these high energy metabolites. 
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In conclusion, we could not demonstrate any harmful effects of prolonged 
high dose creatine supplementation on glomerular filtration or protein 
excretion in an animal model with pre-existing moderate renal 
dysfunction. Muscle intracellular creatine concentration was increased upon 
creatine supplementation in these animals. 
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Note added to manuscript in thesis: 
 
The provided analgesia in relation to surgery in the animals is not 
mentioned in the manuscript. The analgesia was provided 48h post-
operatively, by administration of buprenorphine IM (0.1 mg/kg; Temgesic, 
Schering-Plough) 
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CHAPTER 3.2   
 
 
 
 
 
 
 
 
Effect of creatine supplementation on 
homocysteine metabolism in animals 
and chronic hemodialysis patients 
 
 
 
 
 
 
Creatine supplementation decreases homocysteine in an 
animal model of uraemia.  
Kidney Int 2003;64:1331-1337 
 
Creatine supplementation does not decrease total plasma 
homocysteine in chronic hemodialysis patients. 
Kidney Int 2004;66:2422-2428 
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Abstract 
 
Background. Hyperhomocysteinemia is prevalent in more than 85% of 
patients with end-stage renal disease (ESRD) and is thought to contribute 
to the excess cardiovascular mortality and morbidity. Creatine is 
synthesized by methylation of guanidinoacetate with formation of S-
adenosylhomocysteine and subsequently, homocysteine (Hcy). Creatine 
supplementation down-regulates its endogenous synthesis and, thus, may 
reduce Hcy production. The present study investigates the effect of 
creatine supplementation on Hcy concentrations in an animal model of 
uraemia. 
Methods. Male Wistar rats were either sham-operated and received a 
control diet (N=8) or a 2%-creatine-supplemented diet (N=8), or 
underwent subtotal nephrectomy and received a control diet (N=10) or a 
2%-supplemented creatine diet (N=10). After 2 weeks of treatment, total 
plasma Hcy, creatine, creatinine, folate, and vitamin B12 were determined, 
as well as hepatic folate and vitamin B12 concentrations. 
Results. Plasma creatinine concentrations were higher in nephrectomized 
animals, but similar in creatine-supplemented and control diet–fed animals. 
Plasma Hcy was higher in nephrectomized animals but lower in creatine-
supplemented nephrectomized animals compared to nephrectomized 
control diet–fed animals (12.1 ± 2.4 µmol/L vs. 15.4 ± 1.7 µmol/L; 
P < 0.01). Total plasma Hcy inversely correlated with plasma creatine 
concentrations (r = 0.39; P =0.02). Plasma folate was higher in 
supplemented animals and hepatic tetrahydrofolate (THF) was higher in 
nephrectomized supplemented animals. Plasma vitamin B12 was similar in 
all groups, whereas hepatic vitamin B12 was higher in nephrectomized 
animals. 
Conclusion. Creatine supplementation can effectively lower plasma Hcy 
concentrations in an animal model of uraemia and should be further 
investigated as a potential treatment for hyperhomocysteinemia in patients 
with ESRD. 
 
 
Key words: total plasma homocysteine, tetrahydrofolate, 5- 
methyltetrahydrofolate, end-stage renal disease, creatine. 
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Introduction 
 
Hyperhomocysteinemia is considered an independent risk factor for 
cardiovascular disease in the general population, as well as in patients with 
end-stage renal disease (ESRD) [1, 2]. About 85% of patients with renal 
failure have hyperhomocysteinemia, eventually contributing to the excess 
cardiovascular mortality in this population [3]. The mechanism underlying 
hyperhomocysteinemia in ESRD is poorly understood. Homocysteine (Hcy) 
[2] is a sulfur-containing amino acid, formed by demethylation of 
methionine and plays an important role in the activated methyl and folate 
cycle (Fig. 1).  
 
 
 
 
Fig. 1. Overview of homocysteine and creatine metabolism. Methionine is 
converted to S-adenosylmethionine, which is demethylated to S-
adenosylhomocysteine by methyltransferases. Creatine is formed by 
methylation of guanidinoacetate, which is synthesized from glycine and 
arginine. Creatine supplementation decreases guanidinoacetate synthesis 
by repressing AGAT biosynthesis and consequent reduction of 
guanidinoacetate formation. Homocysteine is either remethylated to 
methionine or degraded in the transsulfuration pathway. Abbreviations 
are: AGAT, arginine:glycine amidinotransferase (EC 2.1.4.1); THF, 
tetrahydrofolate; 5CH3-THF, 5-methyltetrahydrofolate; 5,10-CH2-THF: 
5,10 methylene tetrahydrofolate; Ser, serine; Gly, glycine. 
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Methionine can intracellularly be converted to S-adenosylmethionine, a 
sulfonium compound with a highly reactive methyl group, which acts as a 
universal methyl donor in numerous transmethylation reactions in vivo. 
The demethylated product S-adenosyl homocysteine, a thioether, is readily 
hydrolyzed to Hcy and adenosine by S-adenosyl homocysteine hydrolase. 
Hcy metabolism is nutritionally regulated. In conditions with high 
methionine concentrations, the transsulfuration pathway is favored, in 
which Hcy condenses with serine to cystathionine, which is further 
metabolized to cysteine and sulfate. In conditions of low methionine intake, 
remethylation of Hcy to methionine occurs through methyl donation from 
5-methyltetrahydrofolate (5-CH3THF) by means of methionine synthase. 
Vitamin B12 acts as a cofactor in this remethylation pathway. 5-CH3THF is 
demethylated to tetrahydrofolate (THF), which is reconverted to 5-CH3THF 
in a multiple-step folate cycle with serine glycine conversion by means of 
the methylene tetrahydrofolate reductase. Treatment of 
hyperhomocysteinemia mainly consists of alimentary folic acid and vitamin 
B6 and B12 supplements. An average reduction of about 30% in plasma 
total Hcy (tHcy) is observed in uraemic patients treated with folic acid [3]. 
The effect of vitamin B6 and B12 is in general much less pronounced [3]. A 
randomized analysis by Bostom et al [4] reported a decrease of 12% in 
fasting plasma tHcy with vitamin B6 supplementation. Vitamin B12 
supplementation lowered tHcy concentration with 35%, only in dialysis 
patients with low cobalamin status [5]. However, even combined high-dose 
folic acid and vitamin B6 or B12 supplementation cannot entirely normalize 
tHcy in ESRD patients [3]. Supplementation with other methyl-donating 
molecules such as betaine can decrease postmethionine loading tHcy 
concentrations by 18%, in addition to folic acid supplementation [6]. 
Additional tHcy lowering therapies are required in preventing excess 
cardiovascular mortality in these patients. 
Creatine is increasingly popular as an ergogenic supplement in an athletic 
population [7 9]. Dietary intake and endogenous synthesis in liver 
compensate for a daily loss as creatinine of about 2%. Creatine is 
synthesized in mammals through two successive metabolic steps (Fig. 1). 
First, guanidinoacetate is formed in the kidney from glycine and arginine 
by arginine:glycine amidinotransferase (AGAT) (EC 2.1.4.1). Second, 
guanidinoacetate is methylated in the mammalian liver to creatine by 
guanidinoacetate methyltransferase (GAMT) (EC 2.1.1.2) with S-
adenosylmethionine acting as methyl donor [8]. Creatine supplementation 
down-regulates endogenous creatine synthesis by repression of AGAT 
biosynthesis and consequent guanidinoacetate formation (Fig. 1). 
Mudd and Poole [10] and Mudd, Ebert, and Scriver [11] calculated that 
methylation of guanidinoacetate during creatine biosynthesis accounted for 
up to 70% of the transmethylation reactions in the body. Quantitatively, 
this exceeds all other methylation reactions. Stead et al [12] demonstrated 
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that down-regulation of endogenous creatine synthesis by creatine 
supplementation could decrease methylation demand and tHcy in animals 
with normal renal function. Whether creatine can also lower tHcy in 
conditions of renal failure is presently unknown. 
The present study investigates the effect of creatine supplementation on 
tHcy concentrations in both animals with uraemia and normal kidney 
function. 
 
Methods 
 
Animal procedures 
Male Wistar rats weighing 200 to 230 g were obtained from Iffa Credo 
(Brussels, Belgium). All animal care was in accordance with local 
prescriptions and the NIH Guide for the Care and Use of Laboratory 
Animals. 
Renal failure was induced using a standard procedure of subtotal 
nephrectomy as described before [13, 14]. Rats were anesthetized with 
halothane (Fluothane) (Astra-Zeneca, Destelbergen, Belgium) and a flank 
incision was made exposing the kidney. The upper and lower poles of the 
left kidney were cryoablated, followed 1 week later by a right 
nephrectomy. The sham procedure consisted of a flank incision and 
manipulation of the kidney without tissue destruction. 
Animals were randomly allocated to four groups: (1) sham-operated, 
control diet (N = 8); (2) sham-operated, creatine-supplemented diet (N = 
8); (3) subtotal nephrectomized, control diet (N = 10); and (4) subtotal 
nephrectomized, creatine-supplemented diet (N = 10). The animals had 
free access to food and drinking water. 
Creatine supplementation was started 1 week after the last surgical 
procedure by addition of 2% creatine monohydrate (wt/wt) (Sigma 
Chemical Co., St. Louis, MO, USA) to the control diet. Control animals were 
kept on a soy-based maintenance diet (RM1) (Special Diet Services, 
Witham, UK), containing 14% protein. 
Urine and blood samples were collected at the start and after 14 days of 
creatine supplementation. Body weight and individual food intake were 
recorded on these occasions. Folate intake was calculated from food intake. 
 
Biochemical determinations 
Creatinine clearances. Plasma and urinary creatinine concentrations were 
determined enzymatically (Roche Diagnostics, Mannheim, Germany) on a 
Modular P analyzer (Roche Diagnostics) according to the manufacturer's 
procedure. Creatinine clearances were calculated based upon 24-hour urine 
collections. Plasma urea concentrations were determined enzymatically 
(Roche Diagnostics). 
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Total plasma Hcy concentrations were determined using a fluorescence 
polarization immunoassay on an Axsym analyzer (Abbott Laboratories, 
Abbott Park, IL, USA). 
Plasma folate and plasma and hepatic vitamin B12 concentrations were 
determined using an electrochemiluminescence assay (Roche Diagnostics) 
on an Elecsys 2010 Analyzer (Roche Diagnostics). Plasma and urine 
creatine concentrations were determined enzymatically as described before 
[15]. Total intramuscular creatine concentrations ( mol/wet weight) were 
determined colorimetrically according to Berlet [16]. Urinary sulfate was 
determined colorimetrically using barium chloranilate according to 
Bertolacini and Barney [17]. Hepatic nonsubstituted THF and 5-CH3THF 
(monoglutamates) were determined using high-pressure liquid 
chromatography (HPLC) with fluorometric detection as described before 
[18]. Samples were homogenized in 50 mmol/L acetate buffer (pH 4.9) 
(2% ascorbic acid and 1% 2-mercaptoethanol), deconjugated using rat 
plasma and heated for 5 minutes in boiling water. Samples were flushed 
with nitrogen between every manipulation. The analysis was performed on 
Gilson 307 HPLC pump (Gilson Int., Den Haag, The Netherlands) with a 
Gilson 122 fluorometric detector (ex, 295 nm; em, 356 nm) using a 
Chrompack Spherisorb 3 ODS-2 reversed-phase column. Recoveries were 
86% and 93% for THF and 5-CH3THF, respectively. 
 
Statistics 
Data are expressed as mean ± SD. One-sample Kolmogorov-Smirnov test 
was used to pretest normal distribution. Student t test was used to 
compare separate groups when appropriate. Differences were considered 
significant at P less than 0.05. Correlation between parameters was 
examined using Spearman rank correlation analysis. 
 
Results 
 
Biometrical and biochemical characteristics 
 
Subtotal nephrectomized animals exhibited lower body mass and renal 
function indices compared to sham-operated animals. No significant 
differences in body weight, food, or folate intake were observed between 
creatine-supplemented and control diet fed groups in either subtotal 
nephrectomized or sham-operated groups (Table 1). Creatinine clearance 
rates were similar in creatine-supplemented and control diet fed animals 
(Table 1). Plasma creatine and urinary creatine excretion was significantly 
higher in creatine-supplemented animals. Total intramuscular creatine 
concentrations were similar in nephrectomized and sham-operated animals 
[34.5 ± 2.6  µmol/g vs. 34.8 ± 3.3  µmol/g; P = NS (pooled data)], but 
higher concentrations were observed in creatine-supplemented animals 
than in control diet fed animals [36.1 ± 2.8 µmol/g vs. 33.0 ± 2.0  
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µmol/g; P = 0.001 (pooled data)]. Urinary sulfate excretion did not differ 
between creatine-supplemented and control diet fed animals. 
 
Table 1. Comparative biometric characteristics, baseline glomerular filtration 
markers, and biochemical parameters in control diet (soy-based) and creatine-
supplemented (2% wt/wt) diet–fed animals, with or without preexisting renal failure 
 
 
 
 
 
Plasma tHcy concentrations 
Subtotal nephrectomized, control diet fed animals had higher tHcy 
concentrations compared to sham-operated control diet fed animals (Fig. 
2). Lower tHcy concentrations were observed in nephrectomized creatine-
supplemented animals compared to nephrectomized control diet fed 
animals (Fig. 2). In sham-operated animals, only a tendency toward lower 
tHcy concentrations was observed. Pooled data from sham-operated and 
nephrectomized animals demonstrated significant lower tHcy 
concentrations in the creatine-supplemented groups compared to the 
control diet fed group (12.4 ± 2.2  µmol/L vs. 14.6 ± 1.9  µmol/L; P = 
0.005). 
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Fig. 2. Effect of creatine supplementation on total plasma homocysteine (tHcy) 
concentrations in sham-operated and subtotal nephrectomized animals. 
Subtotal nephrectomized animals had significantly higher tHcy 
concentrations than sham-operated animals. The creatinesupplemented 
subtotal nephrectomized group had lower tHcy concentrations, compared to 
nephrectomized control diet–fed group. Creatine supplementation in the 
sham-operated group did not lower tHcy concentrations significantly. 
 
 
Plasma tHcy concentrations inversely correlated with plasma creatine 
concentrations (r =  0.39; P = 0.02) (Fig. 3), as well as with total 
intramuscular creatine concentrations (r =  0.35; P< 0.05).  
tHcy concentrations correlated significantly with creatinine clearance in 
control diet fed animals (r =  0.68; P = 0.005), but the correlation was lost 
in creatine-supplemented animals (r =  0.06; P = NS) (Fig. 4).  
No correlation between tHcy and urinary sulfate excretion was observed. 
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Fig. 3. Scatter diagram illustrating relation between plasma creatine and total 
plasma homocysteine (tHcy) concentrations. tHcy concentrations inversely 
correlated with plasma creatine concentrations. Data from all groups are 
included in the graph. 
 
 
 
 
Fig. 4. Effect of creatine supplementation on the correlation between total plasma 
homocysteine (tHcy) concentrations and creatinine clearance (mL/min). 
tHcy concentrations correlated with creatinine clearance in control diet–fed 
animals, but the correlation was lost in creatinesupplemented animals. Data 
from all groups are included in the graph. 
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Plasma folate and vitamin B12 concentrations 
 
No differences in plasma folate or vitamin B12 were observed between 
nephrectomized and sham-operated animals (Table 2). Plasma folate was 
higher in creatine-supplemented groups [70.0 ± 24.9 nmol/L vs. 40.8 ± 
17.6 nmol/L; P = 0.001 (pooled data)]. No differences in plasma vitamin 
B12 concentrations were observed between creatine-supplemented and 
control diet fed animals [643 ± 121 pmol/L vs. 618 ± 165 pmol/L; P = NS 
(pooled data)]. No significant correlation was observed between plasma 
folate or vitamin B12 concentrations and plasma tHcy concentrations. 
Plasma creatine concentration correlated significantly with plasma folate (r 
= 0.47; P = 0.01) but not with vitamin B12 (r =  0.03; P = 0.87) 
concentrations. 
 
Table 2. Effect of creatine supplementation on plasma, hepatic folate, and vitamin 
B12 concentrations, in animals with with or without preexisting renal 
failure 
 
 
 
Hepatic folate and vitamin B12 concentrations 
Sham-operated and subtotal nephrectomized animals had similar hepatic 
THF and 5-CH3THF concentrations. Hepatic vitamin B12 concentrations 
were higher in subtotal nephrectomized animals compared to sham-
operated animals [7.0 ± 1.7 pmol/g vs. 4.7 ± 0.6 pmol/g; P = 0.002 
(pooled data)]. Creatine-supplemented animals had higher hepatic THF 
concentrations [11.1 ± 3.2 nmol/g vs. 8.6 ± 2.9 nmol/g; P = 0.02 (pooled 
data)]. Hepatic 5-CH3THF and vitamin B12 concentrations were comparable 
between creatine-supplemented and control diet fed animals. 
 
Discussion 
 
Uraemic animals have higher tHcy than animals with normal renal function, 
an observation in agreement with the well-known high prevalence of 
hyperhomocysteinemia in patients with ESRD [19]. The correlation of 
plasma tHcy with creatinine clearance in rats is in accordance to literature 
[20]. The salient observation of the present study is that oral creatine 
 62
supplementation can effectively lower plasma tHcy concentrations in 
animals with uraemia to normal tHcy concentrations. tHcy concentrations 
were 22% lower in the creatine-supplemented subtotal nephrectomized 
group, compared to the control diet fed group. Creatine supplementation in 
the sham-operated animals did not lower tHcy significantly. The latter 
observation is in line with the absence of an effect of creatine 
supplementation on tHcy in young healthy volunteers [21]. Hcy 
metabolism is tightly regulated under normal conditions, whereas in 
situations with compromised Hcy homeostasis, creatine supplementation 
might have a more direct and prominent tHcy lowering effect [22]. 
Species-related differences in metabolic pathways could also explain the 
difference in effect between humans and rodents. 
Plasma, urine, and muscle creatine concentrations were higher in creatine-
supplemented animals, documenting uptake and metabolization of creatine 
in this animal model. No difference in creatinine clearance was observed 
between supplemented and control diet fed animals in both sham-operated 
and nephrectomized animals. The safety of creatine supplementation and 
the absence of adverse effects on renal function were previously assessed 
by our group in this animal model of chronic renal failure [13]. No adverse 
effects on glomerular filtration or renal protein handling were observed. 
However, adverse effects of creatine supplementation on renal function 
have been reported. Edmunds et al [23] demonstrated diminished 
creatinine clearance rates and increased cyst formation in Han:SPRD-cy 
rats, an animal model of human polycystic kidney disease. So far, none of 
the controlled studies in humans on the effects of creatine supplementation 
have indicated any adverse effect [24]. However, safety of creatine 
supplementation in subjects with preexisting renal failure remains open for 
discussion. 
Creatine supplementation was associated with higher plasma folate 
concentrations and higher hepatic THF concentrations in the subtotal 
neprectomized group, whereas folate intake was comparable in all groups. 
Higher folate concentrations in the creatine-supplemented nephrectomized 
animals reflect differences in folate metabolism, as folic acid intake is 
comparable. Creatine supplementation lowers endogenous creatine 
synthesis and methylation demand, with lower Hcy formation. 
Remethylation of Hcy to methionine might be diminished with an apparent 
folate-saving effect. However, further research is required confirming these 
hypotheses, eventually using stable isotope protocols. In contrast to 
humans [25], no relationship between urinary sulfate excretion and tHcy 
was observed in our animal model, probably due to similar dietary intake 
of methionine and cysteine in all animals, accounting for comparable 
sulfate excretion. 
The influence of creatine on labile methyl pool metabolism, and 
consequently on methionine Hcy cycling and tHcy concentrations, has so 
far been underestimated. Estimation of labile methyl pool consumption 
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[10, 11] demonstrated that creatine biosynthesis accounts for up to 70% 
of the methylation reactions in the human body. The correlation between 
creatinine and tHcy concentrations is attributable to two factors. First, both 
tHcy and plasma creatinine depend on renal elimination. Moreover, 
creatine synthesis is intricately linked to Hcy formation and creatine is 
degraded to creatinine. The correlation observed between tHcy and 
creatinine is partly due to glomerular filtration, but also due to creatine 
creatinine conversion. 
In humans, a low dietary intake of creatine is associated with higher tHcy 
concentrations. Vegetarians, consuming neglectable amounts of creatine, 
have higher tHcy than subjects consuming an omnivorous diet [26-28], 
even when vitamin B12 concentrations are similar [26]. Renal patients are 
generally kept on a low protein diet with low dietary creatine intake. 
Endogenous creatine synthesis and methylation demand could, therefore, 
be higher in these patients, enhancing tHcy concentrations. 
In middle-aged and elderly subjects, tHcy was found to depend on gender 
with lower tHcy concentrations in women than in men [29]. Gender 
transition studies in male or female transsexuals have shown a strong 
dependency of tHcy on creatinine concentrations. Male-to-female 
transsexuals exhibited a substantial reduction in tHcy and creatinine 
concentrations after estrogen and antiandrogen therapy. Female-to-male 
transsexuals exhibited higher tHcy and creatinine concentrations after 
testosterone treatment. Taken together, these studies suggest that Hcy 
production occurs in direct conjunction with creatine synthesis [30]. 
Exogenous methylation demand, defined as increased metabolic methyl 
group consumption by intake of substances (alimentary, drugs) requiring 
methylation during their metabolization, can increase tHcy concentrations 
by increasing methionine Hcy interconversion. The effect of exogenous 
methylation demand on tHcy is illustrated in Parkinson disease patients, 
treated with L-3,4-dihydroxyphenylalanine (L-DOPA). Metabolism of L-
DOPA involves the enzyme catechol-O-methyltransferase, with S-
adenosylmethionine as methyl group donor with formation of S-
adenosylhomocysteine. In Parkinson disease patients treated with L-DOPA, 
plasma tHcy is higher than in controls and untreated patients [31]. 
Increased exogenous methylation demand is also observed with the lipid-
lowering agent niacin, which is metabolized and excreted as methylated 
pyridones. High-dose niacin intake imposes a large methylation demand on 
the activated methyl cycle and increases tHcy concentrations and 
decreases folate and vitamin B12 concentrations [32, 33]. 
 
Conclusion 
 
The present study demonstrated that inhibition of endogenous methylation 
demand with dietary creatine supplementation can effectively lower tHcy in 
an animal model of uraemia. Creatine may thus have a promising 
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therapeutic potential in lowering tHcy concentrations and reducing 
cardiovascular risk in ESRD patients. Further research is required to 
examine whether the present results can be extrapolated to humans with 
ESRD. 
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Note added to manuscript in thesis: 
 
The provided analgesia in relation to surgery in the animals is not 
mentioned in the manuscript. The analgesia was provided 48h post-
operatively, by administration of buprenorphine IM (0.1 mg/kg; Temgesic, 
Schering-Plough). 
 
Blood samples were drawn after 3h fasting to minimize the influence of 
creatine uptake from the gut on plasma creatine concentrations, though 
the pharmacokinetic behaviour of creatine in this animal model was not 
studied. 
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Abstract 
 
Background. Hyperhomocysteinemia is present in the majority of chronic 
hemodialysis patients. Treatment with folic acid, vitamin B12, and vitamin 
B6 cannot fully normalize plasma homocysteine concentrations (tHcy). 
Previously we have demonstrated the tHcy-lowering effect of creatine 
supplementation in an animal model of uraemia (Kidney Int 64:1331-1337, 
2003). The present study investigates the effects of creatine 
supplementation on tHcy in a vitamin-repleted chronic hemodialysis 
population. 
 
Methods. Forty-five hemodialysis patients receiving folic acid and vitamin 
B6 and B12 were included. Patients were treated with creatine (2 g/day) or 
placebo during 2 treatment periods of 4 weeks, separated by a washout of 
4 weeks. Plasma tHcy, creatine, Kt/Vurea, folic acid, vitamin B12, and 
routine biochemistry were determined, as well as the prognostic 
inflammatory and nutritional index. 
 
Results. All patients had elevated tHcy concentrations (21.2 ± 5.6 mol/L). 
Creatine treatment resulted in increased plasma and red blood cell creatine 
levels, documenting uptake of creatine. Creatine did not affect tHcy 
concentrations. There was no relationship between plasma creatine 
concentrations and tHcy concentrations. No changes in body weight, 
routine biochemistry, nutritional status, folic acid, or vitamin B12 were 
observed during the study. 
 
Conclusion. Creatine supplementation at a rate of 2 g/day does not further 
decrease tHcy concentrations in chronic dialysis patients already treated 
with high dose folic acid, vitamin B6, and B12 supplementation. 
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Introduction 
 
Hyperhomocysteinemia, a raised plasma concentration of the sulfur amino 
acid homocysteine, is observed in several genetic and acquired disorders. 
The majority of patients with end-stage renal disease (ESRD) have a 
moderate degree of hyperhomocysteinemia [1]. Treatment of 
hyperhomocysteinemia consists of folic acid and vitamin B6, B12 
supplements. Folic acid supplementation can reduce plasma tHcy about 
30% in uraemic patients, whereas the effect of vitamin B6 and B12 is in 
general much less pronounced [2, 3]. However, the majority of ESRD 
patients maintain elevated plasma tHcy concentrations when treated with 
high dose multivitamin supplementation. Betaine can further decrease 
post-methionine loading tHcy concentrations by 18%, in addition to folic 
acid supplementation [4]. Additional tHcy-lowering therapies are necessary 
in these patients in order to attain normal tHcy concentrations. 
 
 
 
 
 
Fig.  1. Overview of homocysteine and creatine metabolism. 
THF: tetrahydrofolate; 5CH3-THF: 5-methyltetrahydrofolate; 5,10-CH2-THF: 5,10 
methylene tetrahydrofolate ; Ser: Serine ; Gly: Glycine;  SAM: S-Adenosyl 
Methionine ; SAH: S-Adenosyl Homocysteine ; Hcy: Homocysteine; Met: 
Methionine. Enzymes: (1) Arginine:Glycine amidinotransferase (AGAT); (2) 
Methionine Adenosyltransferase ; (3) Guanidinoacetate methyltransferase (GAMT) ; 
(4) S-Adenosyl Homocysteine hydrolase ; (5) Methionine Synthase ; (6) 5,10-CH2-
THF reductase ; (7) Serine-hydroxy methyltransferase ; (8) Cystathionine-β –
synthase . 
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Creatine synthesis and homocysteine (Hcy)-formation are metabolically 
connected (Fig. 1). Hcy [1, 5] is derived from methionine in a multiple step 
metabolic cycle (Fig. 1). Methionine can intracellularly be converted to S-
adenosyl methionine, a sulfonium compound with a highly reactive methyl 
group, which acts as a universal methyl donor in numerous 
transmethylation reactions in vivo. The demethylated product S-adenosyl-
homocysteine, a thioether, is readily hydrolyzed to Hcy and adenosine by 
S-adenosyl-homocysteine hydrolase. Transsulfuration of homocysteine to 
yield cystathionine is favored in conditions with methionine excess. 
Remethylation of homocysteine to methionine occurs in conditions of low 
methionine intake through methyldonation from 5-methyltetrahydrofolate 
(5-CH3THF) by means of methionine synthase. Creatine is synthesized in 
humans by two successive metabolic steps (Fig. 1). Guanidinoacetate is 
synthesized from glycine and arginine by arginine: glycine 
aminidinotransferase (AGAT; EC 2.1.4.1), mainly in the kidney. Second, 
guanidinoacetate is methylated in the liver to creatine by 
guanidinoacetate-methyltransferase (GAMT) (EC 2.1.1.2) with S-
adenosylmethionine as methyl-donor [6,7]. Dietary intake and endogenous 
synthesis in liver compensate for a daily loss as creatinine of about 2%. 
Creatine supplementation represses AGAT biosynthesis and, consequently, 
guanidinoacetate and creatine formation (Fig. 1). Methylation of 
guanidinoacetate during creatine biosynthesis has been estimated to 
account for up to 70% of the transmethylation reactions in the body with 
formation of Hcy [8, 9]. Exogenous creatine supplementation can, thus, be 
expected to decrease endogenous Hcy synthesis. Inhibition of the 
methyltransferase reactions has been described in uraemia due to a 
reduced S-adenosylmethionine (SAM)/S-adenosylhomocysteine (SAH) 
ratio, and protein hypomethylation and reduced protein repair are 
observed in uraemic subjects [10, 11]. The influence of creatine on tHcy 
concentrations, SAM/SAH ratios, and the methyltransferase reactions in 
humans is currently unknown. Creatine supplementation could reduce the 
guanidinoacetate-methyltransferase reaction and consequent Hcy-
formation. In an animal model of chronic renal failure we have recently 
demonstrated a pronounced beneficial effect of creatine supplementation 
on plasma tHcy concentrations. tHcy concentrations were lowered by 22% 
in creatine-treated animals compared to control diet-fed uraemic animals 
[12]. Whether creatine can lower tHcy in humans as observed in our 
animal model is currently unknown. 
 
The present study investigates the effect of creatine supplementation on 
plasma tHcy concentrations in chronic hemodialysis patients already 
treated with high-dose multivitamin supplementation. 
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Methods 
 
Study design and population 
 
Forty-nine hemodialysis patients were recruited. Dialysis was performed 
with a low-flux triacetate dialyzer (Sureflux-L; Nipro, Osaka, Japan) for 4 
to 5 hours 3 times weekly for at least 3 months. Exclusion criteria were: 
acute illness, life expectancy <3 months, low compliance due to cognitive, 
social, or psychiatric problems, and inability to provide informed consent. 
All patients were treated with folic acid 5 mg, pyridoxine 50 mg, and 
vitamin B12 12 µg orally 3 times a week for at least 3 months. Written 
informed consent was obtained from all participants. The study protocol 
was approved by the Ethical Committee of AZ Sint-Jan AV. Sample size 
estimation (type I error = 0.05; type II error = 0.20), based on the Hcy 
lowering in our animal study ( tHcy = 20%) and tHcy concentrations in 
dialysis patients, revealed sufficient statistical power of the present study. 
 
The study followed a double-blind, placebo-controlled, crossover design 
(Fig. 2). Patients received 2 g creatine or placebo daily in the evening 
during 2 treatment periods of 4 weeks, in random order, and separated by 
a washout period of 4 weeks. Creatine monohydrate (CreaPure®) was 
obtained from Degussa Bioactives (Freising, Germany). Placebo tablets 
contained Fast Flo lactose (Foremost Farms, Baraboo, WI, USA). An exact 
number of tablets was supplied, and pills were counted to ascertain 
compliance. Treatment duration, blood flow, dialysate flow, and membrane 
surface area were determined by the attending nephrologists, but no 
changes were made during the study period. Single pool Kt/Vurea was 
calculated at the start and end of the study, where K = dialyzer urea 
clearance, T = duration of dialysis, and V = urea distribution volume at the 
end of dialysis. 
 
 
 
 
 
Fig. 2.  Treatment  schedule 
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Predialysis blood samples were obtained at baseline and after 4 weeks in 
both treatment periods. EDTA-samples for tHcy determinations were 
transported on ice, centrifuged immediately, and stored at -20°C until 
testing. 
  
Biochemical determinations 
 
Plasma creatinine concentrations were determined using a compensated 
rate-blanked Jaffé based method (Roche Diagnostics, Mannheim, 
Germany) on a Modular P analyzer (Roche Diagnostics) according to the 
manufacturer's procedure. Plasma urea concentrations and aspartate-
aminotransferase (AST), alanine-aminotransferase (ALT), alkaline 
phosphatase, creatine kinase, and γ-glutamyl transferase (GGT) activities 
were determined on a Modular P analyzer using commercial reagents 
(Roche Diagnostics). 
 
Total plasma homocysteine concentrations were determined using a 
fluorescence polarization immunoassay on an Axsym analyzer (Abbott 
Laboratories, Abbott Park, IL, USA). 
 
Plasma folate and vitamin B12 concentrations were determined using an 
electrochemiluminescence assay (Roche Diagnostics) on an Elecsys 2010 
analyzer (Roche Diagnostics). Plasma and erythrocyte creatine 
concentrations were determined enzymatically as described before [13]. 
Plasma creatine was determined without deproteinization, whereas 
erythrocyte creatine was determined after deproteinization with 5-
sulfosalicylic acid. No analytical interference of creatine on tHcy was 
observed. The prognostic inflammatory and nutritional index (PINI) was 
calculated as PINI =[(1-acid glycoprotein (mg/L)  CRP (mg/L)]/[(albumin 
(g/L)  prealbumin (mg/L)][14, 15]. 1-acid glycoprotein, albumin, and 
prealbumin were determined nephelometrically using commercial reagents 
(Dade Behring, Marburg, Germany) on a BN II nephelometer. CRP was 
determined turbidimetrically on a Modular P analyzer (Roche Diagnostics). 
  
Statistics 
 
Data are expressed as mean ± SD, unless parameters were not normally 
distributed [median (interquartile range)]. Student t test was used to 
compare separate groups when appropriate; otherwise nonparametric 
group comparison was performed using Mann-Whitney U test. Associations 
between continuous variables were examined using Spearman rank 
correlation analysis. In order to estimate the effect of creatine treatment 
on the tHcy concentrations in this crossover framework, a mixed effect 
model was fitted treating patient as a random effect while the treatment 
mode, period, and carry-over were modeled as fixed effects [16]. Model 
 73
fitting was performed using SAS software (PROC MIXED) (release 8.1, SAS 
Institute, Inc., Cary, NC, USA). Differences were considered significant at P 
less than 0.05. 
 
Results 
 
Baseline patient characteristics 
 
Forty-five hemodialysis patients (24 males, 21 females) with a mean age 
of 70 ± 10 years (range 35-88) were included in this study. Four patients 
were excluded from the study (2 patients were transplanted during the 
study, 1 died, and 1 quit the study). Twenty-five patients received 
creatine, and 20 patients received placebo in the first treatment period. No 
baseline differences in age, gender distribution, body mass index, tHcy 
concentrations, or dialysis parameters were observed between placebo and 
creatine groups for both treatment periods (Table 1). 
  
Table 1. Baseline patient characteristics 
 
 
 
 
Plasma tHCY and creatine concentrations 
 
No significant changes in plasma tHcy concentrations were observed during 
treatment with creatine or placebo. Pre- and post-treatment tHcy 
concentrations were comparable in both creatine or placebo groups during 
the 2 treatment periods (Fig. 3). Plasma and red cell creatine 
concentrations were significantly elevated in the creatine treated groups, 
whereas comparable concentrations were observed before and after 
placebo treatment, documenting the uptake of creatine (Fig. 3 and Table 
3).  
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Fig. 3. Plasma homocysteine (tHcy) and creatine concentrations in both treatment 
periods. Black bars represent concentrations before treatment, whereas 
gray bars represent concentrations after treatment. Creatine concentrations 
were significantly higher in the creatine groups, compared to the placebo 
groups (*: p<0.0001). No difference in tHcy concentrations was observed. 
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No difference in baseline creatine concentrations was observed between 
the first and second treatment period, documenting the washout effect 
(Fig. 3). Male patients had significantly higher tHcy concentrations (23.3 ± 
3.7 µmol/L) compared to female patients (18.7 ± 6.1 µmol/L; P= 0.005). 
No effect of creatine supplementation on tHcy concentrations was observed 
in either male or female patients (data not shown). 
 
The results of the mixed effects model fit for tHcy are shown in Table 2. No 
treatment, period, or carryover effects were detected. No correlation 
between plasma creatine and tHcy concentrations was observed (r=0.08; 
P= 0.76). 
 
  
Table 2. Results of the mixed effects model fit 
 
 
 
Plasma folate and vitamin B12 concentrations 
 
All patients had elevated plasma concentrations of folate and vitamin B12 
(Table 3). No difference in plasma folate or vitamin B12 was observed 
between creatine- or placebo-treated groups. No significant relationship 
between tHcy and plasma folate or vitamin B12 concentrations was 
observed. 
  
Nutritional status and dialysis 
 
Nutritional status remained constant during the study period. No difference 
over time in total protein, albumin, prealbumin concentrations, and PINI 
scores were observed in any of the groups. A significant relationship 
between total protein concentration and tHcy was observed (r= 0.20; P= 
0.006). No relationship between albumin (r= 0.103; P= 0.17), prealbumin 
(r= 0.10; P= 0.20) concentrations, or PINI scores (r= 0.01; P= 0.87) and 
tHcy was observed in this population. Body weight and Kt/Vurea remained 
constant during the study period. No difference in Kt/Vurea between 
creatine- and placebo-treated groups [1.3 ± 0.3 vs. 1.4 ± 0.3 (post-
treatment)] was observed. Baseline tHcy concentrations correlated with 
Kt/Vurea (r=0.35; P= 0.01) and plasma creatinine concentrations (r= 0.40; 
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P= 0.004) (Fig. 4). No relationship after treatment was observed between 
Kt/Vurea and tHcy concentrations. 
 
 
 
 
Fig. 4. Relationship between plasma homocysteine (tHcy) and plasma creatine (A), 
plasma folate (B), KT/Vurea (C) and plasma creatinine concentrations (D). 
Panel A, B represent values (homocysteine, creatine, folate) after 
treatment; panel C, D  represent baseline values (homocysteine, creatinine, 
KT/Vurea). 
 
 
Discussion 
 
Hcy metabolism is tightly regulated under normal conditions. However, in 
situations with compromised Hcy homeostasis such as dialysis, creatine 
supplementation could have a more prominent tHcy-lowering effect [17]. 
In our dialysis patients treated with folic acid, vitamin B6, and B12, plasma 
tHcy concentrations remained moderately elevated, an observation in 
agreement with the well-known resistance to therapy in uraemia. In 
contrast to the effects in experimental animals [12, 18], oral creatine 
supplementation at a rate of 2 g/day did not lower plasma tHcy 
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concentrations in our dialysis population. tHcy concentrations were 
comparable after treatment with creatine and placebo. This observation is 
in line with the absence of an effect of creatine supplementation on tHcy in 
young healthy volunteers [19]. 
 
Plasma creatine and creatinine concentrations were higher in creatine-
supplemented subjects, documenting uptake and metabolization of 
creatine. The absence of effect could, thus, not be attributed to a limited 
uptake of creatine. In addition, the sample size was sufficiently large to 
demonstrate a decrease in plasma tHcy as observed previously in our 
animal study [12]. The dose of 2g creatine daily was chosen on the basis 
of existing treatment schedules. In healthy subjects, creatine at a 
maintenance dose of 2 g is used as a performance enhancing nutritional 
supplement, with documented uptake of creatine in the skeletal muscle 
[20]. Loading doses up to 20 g/day are used by athletes. We have chosen 
not to use a loading dose to avoid extremely high plasma concentrations 
with potential side effects. 
 
In contrast to our experimental animals, our patient population was treated 
with a chronic high-dose multivitamin regimen. High-dose folic acid 
supplementation could mask the Hcy-lowering effect of creatine in this 
population. A clinically relevant tHcy-lowering treatment should be able to 
decrease tHcy levels in vitamin-replete patients. Theoretically, lowering 
methylation demand could be synergistic with folic acid supplementation, 
which enhances the remethylation pathway. In contrast to these theoretic 
expectations, a decreased methylation demand by exogenous creatine 
supplementation did not lower tHcy concentrations, despite documented 
uptake and metabolization of creatine. 
 
In our patient population, creatine supplementation did not alter plasma 
folate concentrations. High-dose folic acid supplementation could have 
masked the folate sparing action of creatine that we have observed in our 
animal model. Lowering methyl group consumption by creatine 
supplementation apparently no longer influences tHcy or folate 
concentrations in conditions of excess folate [12]. 
 
Species-related differences in metabolic pathways could perhaps explain 
the difference in effect between humans and rodents. In rats, about 75% 
of plasma tHcy was found to be free, whereas in humans, about 65% to 
75% of tHcy is bound to protein by a disulfide bond [21, 22]. In dialysis 
patients, protein binding of Hcy was even found to be higher in comparison 
to nondialyzed chronic uraemic patients [23]. These differences in protein 
binding could be reflected in differences found in renal extraction of Hcy in 
humans and rats. In rats, significant clearance of Hcy by the kidneys was 
observed [22], whereas in humans, no arteriovenous difference in Hcy 
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concentrations was observed [24]. Differences in renal handling and in 
general Hcy metabolism could account for the absence of effect of creatine 
supplementation in our study. Aside from dissimilarities in Hcy-metabolism, 
creatine could be metabolized differently in rats than in humans. 
Compartmentalization and possibly regulation of the different enzymes 
necessary for creatine biosynthesis differs substantially between species 
[6, 25]. 
 
In uraemia, a disturbed SAM/SAH ratio inhibits the methyltransferase 
reactions. Creatine supplementation has been described to reduce the 
guanidinoacetate-methyltransferase reaction by lowering guanidinoacetate 
concentrations. The influence of creatine on other methyltransferase 
reactions (e.g., DNA-, protein methyltransferases) is currently unknown. 
Because creatine supplementation fails to lower tHcy concentrations in our 
dialysis population, the effect on other methyltransferase reactions will 
probably be limited in humans. 
 
The safety of creatine supplementation and the absence of adverse effects 
on renal function were previously assessed by our group in an animal 
model of chronic renal failure [26]. No adverse effects on glomerular 
filtration or renal protein handling were observed. Although adverse effects 
of creatine have been suggested, none of the controlled studies in humans 
on the effects of creatine supplementation have revealed any [27]. In our 
hemodialysis population we did not observe any major adverse effect of 
creatine administration. Plasma creatinine concentrations were slightly 
elevated due to increased creatine load in the creatine groups compared to 
the placebo groups. No effect on body weight or liver enzymes was noted. 
 
Protein malnutrition is common in patients on maintenance dialysis. 
Malnutrition and hypoalbuminemia are risk factors for increased morbidity 
and mortality in patients with ESRD [28, 29]. Nutritional status influences 
plasma tHcy concentrations by the strong protein binding of Hcy to 
albumin, and by the increased Hcy formation upon methionine uptake from 
the diet. The PINI is a formula to evaluate nutritional status and prognosis 
in critically ill patients [14, 15]. The PINI score has been measured in 
several settings, and has been found to be a reliable indicator of both 
nutritional status and prognosis. The PINI score was determined in this 
study in order to take into account the effect of protein malnutrition on 
tHcy concentrations. In our population we evaluated the relationship 
between nutritional status by means of the PINI score and tHcy 
concentrations, as tHcy depend greatly on protein intake [30, 31]. During 
the study no changes in nutritional status were observed in either creatine- 
or placebo-treated group. We observed no correlation between PINI scores, 
albumin or prealbumin concentrations, and tHcy concentrations. In 
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conditions of excess folate, nutritional status could be of less importance in 
determining plasma tHcy concentrations. 
 
Creatine supplementation has been shown to exert ergogenic effects in 
several populations. In dialysis patients, creatine supplementation was 
shown to decrease muscle cramps during dialysis [32]. In other conditions 
associated with low muscular mass and performance [33], creatine was 
shown to increase muscular performance and quality of life. Further 
research is necessary to evaluate the potential use and mechanisms of 
creatine as an ergogenic substance in dialysis patients. 
 
Conclusion 
 
The present study demonstrated that inhibition of endogenous methylation 
demand with dietary creatine supplementation does not further decrease 
tHcy concentrations in chronic dialysis patients treated with high-dose folic 
acid, vitamin B6, and B12 supplementation. 
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Note added to manuscript in thesis: 
 
As stated in the introduction of this thesis, the relation between tHcy and 
cardiovascular risk remains unknown and several epidemiological studies 
could not demonstrate an effect of tHcy-lowering therapy on cardiovascular 
mortality. Till today, the importance of Hcy in the pathogenesis of 
atherosclerosis remains elusive (Suliman, 2005). In this regard, the 
statements about tHcy-lowering therapy in this manuscript should be 
considered in this perspective. 
 
This study was carried out in a chronic hemodialysis population, 
intermittently treated with erythropoietin (EPO). Theoretically EPO-
treatment could have influenced the red cell creatine content, as EPO 
enhances the red cell creatine concentrations (Schmidt et al., 1990). The 
red cell creatine concentrations in this study were determined to confirm 
the creatine uptake in the body and not as a marker for muscular creatine 
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concentrations. Recent evidence points out that the red cell creatine 
content is a poor marker for the muscular creatine content and should 
therefore not be used as a surrogate marker (Preen et al., 2005).  
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Abstract 
 
The effect of oral creatine supplementation (CR; 5 g/day) in conjunction 
with exercise training on physical fitness was investigated in men between 
55 and 75 yr of age (n = 46). A double-blind randomized placebo-
controlled (PL) trial was performed over a 6-mo period. Furthermore, a 
subgroup (n = 20) completed a 1-yr follow-up. The training program 
consisted of cardiorespiratory endurance training as well as moderate 
resistance training (2–3 sessions/wk). Endurance capacity was evaluated 
during a maximal incremental bicycle ergometer test, maximal isometric 
strength of the knee-extensor muscles was assessed by an isokinetic 
dynamometer, and body composition was assessed by hydrostatic 
weighing. Furthermore, in a subgroup (PL: n = 13; CR: n = 12) biopsies 
were taken from m. vastus lateralis to determine total creatine (TCr) 
content. In PL, 6 mo of training increased peak oxygen uptake rate 
(+16%; P < 0.05). Fat-free mass slightly increased (+0.3 kg; P < 0.05), 
whereas percent body fat slightly decreased (-1.2%; P < 0.05). The 
training intervention did not significantly change either maximal isometric 
strength or body weight. The responses were independent of CR. Still, 
compared with PL, TCr was increased by  5% in CR, and this increase was 
closely correlated with initial muscle creatine content (r = -0.78; P < 
0.05). After a 1-yr follow-up, muscle TCr was not higher in CR than in PL. 
Furthermore, the other measurements were not affected by CR. It is 
concluded that long-term creatine intake (5 g/day) in conjunction with 
exercise training does not beneficially impact physical fitness in men 
between 55 and 75 yr of age. 
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Introduction 
 
A primary strategy to optimize health in older people is to prevent potential 
medical problems from reaching an overt clinical state (29). In this 
respect, research over the last 20–30 yr has clearly shown that increasing 
the level of physical activity is an effective intervention to alleviate the 
normal deterioration of health-related fitness parameters (35), which 
include functional capacity of the musculoskeletal and cardiovascular 
system, body composition, and metabolic health (8). Resistance training 
can reduce the pace of age-related muscle atrophy and the concomitant 
decline of muscular functional capacity (19, 21, 28). The latter is very 
critical to maintain the ability to perform activities of daily living. 
Furthermore, endurance exercise training can enhance cardiorespiratory 
fitness in older people (14). Endurance training also reduces cardiovascular 
risk by beneficially impacting cardiovascular risk factors such as adverse 
blood lipid profile, high blood pressure, and impaired glucose tolerance due 
to peripheral insulin resistance (29, 50). Thus published literature provides 
strong evidence to suggest that both aerobic endurance and resistance 
training can beneficially impact physical fitness in older people.  
Another intervention that might contribute to enhance physical fitness in 
older people is oral creatine supplementation (CR). The potential of oral 
creatine (Cr) intake to increase muscle Cr content, and thereby enhance 
muscular performance during short maximal exercise over repeated bouts 
in the young, has been extensively documented over the last 10 yr (47, 
53). The finding that CR can stimulate the beneficial effects of resistance 
training on muscle volume and functional capacity, at least in young 
healthy subjects (5, 27, 34, 48, 50), is interesting in the context of the 
preservation of muscle functional capacity in the elderly. Furthermore, 
consistent with the observations in young healthy subjects, CR has been 
found to enhance muscular functional capacity in patients afflicted by 
neuromuscular diseases (45, 51, 52) as well as in cardiac patients (11, 
22). It has been suggested that older people might respond better to CR 
than young people, because they may have a lower muscle Cr content 
(46). However, literature data are not consistent with regard to the latter 
issue (12, 31, 36, 37), and a recent study (41) has even shown Cr content 
in muscles from older people to be higher than in younger people. 
Furthermore, some earlier studies have found the effects of CR in 
conjunction with resistance training on muscular performance capacity in 
the elderly to be either absent (7, 42), small (11), or moderate (10). 
However, the intervention periods in the latter studies were short (7 days 
to 14 wk) relative to the need for long-term physical activity in the older 
population. Moreover, the training interventions used in the above studies 
involved only heavy resistance training. However, in older persons, a 
mixed training program combining both cardiorespiratory stimulation and 
moderate resistance training probably is more optimal than selective high-
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load weight training (3, 29). Therefore, to improve our understanding of 
the efficacy of Cr intake as a potential ergogenic aid in the older 
population, it is warranted to evaluate the effects of long-term Cr intake in 
conjunction with an exercise training program involving both endurance 
training and moderate resistance training (47).  
 
Long-term Cr intake currently is being promoted as a health-enhancing 
substance. At present, however, no study has investigated the impact of 
long-term (12 mo) low dose (5 g/day) Cr intake on a variety of safety 
parameters. Because knowledge regarding the occurrence of adverse side 
effects after the supplementary intake of any "ergogenic" substance is 
essential, it is necessary to investigate this matter. Furthermore, some (1, 
17), but not all (49), studies have reported CR in combination with 
resistance training to have a cholesterol-lowering effect. Because of the 
high prevalence of elevated blood cholesterol at older age, it is therefore 
warranted to further investigate the potential cholesterol-lowering effect 
after long-term Cr intake.  
 
Therefore, the purpose of the present study was to evaluate whether long-
term Cr intake in conjunction with exercise training in older men is safe 
and can have a beneficial impact on physical fitness, including muscle 
strength and cardiorespiratory endurance.  
 
Methods 
 
Subjects  
Subjects were recruited from the staff (active or retired) at the local 
university. Men older than 55 yr were invited to participate in a meeting 
aimed to explain the purpose and details of the study protocol. Within the 
next week, 57 subjects, who met the inclusion criteria, volunteered to 
participate in the study. After being informed of all the experimental 
procedures to be undertaken, they gave their written, informed consent 
and were enrolled in the study. Inclusion criteria were 1) men between 55 
and 75 yr of age; 2) no participation in strength training for at least 5 yr; 
3) participation in low-intensity physical activity, such as gardening and 
walking, for <4 h/wk; and 4) no history of oral Cr intake. All volunteers 
underwent a preliminary clinical examination and were submitted to an 
electrocardiogram (ECG)-controlled maximal exercise test. Exclusion 
criteria on admission were prehistory of kidney disease, albuminuria, 
consistent intake of any medication known to impair exercise capacity, and 
any disease contraindicating high-intensity exercise training. From the 57 
volunteers screened, 11 were excluded because of a significant ST 
depression (1.5 mm or more; n = 4), complicated ventricular arrhythmias 
(n = 3), arterial fibrillation (n = 1), hypertension (n = 2), and ECG-
diagnosed posterior myocardial infarction (n = 1). Subjects were asked to 
 90
avoid changes in their diet and level of physical activity (except for the 
fitness training program prescribed by the study protocol), and to maintain 
constant living habits during the period of the study.  
 
Study Protocol  
 
The local ethics committee approved the study protocol. A double-blind 
study was performed over a 1-yr period that involved two phases (phase I: 
0–6 mo; phase II: 6 mo to 1 yr). Baseline measurements were performed 
on 3 separate days, each separated by a 2-day interval. On day 1, after a 
standardized warm-up, subjects performed an exercise test on an 
isokinetic dynamometer to evaluate maximal torque and fatigue of the 
knee extensor muscles. Test-retest reliability for these torque 
measurements was 0.93 (intraclass correlation [2,1]). Immediately 
afterward, body composition was assessed in the seated position by 
hydrostatic weighing. On day 2, subjects reported to the laboratory for a 
maximal incremental exercise test on an electromagnetically braked bicycle 
ergometer. Finally, on day 3, the subjects reported to the laboratory in the 
morning after an overnight fast. A blood sample was taken from an 
antecubital vein into heparinized tubes (Vacutainer) for clinical 
biochemistry. Furthermore, in a subgroup of subjects, a muscle biopsy was 
taken from the vastus lateralis muscle under local anesthesia for 
biochemical and histochemical analysis on day 4. After the baseline 
measurements, subjects were coupled into pairs that were matched for 
age, maximal isometric knee-extension torque, and peak oxygen uptake ( 
O2peak). Thereafter, each pair was assigned, in a double-blind manner and 
by an independent investigator who was otherwise not involved in the 
study, to either a PL (n = 23; age: 62.2 ± 1.3 yr: body weight: 81.3 ± 2.5 
kg) or a CR (n = 23; age: 63.9 ± 1.1 yr; body weight: 79.2 ± 2.3 kg) 
group.  
After baseline measurements, subjects were enrolled in a well-controlled 
and supervised fitness training program. The training-program aimed to 
increase cardiorespiratory fitness as well as enhance strength of the 
abdominal and back muscles and the primary peripheral muscle groups. 
During phase I, subjects were instructed to participate in 10 training 
sessions per 4-wk "window." To ensure adequate recovery between 
training sessions, training sessions were interspersed by at least 1 rest 
day. Each training session ( 75 min) started with two endurance exercise 
bouts, which first involved bicycle ergometry (12 min) and thereafter 
treadmill walking/jogging or rowing ergometry (12 min). To monitor the 
training workload, exercise intensity was controlled by heart rate 
monitoring. Exercise intensity was initially set at 65% of the individual 
heart rate reserve (Karvonen formula) and was increased gradually to 80% 
of heart rate reserve toward the end of the training period. The bicycle 
ergometers and treadmills used (Technogym) automatically estimated the 
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number of calories spent during the exercise performed. These values were 
noted in the individual training diary. For the rowing ergometry, resistance 
was fixed and the estimated distance covered was noted in a training 
diary. The latter values were later used as a global measure to compare 
the amount of endurance work performed between groups. After the 
endurance training bouts, the subjects started a moderate-resistance 
weight training session. They performed seven exercises (sit-ups, arm curl, 
back extension, leg extension, leg press, vertical row, and lateral pull on 
Technogym gym apparatus). Each exercise consisted of two series of 30 
repetitions at 30-repetition maximum (RM) workload. To monitor training 
workload, subjects were instructed to note the resistance used (in kg) in 
their training diary for the two series of each exercise.  
From the start of the training program, CR received 5 g of Cr monohydrate 
tablets per day, whereas the placebo-controlled (PL) group received 
placebo tablets. On nontraining days, subjects ingested one tablet before 
breakfast, three before lunch, and one before dinner. However, on training 
days, the 3-g dose was to be ingested immediately after the training 
session. Hence, before lunch and dinner on morning training days, and 
before breakfast and lunch on evening training days, subjects ingested one 
tablet. After 3 and 6 mo, and at least 48 h after their last training session, 
subjects returned to the laboratory to participate in the same 
measurements as at baseline. However, at 3 mo, no muscle biopsy was 
taken. At each occasion, the tests were performed at the same time of day 
and by the same investigator. At the end of phase I, subjects were asked 
to either engage for an additional 6 mo of follow-up (phase II) or to 
withdraw from the study. Thirty-six subjects agreed to continue 
participating in the study (PL: n = 21, age: 61.8 ± 1.3 yr; CR: n = 15, 
age: 65.3 ± 1.3 yr) and 10 withdrew (PL: n = 2; CR: n = 8). Thus, in 
phase II of this study, subjects were not randomly selected but instead 
voluntarily chose to remain in the study. To enhance training compliance 
on the one hand and to meet the expectations by the subjects on the 
fitness training on the other hand, the training protocol was slightly 
adapted. Minimum training rate was reduced from 10 to 8 sessions per 4-
wk window. Furthermore, every third training session workload for the 
weight-lifting exercises was increased from 30 to 20 RM. Finally, the 
duration of the endurance exercise bouts was increased from 12 to 15 min. 
Otherwise the study protocol was identical to phase I of the study. After 12 
mo, subjects returned to the laboratory to participate in the same 
measurements as at baseline. However, muscle biopsies were only taken 
at the end of the study and only in the subjects who had been biopsied in 
phase I. At each occasion (phase I and phase II), tests were performed at 
the same time of day and by the same investigator. None of the study 
results were disclosed to either the subjects or to the investigators until 
the end of the entire study.  
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Maximal Exercise Testing and Spirometry  
The maximal exercise tests on an electromagnetically braked bicycle 
ergometer (Ergometrics model 800S, Bitz, Germany) were performed in a 
laboratory where room temperature was stabilized at 18–22°C. At the 
occasion of the first test, seat height was noted and reproduced for all 
subsequent tests. Subjects first rested for 10 min in the upright seated 
position on the ergometer, where their blood pressure was measured by 
using an automated sphygmomanometer (model STBP-780, Colin, Komaki, 
Japan). Thereafter, the exercise test was started at an initial workload of 
20 W, which was increased by 20 W every minute until volitional 
exhaustion. During the test, a 12-lead ECG (Marquette, WI) was 
continuously monitored. Furthermore, ventilation and oxygen and carbon 
dioxide concentrations in the inspired and expired air were continuously 
measured by a calibrated breath-by-breath system (Oxycon Alpha, Jaeger-
Mijnhardt, Bunnik, The Netherlands) and oxygen uptake ( O2), carbon 
dioxide output ( CO2), and the respiratory gas exchange ratio (RER;  CO2/ 
O2) were automatically calculated. The Vslope threshold, to be used as an 
estimate of the "anaerobic threshold" in the context of this manuscript, 
was determined as the exercise intensity corresponding with the transition 
of the RER relationship from a linear to an exponential curve (4).  
 
Determination of Maximal Dynamic Knee-Extension and Isometric 
Force  
Maximal voluntary torque and power of the knee extensors was evaluated 
on an isokinetic dynamometer that consisted of a computer-controlled 
asynchronous electromotor (AMK Dynasyn, 19 kW), instrumented with a 
torque transducer (Lebow, maximal torque 565 N•m, 0.05% precision). 
The exercise test consisted of unilateral knee extensions performed in a 
semisupine sitting position on the dynamometer. After a 5-min 
standardized warm-up, the subjects performed two voluntary maximal 
isometric contractions (3 s), interspersed by 2-min rest intervals, at knee 
angles of 90, 110, and 130°, respectively. Maximal isometric torque (in 
N•m) was obtained from the smoothed curve of the static torque and was 
calculated as the average of the three knee angles (90, 110, and 130°). 
Thereafter, subjects performed two bouts of 30 dynamic maximal 
voluntary knee extensions, interspersed by a 2-min rest interval, at a 
constant velocity of 180°/s, starting from 90° to full extension (180°). 
After each contraction, the leg was returned (180°/s) passively to the 
starting position from which the next contraction was immediately initiated. 
Torque and angular velocity were measured during each contraction and 
were simultaneously digitized (250 Hz) by an on-line computer.  
 
Body Composition  
Body composition was assessed in the seated position by hydrostatic 
weighing. Residual lung volume was measured by the helium-dilution 
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technique, and gastrointestinal tract air volume was assumed to be 150 
ml. Body density was converted to percent body fat by using Siri's equation 
(43), where percent body fat is equal to [4.95/(density - 4.5)] x 100.  
 
Muscle Biochemistry and Histochemistry  
Muscle samples were obtained from the vastus lateralis muscle of the right 
leg by using the needle biopsy technique. Incisions were made through the 
skin and muscle fascia after the administration of 2–3 ml of local 
anesthesia (lidocaine, 1%). After removal from the limb, a piece of each 
muscle biopsy was immediately freed from blood and visible connective 
tissue, rapidly frozen in liquid nitrogen, and stored at -80°C for subsequent 
biochemical analysis. The remaining muscle was mounted in embedding 
medium, frozen in isopentane, cooled to its freezing point in liquid 
nitrogen, and stored at -80°C until analyses were performed at a later 
date. For muscle substrate assays, muscle samples were freeze-dried. 
Thereafter, a portion (3–5 mg) of each sample was dissected free of visible 
blood and connective tissue. Muscle ATP, free Cr, and phosphocreatine 
(PCr) contents were analyzed from perchloric acid precipitated extractions 
by using standard fluorometric assays (6). Because muscle ATP content 
normally does not change as a result of the interventions or treatments 
used, free Cr and PCr content was corrected for the individual mean ATP 
content over the time points. Total Cr (TCr) content was calculated by 
summing free Cr and PCr content. For the histochemical analyses, serial 
transverse sections (10 µm) were cut from the biopsies with a microtome 
at -20°C and stained for myofibrillar ATPase to identify fiber types (9).  
 
Clinical Chemistry  
Routine blood and urine clinical screening tests were performed during the 
course of the study. The serum samples were immediately transferred to a 
local routine clinical biochemistry laboratory for determination of white and 
red blood cells, hemoglobin, hematocrit, mean cell volume, mean cell 
hemoglobin, mean cell hemoglobin concentration, and red cell distribution 
width by using a Beckman-Coulter autoanalyzer, and of glutamate oxalate 
transaminase, glutamate pyruvate transaminase, alkaline phosphatase, Cr 
kinase, urea, and urate by using a Hitachi autoanalyzer both running on 
Roche diagnostic reagents. All plasma samples and a fraction of the 24-h 
urine samples were stored at -20°C to be analyzed at the end of the study. 
Plasma and urinary Cr concentrations were measured by a standard 
enzymatic fluorometric assay (6). Plasma and urinary creatinine 
concentration were assayed by a rate-blanked kinetic Jaffé-based method 
(alkalic picrate, Roche Diagnostics).  
In the subgroup that completed the 1-yr follow-up, we also measured 
blood lipids. Total cholesterol, triglycerides, and high-density lipoprotein 
(HDL) cholesterol were analyzed using a cholesterol oxidase-based 
method, after which lowdensity lipoprotein (LDL) cholesterol was calculated 
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according to the following formula: total cholesterol - HDL-cholesterol - 
(triglicerides/5).  
 
Statistical Analyses  
Separate statistical analyses were performed on the data in the total group 
of subjects (phase I, 6-mo follow-up; n = 46) and on the subgroup that 
also participated in phase II of the study (phase I and II, 1-yr follow-up; n 
= 20). Missing data ( 5% for the muscle histochemistry and blood 
biochemistry data;  2% for all other data) were imputed according to the 
null hypothesis. Phase I data were analyzed according to the "intention-to-
treat" principle. Phase I and II data were analyzed according to the "as-
treated" principle. Treatment effects were evaluated by using two-way 
analyses of variance that were covariate adjusted for the baseline value 
(Statistica, Statsoft, Tulsa, OK). When appropriate, Tukey's post hoc tests 
were applied. In addition, we also performed a one-way analysis of 
variance to compare within the groups the baseline values with the values 
obtained after 3, 6, and 12 mo of follow-up. The relationship between 
variables was calculated by using Pearson's correlation coefficient. 
Statistical significance was taken at a probability level of P < 0.05. All data 
are expressed as means ± SE. 
 
 
Results 
 
Training Compliance  
Six-month follow-up. The number of training sessions completed was 
similar between PL (56 ± 3 training sessions) and CR (59 ± 2 training 
sessions). Furthermore, the total number of calories spent in walking 
and/or running (PL: 4,420 ± 370 kcal; CR: 4,340 ± 210 kcal) and bicycling 
(PL: 6,880 ± 410 kcal; CR: 6,560 ± 280 kcal), as well as the total 
estimated distance covered during rowing ergometry (PL: 56 ± 5 km; CR: 
58 ± 4 km) did not differ between groups. Workloads for leg extension and 
arm curl, the two exercises that were obligatory throughout the training 
period, were similar between PL and CR both during the initial 4 wk of the 
6-mo training period (PL leg extension: 27 ± 2 kg, arm curl: 16 ± 1 kg; CR 
leg extension: 29 ± 2 kg, arm curl: 16 ± 1 kg), increasing to the period 
(PL leg extension: 49 ± 5 kg, arm curl: 27 ± 2 kg; CR leg extension: 49 ± 
5 kg, arm curl: 26 ± 2 kg) during the final 4 wk (P < 0.05).  
One-year follow-up. The number of training sessions completed during 
phase I was 67 ± 2 in both PL and CR. Furthermore, the number of 
calories spent in walking and/or running (PL: 5,160 ± 570 kcal; CR: 4,530 
± 260 kcal) and bicycling (PL: 8,200 ± 520 kcal; CR: 7,490 ± 320 kcal), 
and the distance covered during rowing ergometry (PL: 68 ± 9 km; CR: 69 
± 5 km) did not vary between groups. During phase II of the study, 
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minimum training rate was reduced from 10 to 8 sessions per 4-wk 
training cycle. Hence, compared with phase I, the number of training 
sessions completed decreased (PL: 41 ± 3 training sessions; CR: 46 ± 2 
training sessions). Compared with PL (3,020 ± 420 kcal), the number of 
calories spent in walking and/or running was higher (P < 0.05) in CR 
(3,940 ± 280 kcal). However, neither the number of calories spent in 
cycling (PL: 6,220 ± 600 kcal; CR: 6,430 ± 530 kcal) nor the distance 
covered during rowing (PL: 59 ± 7km; CR: 56 ± 6 km) was different 
between PL and CR. Workloads for leg extension and arm curl during the 
first 4-wk training period were similar in PL (leg extension: 28 ± 3 kg; arm 
curl: 17 ± 2 kg) and CR (leg extension: 31 ± 3 kg; arm curl: 16 ± 1 kg). 
Six months of training increased leg extension and arm curl workloads by  
75% in either group. At month 12, compared with baseline, leg extension 
workload was increased by another  15% in both PL and CR (P < 0.05), 
whereas arm curl workload was decreased by  20% in both groups (P < 
0.05).  
 
Side Effects  
All subjects underwent cardiological screening, including stress ECG 
testing, before the start of the study. Still, during phase I of the study, five 
subjects (4 in CR vs. 1 in PL; P value not significatnt) developed significant 
ST depression at the occasion of the exercise test at either month 3 (n = 
3) or month 6 (n = 2). Three of these subjects were immediately treated 
by coronary balloon dilatation (percutaneous transluminal coronary 
angioplasty). Thereafter, they participated in a cardiac rehabilitation 
exercise program for 1 mo and eventually resumed the experimental 
training program. Within 1 mo after resuming the training program, they 
reached the same intensity level as before treatment, yet they did not 
exhibit ST depression in any later exercise test. The two other subjects 
were instructed to quit the training study and were enrolled in a 
cardiovascular rehabilitation program after having received the appropriate 
treatment. Furthermore, during the study, one subject of the CR group was 
afflicted from overuse trauma at the level of the left shoulder joint. This 
subject continued to follow the exercise training program except for the 
weight-lifting exercises involving shoulder activity. However, after 
appropriate physiotherapy (6 wk), this subject also resumed the latter part 
of the training program.  
 
Cardiorespiratory Measurements  
Six-month follow-up. At the start of the study,  O2, workload, heart rate, 
and RER at Vslope threshold (VT) intensity as well as at exhaustion (peak) 
were similar between groups (Table 1). In PL, 3 and 6 mo of training 
increased  O2 at VT intensity by  27 and 19%, respectively (P < 0.05). At 
peak intensity, corresponding increases in  O2peak were 13 and 16% (P < 
0.05). Compared with baseline, workload at VT was increased by 16% 
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after 3 mo of training (P < 0.05) but not after 6 mo [+3%; not significant]. 
Peak workload was increased by  7 and 11% at 3 and 6 mo, respectively (P 
< 0.05).  O2 and workload corresponding with either VT or peak were not 
significantly different between PL and CR at any time of the study. 
Furthermore, heart rate and RER at VT and peak were similar between PL 
and CR after both 3 and 6 mo of training. At baseline, resting diastolic (PL: 
84 ± 2 mmHg; CR: 80 ± 2 mmHg) and systolic blood pressures (PL: 139 ± 
3 mmHg; CR: 136 ± 3 mmHg) were similar in PL and CR. Compared with 
PL (138 ± 5 mmHg), 3 mo of training decreased systolic pressure in CR 
(125 ± 2 mmHg; P < 0.05). However, this difference had disappeared by 6 
mo of training. Diastolic blood pressure was not different between the 
experimental groups at any time of the study.  
 
 
 
 
 
Table 1. Effect of creatine intake in conjunction with fitness training on 
cardiorespiratory endurance in men 55-75 yr old 
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One-year follow-up. As shown in Table 1,  O2, workload, heart rate, and 
RER values measured at both VT and peak, at 0, 3, and 6 mo of training, 
were nearly identical in the total groups of subjects (6-mo followup) and in 
the subgroup of subjects who completed the 1-yr follow-up. Compared 
with baseline, in PL at the end of the 1-yr training period,  O2peak was 
increased by 20% (P < 0.05). However, neither  O2 at VT intensity nor 
workload at VT and peak at the end of the study were different from 
baseline values.  O2, workload, heart rate, and RER at VT and peak were 
similar between PL and CR at any time of the study. Furthermore, neither 
the training nor Cr intake per se significantly impacted blood pressure.  
 
Muscle Force Measurements  
Six-months follow-up. At baseline, maximal isometric knee extension force 
(Fmax) was 143 ± 7 N•m in PL vs. 140 ± 7 N•m in CR (not significant) 
(Fig. 1). In PL, the training intervention increased Fmax by  7% to 153 ± 8 
N•m by 3 mo (P < 0.05); yet at 6 mo, values had reverted to baseline 
(146 ± 8 N•m). Fmax values in CR (3 mo: 146 ± 7 N•m; 6 mo 136 ± 8 
N•m) were similar to PL at any time of the study. Dynamic force and 
fatigue were measured during an exercise test that consisted of two bouts 
of 30 maximal contractions with a 2-min rest pause in between. Because 
power curves were independent of either training or CR, Table 2 only 
shows mean dynamic torque outputs per bout. In PL, power output after 3 
and 6 mo of training was not significantly different from baseline. Dynamic 
torque curves during either bout 1 or 2 were similar between PL and CR at 
any time of the study.  
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Fig. 1. Effect of creatine intake in conjunction with fitness training on static force 
of the knee extensor muscles in men 55–75 yr of age.  
 
Values are means ± SE of 23 and 10 observations for the 6-mo (A) and 1-
yr follow-up (B), respectively. Maximal isometric torque of the knee 
extensor muscles of the right leg was assessed using an isokinetic 
dynamometer before (baseline) and after 6 and 12 mo of fitness training 
combined with either placebo (open bars) or creatine intake (5 g/day; solid 
bars). *P < 0.05 and  P = 0.08 compared with the corresponding baseline 
value. See METHODS for further details.  
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Table 2. Effect of creatine intake in conjunction with fitness training on dynamic 
force of the knee extensor muscles in men 55-75 yr old  
 
 
 
 
 
  
One-year follow-up. Changes in Fmax during the initial 6 mo of the follow-up 
mirrored the changes measured in the total group of subjects. However, 
because of the smaller number of observations, the increase (+4%) in 
Fmax after 3 mo of training was not statistically significant. Accordingly, 
Fmax at the end of the study was similar to baseline. Dynamic torque 
outputs during the dynamic fatigue test were not altered either by the 
training per se or by CR.  
 
Body Composition  
Six-months follow-up. Baseline values for body weight, percent body fat, 
and fat-free mass were similar between PL and CR (Table 3). Compared 
with baseline, body weight tended to decrease by 6 mo of training in PL (P 
= 0.07), whereas it was stable in CR. However, analysis of covariance did 
not yield a significant treatment effect for body weight. In PL, percent body 
fat slightly decreased by 6 mo of training (-1.1%, P < 0.05), whereas fat-
free mass slightly increased (P < 0.05). Training-induced changes of both 
percent body fat and fat-free mass were similar between PL and CR.  
 
Table 3. Effect of creatine intake in conjunction with fitness training on body 
composition in men 55-75 yr old  
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One-year follow-up. Changes of body weight, percent body fat, and fat-free 
mass up to 6 mo follow-up paralleled changes observed for the total group 
of subjects. Compared with baseline, in PL at the end of the study, body 
weight and fat-free mass were not significantly changed. However, percent 
body fat was decreased by 1.7% (P < 0.05). There were no significant 
differences for the body composition measurements between PL and CR at 
any time of the study.  
 
 
Muscle Biochemistry and Histochemistry  
Six-months follow-up. Muscle Cr, PCr, and TCr content at baseline were 
similar between PL and CR, yet ATP content was slightly higher in CR (P < 
0.05) (Table 4). Furthermore, in PL, values at month 6 were similar to 
baseline. In CR, compared with baseline, Cr (+21%, P < 0.05) and TCr 
(+5%, P = 0.07) increased, whereas PCr and ATP were stable. As shown in 
Fig. 2, a high negative correlation (r = -0.78, P < 0.05) was found between 
initial muscle TCr and the increase of muscle TCr produced by 6 mo of CR.  
 
 
 
 
Table 4. Effect of creatine intake in conjunction with fitness training on muscle 
biochemistry in men 55-75 yr old  
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Fig. 2. Correlation between the individual changes in muscle total creatine content 
and initial muscle total creatine content after 6 mo of creatine supplementation in 
men 55–75 yr of age. Muscle biopsies (n = 12) were taken from the m. vastus 
lateralis of the right leg before and after 6 mo of fitness training combined with 
creatine intake (5 g/day). Total creatine was calculated as the sum of creatine and 
phosphocreatine values. dw, Dry weight. See METHODS for further details.  
 
One-year follow-up. Muscle ATP, Cr, PCr, and TCr content at 0 and 6 mo 
were similar to the values found in the total group of subjects. However, 
because of the smaller number of observations, changes were not 
statistically significant. In PL, at the end of the 1-yr training intervention, 
ATP, Cr, PCr, and TCr values were similar to baseline. Conversely, in CR 
compared with baseline, PCr and TCr were 20–25% higher (P < 0.05), 
whereas Cr and ATP were unchanged. However, no statistically significant 
treatment effects for either PCr or TCr were detected. Because of the 
labor-intensive nature, histochemical analyses were only performed in 
subjects who completed the 1-yr follow-up and in whom muscle biopsies 
were available (PL: n = 7; CR: n = 6). As shown in Table 5, neither mean 
fiber area nor fiber area relative to total cross-sectional area for either type 
I, IIa, and IIx/b fibers significantly changed during the study in either 
group. Furthermore, in PL, relative type I, IIa, and IIx/b fiber number was 
stable throughout the study. Conversely, in CR compared with baseline, 
the relative distribution of type IIa fibers increased by  40%, whereas type 
IIx/b number decreased by  70% (P < 0.05). However, the latter changes 
were not significantly different from PL.  
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Table 5. Effect of creatine intake in conjunction with fitness training on muscle 
histochemistry in men 55-75 yr old  
 
 
 
  
Clinical Chemistry (Data Not Shown)  
To investigate the safety profile of long-term Cr intake, routine blood and 
urine clinical chemistry screening tests were performed during the 6-mo 
and 1-yr follow-up. All values remained within the normal clinical range 
throughout the study, with no significant differences between PL and CR. 
In CR, urinary Cr excretion obviously increased from 0.76 ± 0.12 g/24 h at 
baseline to 3.46 ± 0.26 g/24 h throughout the 1-yr period of CR. During 
the course of the 1-yr intervention period, plasma Cr concentration also 
slightly increased from 1.13 ± 0.02 mg/dl at baseline to 1.24 ± 0.04 
mg/dl. Blood lipids were only measured in the 1-yr follow-up group. There 
were not differences either within or between the groups for total 
cholesterol, HDL-cholesterol, and LDL-cholesterol at any time of the study. 
However, at 12 mo of training, compared with PL (141 ± 18 mg/dl), 
triglycerides were lower (P < 0.05) in CR (88 ± 14 mg/dl).  
 
Discussion 
 
In this study, we investigated the potential of oral CR to improve physical 
fitness (8) in older men. Increasing the level of physical activity is a first-
line strategy to improve fitness in older people (8, 29, 44). It is known 
from studies in young volunteers that CR can enhance the beneficial effects 
of resistance training on muscular functional capacity (48, 50). Therefore, 
we used CR as a "therapeutic" intervention additive to an exercise training 
program. Our data show that long-term oral Cr intake at a rate that has 
been proven to be effective in young subjects, does not enhance physical 
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fitness in older men.  
Functional capacity of skeletal musculature is an important component of 
physical fitness (8). Deterioration of muscle performance capacity due to 
atrophy can reduce mobility and thus impair the quality of life in older 
individuals. On the basis of recent observations in young healthy 
volunteers (27, 34, 48, 50), it was reasonable to assume that CR might 
stimulate the effects of resistance exercise training on muscle force and 
power output in the elderly (46). We assessed static and dynamic strength 
of the knee extensor muscles on an isokinetic dynamometer. The training 
program, which among other exercises involved weight-lifting exercises for 
the knee extensors (leg press and leg extension), slightly increased Fmax 
most prominently during the initial stage of the training intervention. 
Hereafter, Fmax surprisingly normalized, despite regular training 
attendance ( 2.5 training sessions/wk) and normal progress of the training 
intensity. At present, it is unclear why by 6 mo of training the adaptations 
that had been elicited with 3 mo of training had been lost. Furthermore, Cr 
intake did not beneficially impact muscle force and power production, 
either in the total group of subjects (6-mo follow-up) or in the subgroup of 
subjects completing the full 1-yr training intervention (see Fig. 1). There is 
evidence from one study (50) to indicate that CR may enhance the effects 
of a resistance training program on muscle strength by facilitating the 
progress of training workloads. However, analysis of the training diaries 
showed that workloads of the weight-lifting exercises were similar between 
the placebo and CR subjects at any time of the study. Consistent with our 
present findings, one earlier study, performed by Bermon et al. (7), found 
no benefit to combining 8 wk of heavy resistance training with Cr intake in 
older persons. Conversely, two other studies reported improved muscle 
strength characteristics after either 12 (11) or 14 wk (10) of Cr intake in 
conjunction with a heavy resistance training program in men >60 yr old 
(11).  
Another factor contributing to physical fitness as well as health is body 
composition (8). Increased fat-free mass relative to fat mass, by virtue of 
the high potential of energy turnover in skeletal muscle tissue, can 
significantly contribute to improved health status. There is evidence from 
long-term CR studies to indicate that supplementary oral Cr intake in 
conjunction with resistance training can stimulate muscle hypertrophy (27, 
34, 47, 48, 50). Fat-free mass, assessed by hydrostatic weighing, was only 
marginally increased by the resistance training program used, and there 
was no additional benefit from the ingestion of Cr (Table 3). Accordingly, 
fat mass and body weight were not affected by CR. Thus the older subjects 
enrolled in this study clearly did not exhibit the increase of body weight 
inherent to CR in samples of young subjects (26, 30, 47). In fact, the 
failure of CR to increase fat-free mass probably also largely explains the 
unchanged Fmax.  
Functional capacity of the cardiorespiratory system also is an important 
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factor contributing to physical fitness. We evaluated cardiorespiratory 
fitness by means of a maximal exercise test on a bicycle ergometer. In 
fact, there is no clear rationale from literature data to anticipate that CR 
might enhance endurance exercise capacity (26, 30, 47). However, 
because the ability to cope with high workloads in cycling in older 
individuals is often limited by peripheral muscle weakness rather than by 
cardiorespiratory factors (2), we assumed that CR in this population might 
enhance cycle performance in both training and testing. However, training 
workloads were identical between groups from the start to the end of the 
study. Furthermore, indexes of submaximal and maximal endurance 
exercise performance during the maximal exercise test were significantly 
improved by the training intervention, yet were independent of CR.  
Our present findings clearly indicate that the potential of CR to enhance 
muscular functional capacity, which is explicit in samples of young healthy 
volunteers (26, 30, 47, 48), is absent in the population of men between 55 
and 75 yr of age studied here. Two obvious arguments can be cited to 
explain the apparently differential response of younger and older 
individuals to CR. First, it is well established that low initial muscle Cr 
content predisposes to good responsiveness to CR (24, 25). In the present 
study, we showed a similar relationship also to exist in older individuals: 
CR produced the largest increase of muscle TCr content in these subjects 
with the lowest initial values (see Fig. 2). However, because mean initial 
TCr contents were substantially higher [140–145 mmol/kg dry wt (dw)] 
than common values for young healthy subjects (115–125 mmol/kg dw) 
(24, 25), the increases of muscle Cr content due to supplementation on the 
average were very small. Similar findings were reported by Rawson et al. 
(41), who found muscle PCr content to be  20% higher and the response to 
acute CR to be smaller in old (70 ± 3 yr) compared with young (24 ± 1 yr) 
subjects. However, it is important to note that the duration of the present 
intervention trial (1 yr) was substantially longer than any earlier CR study 
in either young volunteers (27, 48) or older subjects (7, 10, 11, 42). In 
this respect, there are some data to suggest that the effects of short-term 
Cr intake may fade on long-term supplementation (13, 27, 48, 50). We 
thus cannot exclude that Cr ingestion produced some beneficial effects on 
muscle performance capacity during the initial stage of the intervention, 
which then disappeared by 6 mo of training. Two studies found 7 days (23) 
and 8 wk (11) of CR to cause a small increase of dynamic and isometric 
muscle force in elderly subjects. Accordingly, Brose et al. (10) recently 
demonstrated that, compared with placebo, CR in conjunction with 14 wk 
of heavy resistance training increased fat-free mass and isometric knee 
extention torque in male subjects by  3 and 25%, respectively. However, 
these investigators also reported that the gain in isometric ankle 
dorseflexion torque in female subjects after combined Cr intake and 
resistance training was smaller compared with their placebo counterparts.  
Some (1, 17), but not all (49), studies have reported CR in combination 
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with resistance training to have a cholesterol-lowering effect. In this study 
in older individuals, we could not demonstrate a beneficial effect of 
supplementary Cr intake on either blood total cholesterol or on the HDL- 
and LDL-cholesterol fractions measured by routine clinical screening tests. 
Cholesterol levels were stable in either experimental group throughout the 
study, which also indicates that the exercise training-program per se did 
not alter blood lipid profile. This is probably explained by the fact that the 
training volume did not meet the threshold to decrease blood lipids (15, 
16).  
Long-term data with regard to potential adverse side effects of CR are very 
scarce. With the exception of two negative case reports in patients with 
preexisting renal disease (33, 40) and one study in Sprague-Dawley rats 
serving as a model for cystic renal disease (18), data to prove that CR per 
se could harm renal function in healthy individuals are entirely lacking (38, 
39). In the present study, Cr intake at a rate of 5 g/day for 1 yr did not 
alter urinary albumin excretion. Furthermore, Cr ingestion produced a 
small, yet insignificant, increase of plasma Cr concentration in the early 
stage of the intervention period, but no further increase was observed from 
month 3 to month 12 of the study. However, four subjects of the Cr group 
vs. only one in the placebo group ( 2 test; not significant) developed ST 
depression during ECG stress testing during phase I of the intervention. 
Although the incidence of ST depression was not statistically significant 
between the experimental groups, this issue deserves particular attention 
in future studies, in particular in subjects at risk of or afflicted by 
cardiovascular disease.  
It may be argued that CR did not enhance muscular functional capacity 
because the resistance training workloads used (20–30 RM) were too low. 
Indeed, it is clearly established that high workloads (5–10 RM) are needed 
for resistance training to produce muscle hypertrophy in older individuals 
(20, 21). Therefore, we cannot exclude that older persons involved in 
heavy resistance training, in contrast with the moderate resistance plus 
cardiorespiratory training program used in the present study, still might 
benefit from Cr intake. However, only a marginal fraction of the older 
population is involved in heavy resistance training. In fact, the training 
volume and intensity used in this study even largely exceed the level of 
physical activity typical to the vast majority of the sedentary Western older 
population, and there is no evidence from literature data that long-term CR 
alone, in the absence of exercise training, can beneficially impact 
neuromuscular performance capacity. In addition, the potential of exercise 
training programs to improve performance-related measures of functional 
capacity in older individuals as a rule is small (32), which is in keeping with 
our present observations.  
In conclusion, the present study clearly shows that CR at a rate of 5 g/day 
is not an effective intervention to enhance physical fitness in men 55–75 yr 
of age enrolled in an exercise training program involving both endurance 
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exercise and moderate resistance training.  
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Abstract 
 
Background: Chronic renal failure is accompanied with muscle dysfunction 
and myopathy, characterized by muscle weakness and increased fatigue. 
Myosin heavy chain (MHC) is the principal structural protein that controls 
the intrinsic contractile properties of striated muscle.  Creatine is widely 
used as an ergogenic nutritional supplement in sportsmen. This study 
investigates the effect of creatine supplementation on the myosin heavy 
chain expression in the setting of  uraemic myopathy.  
 
Methods: Male Wistar rats were either sham-operated or subtotal 
nephrectomized and received a control diet or creatine (2% w/w) 
supplemented diet. After 4 weeks of treatment, serum creatinine, creatine, 
urea and creatinine clearances were determined. MHC isoforms were 
determined electrophoretically in the extensor digitorum longus (EDL) and 
soleus muscle. 
 
Results: Creatinine clearances were lower in nephrectomized animals, but 
similar in creatine supplemented and control diet animals. Nephrectomized 
animals had significantly higher MHC IIb and lower MHC IIx isoform  
expression in the EDL muscle, compared to sham-operated animals. In the 
soleus muscle MHC IIb expression was increased in nephrectomized 
animals. Creatine supplementation reversed the MHC transitions observed 
in uraemia in the soleus muscle, but not in the EDL muscle. 
 
Conclusion: We observed altered expression of MHC isoforms in uraemia. 
Fast MHC IIb isoforms in uraemia were increased, whereas MHC I and IIx 
isoform predominate in control animals. Dietary creatine supplementation 
reversed the altered MHC expression during uraemia in slow-twitch, but 
not in fast-twitch muscle. 
 
Key words:  
Creatine supplementation, myosin heavy chain isoform, end stage renal 
disease 
 
 
Abbreviations 
ESRD, end stage renal disease ;  MHC, Myosin Heavy Chain  
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Introduction 
  
Chronic renal failure and especially dialysis is associated with muscle 
dysfunction [1]. The progressive loss of skeletal muscle mass leads to 
general weakness, low mobility and a general decrease in quality of life. 
Apart from a specific uraemic myopathy, which is mainly caused by an 
abnormal vitamin D metabolism there are numerous other causes of 
muscle dysfunction in uraemia such as inactivity, malnutrition, neuropathy, 
underlying diseases, drugs and ischemia [2]. The progression of uraemic 
myopathy runs parallel with the decline in renal function. Significant 
correlation was described between glomerular filtration rate and muscle 
peak oxygen uptake [3]. Animal studies revealed several biochemical 
abnormalities, such as mitochondrial alterations, disturbed intracellular 
calcium transport, myofibrillar ATPase activity and abnormal nucleotide and 
phosphocreatine concentrations, contributing to disturbances in  force 
generation and muscle wasting [2,3]. Proteolysis is accelerated in the 
uraemic muscle by activation of the ubiquitin-proteasome system through 
metabolic acidosis, low insulin sensitivity and glucocorticoids [4]. 
Muscle contraction is biochemically regulated by interaction between actin 
and myosin [5]. Myosin exhibits enzymatic properties catalyzing ATP 
hydrolysis during contraction. Myosin heavy chain (MHC) is the main 
determinant of the myofibrillar ATPase activity and contractile properties of 
the muscle fiber [6]. Up to nine MHC isoforms have been described in 
mammalian  muscle, exhibiting different ATPase activity and accounting for 
the differences in contractile properties between fast and slow skeletal 
muscles. In adult rodent skeletal muscle four isoforms are generally 
described. MHC I is predominant in slow-twitch muscle and exhibits low 
ATPase activity, whereas MHC IIa, IIx and IIb are fast MHC isoforms with 
increasing ATPase activities. Slow-twitch muscle, with predominant 
expression of MHC I isoforms are more resistant to fatigue, compared to 
fast-twitch muscles with predominant type II fibers. The shortening 
velocity  of the sarcomere however is lower in fibers with predominant MHC 
I, compared to fibers with predominant MHC II. Muscle fiber type is not 
static, but should be regarded as dynamic and capable of changing type in 
response to altered functional demand, innervation or metabolic conditions. 
The fiber type distribution of the muscles is a dynamic state constantly 
adjusting to the current conditions [5,7,8].    
Transitions in  MHC isoforms have been demonstrated in several animal 
models [7,8]. Models resulting in muscle atrophy such as hindlimb 
suspension or weightlessness induce phenotype transitions from slow to 
fast MHC isoforms, whereas models producing hypertrophy exhibit a shift 
in MHC towards slower isoforms. Fiber type transitions generally occur 
gradually and sequentially from slow to fast isoforms (I >IIa>IIx>IIb), or 
in the reverse order, though recent evidence suggests that shifts in MHC 
can  proceed more dramatically and do not need to follow this strict 
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sequence [7,9-10] . In humans, marathon runners and ultra-endurance 
athletes exhibit a remarkably high percentage type I fibers in their major 
muscles, whereas sprinters and power lifters have predominantly IIa/IIx 
fibers. Apart from this training effect, MHC composition of the muscles is 
genetically determined [5,7-8]. 
 
Creatine [11-13] is increasingly popular as an ergogenic supplement in an 
athletic population. Normal dietary intake and endogenous synthesis in 
kidney and liver compensate for a daily loss as creatinine of about 2%. 
Creatine uptake in muscle is mediated by a specific sarcolemmal creatine 
transporter. Intramuscular creatine is phosphorylated to phosphocreatine 
by means of creatine kinase. Phosphocreatine serves as a temporal and 
spatial energy buffer in muscle, preventing a decrease in the ATP/ADP ratio 
during sudden increases in energy expenditure such as muscle contraction 
[11-12]. Furthermore the phosphocreatine/creatine kinase system acts as 
an energy carrier between sites of energy production (mitochondria) and 
sites of energy consumption (e.g. myofibrils). Short- and long-term 
creatine supplementation results in augmented intramuscular creatine 
concentrations and has been associated with increased muscle 
performance during high-intensity exercise in healthy volunteers. In 
addition to these reports in healthy subjects several studies have been 
performed studying the effect of creatine supplementation on muscle 
function in patients with neuromuscular or neurodegenerative diseases, or 
in animal models of these diseases [13-14]. 
 
The present study investigates the expression of MHC isoforms in an 
animal model of chronic uraemia. The effect of uraemia and creatine 
supplementation on MHC transitions in both slow (M. soleus) and fast 
muscles (M. extensor digitorum longus) were studied using animals with 
normal and impaired renal function.  
  
Materials and Methods 
 
Animal procedures 
Male Wistar rats weighing 200-230 g were obtained from Iffa Credo 
(Brussels, Belgium). All animal care was in accordance with local 
prescriptions and the NIH Guide for the care and use of laboratory animals.  
Renal failure was induced by reducing renal mass using a standard 
procedure of subtotal nephrectomy as described before [15-16]. Rats were 
anesthetized with halothane (Fluothane, Astra-Zeneca) and a flank incision 
was made exposing the kidney. The upper and lower pole of the left kidney 
were cryoablated, followed 1 week later by a right nephrectomy. The sham 
procedure consisted of a flank incision without tissue destruction.  
Animals were randomly allocated to 4 groups: 1. sham-operated, control 
diet  (n=10); 2. sham-operated, creatine-supplemented diet (n=10); 3. 
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subtotal nephrectomized, control diet (n=10); 4. subtotal nephrectomized, 
creatine-supplemented diet (n=10). The animals were sedentary and 
provided free access to food and drinking water.  
Creatine-supplementation was started 1 week after the last surgical 
procedure by addition of 2% creatine monohydrate (w/w; Sigma) to the 
diet. Control diet consisted of a soy-based maintenance chow (RM1, 
Special Diet Services, Witham, UK), containing 14 % protein.  
Urine and blood samples were collected at the start and after 28 d of 
creatine-supplementation. Body weight and individual food intake were 
recorded on these occasions.  
Animals were sacrificed by cervical dislocation under pentobarbital 
anesthesia (Nembutal, Sanofi) and hindlimb muscle were quickly excised, 
trimmed of connective tissue and frozen in liquid nitrogen until further 
processing.   
 
Myosin heavy chain isoforms 
Frozen muscles were homogenized by hand in 10 volumes of cold 
homogenization buffer [250 mmol/L sucrose, 100 mmol/L KCl, 5 mmol/L 
EDTA and 20 mmol/L Tris] in glass tissue grinders. The homogenates were 
further processed to prepare washed myofibrils [17]. The washed 
myofibrils were further diluted with sample buffer [62.5 mmol/L Tris (pH 
6.8), 25 % glycerol, 1% sodium dodecyl sulphate, 2.5 % 2-
mercaptoethanol and 0.01% bromophenol blue] and heated for 4 min at 
95° C. 
Myosin heavy chain isoforms were separated and analyzed by sodium 
dodecyl sulphate- polyacrylamide gel electrophoresis (SDS-PAGE) 
according to Talmadge and Roy [18]. Gels were run for 24h at 70 V 
(constant voltage) using 0.75 mm mini-slab gels (Mini-Protean II, 
BIORAD). The stacking gel consisted of 4% bis-acrylamide (1:50), 30% 
glycerol , 70 mmol/L Tris(hydroxymethyl)aminomethane (Tris) (pH 6.8), 4 
mmol/L EDTA and 0.4% SDS. The separating gel was composed of 8 % 
bis-acrylamide (1:50), 30% glycerol, 0.2 M Tris (pH 8.8), 0.1 M glycine 
and 0.4% SDS. Upper running buffer consisted of 100 mM Tris, 150 mM 
glycine and 0.1% SDS. Lower running buffer consisted of 50 mM Tris, 75 
mM glycine and 0.05% SDS. All reagents were of electrophoretic grade. 
Two µg of washed myofibrillar protein were loaded on the gel. Gels were 
stained with Coommasie Blue and scanned and the bands quantitated 
using Gel-Pro analyzer software. The different myosin isoforms were 
identified according to their migration. Myosin heavy chain isoforms were 
determined in both slow (M. soleus) and fast-twitch muscle (M. extensor 
digitorum longus). Both muscles are well characterized and were chosen 
for their opposite contractile characteristics. M. soleus is a model for a slow 
antigravity muscle, whereas M. extensor digitorum longus is a fast non-
weight bearing muscle.   
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Biochemical determinations 
Creatinine clearances. Serum and urinary creatinine concentrations were 
determined using a non-compensated rate-blanked Jaffé method (Roche 
Diagnostics, Mannheim, Germany) on a Modular P analyzer (Roche 
Diagnostics) according to the manufacturer’s procedure. Creatinine 
clearances were calculated based upon 24 h urine collections. Serum urea 
concentrations were determined enzymatically (Roche Diagnostics).  
Serum and urine creatine concentrations were determined enzymatically as 
described before [19]. Total intramuscular creatine concentrations 
(mmol/wet weight) were determined colorimetrically according to Berlet 
[20].  
 
Statistics 
Data are expressed as mean ± SD. Comparison between groups was 
performed using a one-way ANOVA, followed by post-hoc Student-
Newman-Keuls (SNK) testing. Differences were considered significant at p 
≤ 0.05. Correlation between parameters was examined using Spearman 
rank correlation analysis. 
  
Results 
 
Biometrical and biochemical characteristics 
Subtotal nephrectomized animals exhibited lower body mass and renal 
function indices compared to sham-operated animals. No significant 
differences in body weight or food intake were observed between creatine 
supplemented and control diet groups in either subtotal nephrectomized or 
sham-operated groups (Table 1). Creatinine clearance rates were similar in 
creatine supplemented and control diet animals. In the subtotal 
nephrectomized group serum creatinine was higher in creatine 
supplemented animals, compared to control diet animals, whereas no 
differences in serum creatinine concentrations were observed in the sham-
operated group (Table 1). Serum creatine and urinary creatine excretion 
was significantly higher in creatine supplemented animals. Total 
intramuscular creatine concentrations were similar in nephrectomized and 
sham-operated animals, but higher concentrations were observed in 
creatine supplemented animals than in control diet animals [35.9 ± 2.9 
mmol/kg vs. 32.9 ± 3.0 mmol/kg ; p=0.003 (pooled data)].  
 
Muscle mass  
Muscle mass (Table 1)  was signicantly lower in nephrectomized animals in 
both fast [M. extensor digitorum longus 171 ± 17 vs. 183 ± 15 mg; 
p=0.024 (pooled data)] and slow-twitch muscles [M. soleus 141 ± 19 vs. 
158 ± 17 mg ; p=0.005) (pooled data)] . Higher soleus mass was 
observed in creatine supplementated nephrectomized animals compared to 
control diet nephrectomized animals (p≤0.05 (SNK)).  
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Table 1.  Comparative biometrical and biochemical parameters in animals fed a 
control or creatine-supplemented diet with or without preexisting renal 
failure 
 
 
 
 
    
Myosin heavy chain isoform distribution 
Separation of all four adult skeletal MHC isoforms was attained using the 
protocol. A typical electropherogram is illustrated in Figure 1. Subtotal 
nephrectomized animals had a significantly different MHC isoform 
distribution, compared to sham-operated animals (Fig 2). An increased 
proportion of the fast-twitch isoform IIb was observed in control diet 
nephrectomized animals, compared to control diet sham-operated animals 
in both slow-twitch (M. soleus: 18 ± 5 % vs. 2 ± 2 %; p≤0.05 (SNK)) and 
fast-twitch muscle (M. extensor digitorum longus: 60 ± 5 % vs. 44 ± 6 %; 
p≤0.05 (SNK)). The MHC IIx expression in M. extensor digitorum longus 
(38 ± 5 % vs. 56 ± 4 %; p≤0.05 (SNK)) was significantly lower in 
nephrectomized control diet animals, compared to sham-operated control 
diet animals. 
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Fig. 1. Representative electrophoretic separation of the MHC isoforms. The 
reference lane (control) presents all four MHC isoforms, musculus soleus 
predominantly type I (slow) and musculus extensor digitorum longus 
predominantly fast MHC isoforms (MHC IIx and IIb). 
 
 
Creatine supplementation was associated with lower MHC IIb expression 
(p≤0.05 (SNK) in the soleus muscle in the subtotal nephrectomized group.  
No difference in MHC isoform expression was observed between sham-
operated creatine supplemented animals and sham-operated control diet 
animals in M. soleus (Fig 2). 
No effect of creatine supplementation was observed on MHC isoform 
expression in the M. extensor digitorum longus in both sham-operated and 
subtotal nephrectomized animals.  
 
In fast-twitch muscles the expression of myosin isoforms correlated with 
renal function. MHC IIx expression correlated negatively with serum 
creatinine (r=-0.51 ; p=0.001) (Figure 3) and serum urea (r=-0.50 ; 
p=0.01), but not with muscle mass (p=NS). MHC IIb expression correlated 
positively with serum creatinine (r=0.50 ; p=0.01) (Figure 3) and serum 
urea (r=0.48; p=0.02). 
In slow-twitch muscles the relation of  MHC expression and renal function 
failed to reach significance (MHC I expression vs.  serum urea: r= -0.32: 
p=0.06). No significant relation was observed in M. soleus between the 
expression of fast MHC isoforms and renal function indices.  In slow-twitch 
muscle expression of myosin heavy chain isoforms correlated with muscle 
mass (MHC I ~ M. soleus mass: r= 0.41 ; p= 0.02). In sham-operated 
animals no correlation between serum or muscular creatine and MHC 
isoform expression was observed in both fast and slow-twitch muscles. In 
subtotal nephrectomized animals, serum creatine concentrations inversely 
correlated with MHC IIb isoform expression: r=-0.55; p=0.02). 
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Fig. 2. Relative distribution of the MHC isoforms in sham-operated and subtotally 
nephrectomized animals in both extensor digitorum longus (b) and soleus muscles 
(a). * p ≤ 0.05: subtotally nephrectomized animals compared to sham-operated 
control diet animals (SNK), ** p ≤ 0.05: creatine-supplemented subtotally 
nephrectomized animals compared to control diet nephrectomized animals (SNK).
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Discussion 
 
 
The present study is the first to demonstrate altered MHC expression in 
animals with renal failure, compared to sham-operated animals. Ultra-fast 
IIb expression was increased in subtotal nephrectomized animals. The 
relative increase in expression of fast MHC isoforms has been described 
before in other animal models of muscle wasting. 
 
 
 
 
Fig. 3. Relationship between serum creatinine concentration and MHC isoform IIb 
(%) and IIx expression (%) in musculus extensor digitorum longus 
(Spearman’s rank correlation analysis). 
 
Microgravity during spaceflight and hindlimb suspension in animals induces 
muscle atrophy, together with significant changes in MHC isoform 
expression [7]. These adaptations are most prominent in slow muscle 
types and involve downregulation of the slow isoform MHC I and de novo 
expression of fast MHC IIx [21-22]. Cancer cachexia has been described to 
be associated with expression of fast  MHC isoforms in soleus muscle. 
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Lower muscle mass, together with de novo expression of MHC IIb isoform 
expression at the expense of MHC I  in the tumor bearing mice [23]. 
Congestive heart failure is also associated with lower exercise capacity and 
muscle wasting, as observed in uraemia. Skeletal MHC isoform expression 
is  altered in rats with congestive heart failure with higher expression of 
MHC IIb at the expense of MHC IIx isoforms. These shifts in MHC isoforms 
are correlated to heart failure indices [24]. Histochemical analysis of 
skeletal muscle in uraemic subjects has mainly demonstrated a type II 
fiber atrophy. Type II fibers were smaller in uraemic subjects, compared to 
the reference population [1,25-26]. Light microscopy anomalies are mainly 
fiber atrophy, fiber splitting, increased intracellular lipid and moth-eaten 
fibers [25]. In this study we have examined MHC composition in animals 
using whole muscle homogenates and observed mainly a slow-to-fast 
transition in MHC composition. This observation is in line with other models 
of muscle wasting [21-24], though do not correspond with the above 
mentioned microscopic findings. However Clyne et al. described an inverse 
relationship between the proportion slow (type I) fibers and renal function 
[1]. This finding is in accordance with the observed slow-to-fast transition 
in our animal model. Comparison of animal and human studies are 
complicated by the presence of 3 fast MHC isoforms in rats, whereas 
humans exhibit only 2 fast MHC isoforms, by differences in methodologies 
and differences in muscle composition [7]. The soleus muscle in rats 
contains proportionally much more type I fibers, compared to human 
soleus which is more heterogeneous in fiber composition [7].   
In humans resistance training and creatine supplementation demonstrated 
significant changes in MHC isoform composition [27-28]. Resistance 
training resulted in higher expression of slow MHC isoforms and a 
decreased expression of fast MHC isoforms. Combined training and 
creatine supplementation resulted in increased slow MHC I expression and 
decreased MHC IIx expression, compared to sedentary controls and trained 
placebo subjects. These data suggest that creatine supplementation can 
enhance training effects in humans [28].  
 
Increased expression of fast MHC isoforms in both fast-twitch and slow-
twitch muscles could affect contractile properties of the different muscle 
types in animals with renal failure. These transitions in MHC could account 
for the increased fatigability and dimished fatigue resistance observed in 
patients with renal failure. Fast MHC, especially  IIb and IIx isoforms 
exhibit higher shortening velocities and ATP consumption rates but have 
higher fatigability [6,8]. The increase in fast MHC isoforms in our animal 
model of uraemia is mainly an increase in IIb isoforms (fastest), whereas 
disuse demonstrated mainly a decrease in type I and an increase IIa/IIx. 
Increases in MHC IIb isoform in M. soleus has been described during 
unloading, though the proportion was lower than reported here [21,29]. 
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Diffee et al. reported comparable MHC IIb expression in M. soleus in tumor 
bearing mice as in our uraemic animals [23]. 
The MHC differences between sham-operated and nephrectomized animals 
could have arisen from changes in neuromuscular control [30]. Uraemia is 
associated with neuropathy [31] and could result in alterations in muscular 
innervation, apart from intrinsic muscular alterations. Neurons controlling 
fast- and slow muscle could differ in susceptibility to uraemic toxins and 
neuronal survival. These neuronal causes could partly influence MHC 
expression in skeletal muscle. 
The observed MHC transitions in nephrectomized animals could also be 
attributed to decreased physical activity in these animals. Disuse has been 
associated with slow-to-fast transitions in MHC isoforms. However the 
observed MHC transitions  by complete removal of mechanical load or 
nerve activity are less pronounced than the current changes observed  in 
uraemia [5,7,22]. Moreover no training scheme was applied in this study 
protocol, therefore the differences in physical activity between the sham-
operated and nephrectomized animals should be minimal. 
The underlying mechanism causing MHC transitions in disease states, such 
as sepsis or cancer cachexia is poorly understood. Increased 
concentrations of circulating proinflammatory cytokines could influence 
muscle metabolism and could contribute to the altered muscle MHC isoform 
expression, observed in uraemia, cancer cachexia or heart failure [32].  
Apart from acting on muscle energy metabolism, creatine could also 
interfere with the augmented inflammatory state as observed in uraemia. 
Creatine has been described to exhibit direct antioxidant properties. 
Creatine acted as a direct antioxidant against aqueous radical and reactive 
oxygen species [33-34]. These systemic effects of creatine 
supplementation could have influenced the proinflammatory state and 
circulating cytokines. 
 
Serum creatinine concentrations were higher in creatine supplemented 
nephrectomized animals, compared to control diet nephrectomized 
animals, due to creatine-creatinine conversion. No effect of creatine 
supplementation on serum creatinine was observed in sham-operated 
animals. Previously we examined the effect of creatine supplementation on 
renal function and did not observe alterations in inulin or creatinine 
clearance nor in renal protein handeling [16]. No adverse effect of creatine 
supplementation on renal function could be demonstrated in this animal 
model of chronic uraemia [16]. 
 
Creatine supplementation increased expression of slow MHC isoforms of 
the soleus muscle in subtotal nephrectomized animals, therefore partially 
reversing the effect of uraemia on MHC expression. In fast-twitch muscle 
no effect of creatine supplementation was observed in either sham-
operated or subtotal nephrectomized animals. These findings could have 
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therapeutic applications. Creatine supplementation could increase fatigue 
resistance and muscular performance in uraemia. Further research is 
warranted examinating the effects of creatine supplementation on 
muscular contractile properties and fatigue resistance in uraemic animals. 
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Note added to manuscript in thesis: 
 
The provided analgesia in relation to surgery in the animals is not 
mentioned in the manuscript. The analgesia was provided 48h post-
operatively, by administration of buprenorphine IM (0.1 mg/kg; Temgesic, 
Schering-Plough). 
 
In this study, creatine concentrations were determined in the white 
gastrocnemius muscle for technical reasons. In order to draw final 
conclusions, creatine concentrations should also be determined in the M. 
soleus and M. extensor digitorum longus separately. This allows 
differentiation between the effects of creatine on slow- and fast muscle 
types. Furthermore the effects of creatine on contractile characteristics 
should be studied in addition to the altered MHC-distribution. 
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                    HAPTER 4 
 
 
 
 
 
 
General discussion & 
future perspectives 
 
 
 
When the people of the world all know beauty as beauty,  
there arises the recognition of ugliness.  
When they all know the good as good,  
there arises the recognition of bad.  
Therefore being and non-being produce each other;  
difficult and easy complete each other;  
long and short contrast each other;  
high and low distinguish each other;  
sound and voice harmonize with each other;  
beginning and end follow each other. 
 
Tao Te King 2/81  
Lao Tse 
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GENERAL DISCUSSION & 
FUTURE PERSPECTIVES 
 
 
 
1. Major findings 
 
This thesis addresses the effect of creatine supplementation on renal 
function, skeletal muscle metabolism and homocysteine metabolism in 
both laboratory animals and humans.  
We considered creatine as an interesting molecule with possible application 
in renal failure patients. Two aspects of creatine metabolism are especially 
important in uraemia.  
First, creatine is metabolically linked to the homocysteine metabolism. We 
hypothesized that creatine could lower the increased homocysteine 
concentrations associated with renal failure. In general, new homocysteine 
lowering therapies could be important in lowering cardiovascular risk in 
these patients.  
Secondly, creatine is an ergogenic molecule in young athletes. Older 
subjects and especially uraemic patients are characterized by low muscle 
mass and low exercise tolerance. Creatine could increase the muscular 
performance and quality of life of these patients. 
However, safety of prolonged creatine intake in conditions with diminished 
renal function was to be investigated, as only limited data are available on 
the prolonged intake of creatine. In this regard we have started by 
investigating the effects of creatine on renal function and uptake of 
creatine in our animal model as a prerequisite for further investigations 
(Taes (1) et al., 2003). 
In our experiments with laboratory animals and in our studies in patients 
we did not observe any negative effect of creatine on the renal function. 
Creatine supplementation increased serum creatinine concentrations due to 
the elevated creatine-creatinine load without affecting glomerular filtration. 
Analytical interference could have influenced the apparent creatinine 
concentrations, although only to a minor extent (Taes et al., 2005).  
In animals, creatine was found to decrease the plasma homocysteine 
concentration, whereas in dialysis patients no effect of creatine on plasma 
homocysteine concentrations was observed (Taes (2) et al., 2003; Taes (1) 
et al., 2004).  
In laboratory animals we have investigated the myosin heavy chain 
expression in skeletal muscle and observed a protective effect of creatine 
in preventing the slow-to-fast isoform transition in myosin heavy chain 
during uraemic muscle wasting (Taes (2) et al., 2004). In this regard, 
treatment with creatine could be theoretically interesting in patients to 
prevent skeletal muscle wasting and increased fatigability. In aging men, 
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however, no major effect of creatine supplementation on exercise 
performance was observed in our study (Eijnde et al., 2003)  
 
2. Analytical considerations 
 
When evaluating kidney function in both rats and humans, it is important 
to use gold-standard methods such as inulin clearance or 51Cr-EDTA-
clearance rates (Kühnle et al., 1993). Calculated creatinine clearance rates 
give a good estimation of the renal function in conditions where the 
creatinine production is constant. When this condition is not met, 
creatinine clearance rates can provide a false estimation of the glomerular 
filtration rate. Tubular secretion of creatinine can also influence the 
calculated clearance rates. Creatine ingestion changes the steady state 
between creatinine formation and creatinine excretion, until a new 
equilibrium is set at higher (or lower) plasma creatinine concentration. In 
this situation, creatinine concentrations and creatinine clearance are no 
valuable markers of glomerular filtration. Independent markers of 
glomerular filtration are better suited in these conditions. The use of 
creatinine as a marker for glomerular filtration in several reports about 
creatine could have influenced the reported values for creatinine clearance 
and could explain the discrepancies in the literature about the effects of 
creatine on renal function (Van Liew et al., 1993). Moreover, as described 
in the introduction, the different creatinine assays suffer from interference 
with creatine (Taes et al., 2005; Weber et al. 1991). In the majority of the 
assays higher creatinine concentrations are reported with creatine 
ingestion and these interferences could have influenced the results.  
 
 3. Creatine and renal function 
 
Models of renal mass reduction have been extensively used to investigate 
the pathogenetic mechanisms responsible for the progressive nature of 
chronic renal disease in humans. The 5/6 nephrectomy model with a partial 
reduction of the renal mass of one kidney and a collateral nephrectomy is 
commonly used (Gagnon et al., 1983).  
A possible limitation of this animal model to study human renal injury is 
the time-frame in which the renal lesions occur. In this animal model the 
renal mass reduction is instantaneous and mimics poorly the situation in 
humans, where renal lesions occur gradually and progressive. Moreover, 
intrinsic renal disease is absent in these animals and does not mimic the 
course of renal disease in humans where the intrinsic renal disease 
contributes to the reduction in glomerular filtration. In general, the 
remnant kidney model is a good and widely used model for studying renal 
failure in various animal species. However the natural history of renal 
disease in these animals could be different from humans and could differ 
between the different animal models of renal disease.   
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In contrast to the absence of adverse effects of creatine on renal 
function in our animal model, other investigators have observed 
negative effects in animals. Edmunds et al (Edmunds et al., 2000) have 
investigated the effects of creatine on renal function in Han: Sprague-
Dawley (SPRD)-cy rats. The Han:SPRD-cy rat is an animal model of 
inherited renal cystic disease that resembles human autosomal 
dominant polycystic kidney disease. Creatine supplementation resulted 
in greater cyst growth and worsened renal function in the Han: SPRD-
cy rat, evidenced by greater kidney weights, renal cysts, serum urea 
concentrations and lower creatinine clearances. These authors conclude 
that creatine supplements could exacerbate disease progression in an 
animal model of cystic renal disease. Unfortunately no independent 
marker for glomerular filtration or renal protein handling was measured 
in this study and some methodological and physiological pitfalls were 
not taken into account. As mentioned before, creatine can interfere 
with the creatinine determinations and this interference could have 
influenced the results obtained for glomerular filtration. The difference 
in animal strain could also account for the differences between the 
study by Edmunds and our study as Esposito et al. demonstrated that 
the glomerular response to nephron reduction is dependent on the 
inbred strain of studied mice (Esposito et al., 1999). The use of animal 
experiments in evaluating biochemical effects of creatine can provide 
valuable information (Kreider, 2003), difficult to obtain in humans.  
 
4. Creatine and homocysteine metabolism 
 
In our studies, creatine decreased the homocysteine concentrations in rats, 
but not in humans. Several hypotheses can be advanced to explain this 
discrepancy. 
First, in rats a higher dose ( /kg body weight) of creatine was used than in 
humans. Theoretically, higher dosages in humans could have been efficient 
in lowering homocysteine concentrations. However, the attained plasma 
concentration of creatine was comparable between the laboratory animals 
and patients, owing to the lower residual renal function in the dialysis 
patients than in uraemic rats. Therefore, higher doses in humans would 
probably not have increased the efficiency of creatine in lowering 
homocysteine concentrations. In addition, patient compliance might have 
decreased as these patients were already taking several medications and 
gastrointestinal side effects were not uncommon. Finally, the plasma 
concentrations of guanidinoacetic acid were significantly diminished in the 
creatine supplemented dialysis patients, indicative for suppression of the 
endogenous creatine synthesis (Y. Taes, unpublished data). 
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Secondly, species-related differences could perhaps explain the difference 
in effect between humans and rodents. Considering homocysteine 
metabolism by the kidney, results obtained in the rat model showed 
decreased renal metabolism in uraemia. In rats about 75 % of plasma tHcy 
was found to be free, whereas in humans about 65-75 % of tHcy is bound 
to proteins by a disulfide bond. Only a small fraction of homocysteine 
circulates in a free form in human plasma, and is therefore available for 
glomerular filtration (Friedman et al., 2001; House et al., 1998). In dialysis 
patients protein binding of Hcy was even found to be higher in comparison 
to non-dialyzed chronic uraemic patients (Suliman et al., 1997). These 
differences in protein binding could be reflected in differences found in 
renal extraction of Hcy in humans and rats. In rats significant clearance of 
Hcy by the kidneys was observed (House et al., 1998), whereas in humans 
no arteriovenous difference in Hcy concentrations was observed. Van 
Guldener et al. measured homocysteine levels in the renal vein and renal 
artery of 20 patients with normal renal function undergoing a 
coronarography, in the fasting state, and they reported no significant 
difference (Van Guldener et al., 1998). Differences in renal handling of Hcy 
and in general Hcy-metabolism could account for the discrepancy in our 
studies. Another species-related aspect could be a possible difference in 
regulation of the creatine metabolism. The compartmentalization between 
the two key enzymes (AGAT, GAMT) varies from species to species (Wyss 
et al., 2000) and regulation and quantitative aspects can differ 
substantially. Another difference between rats and man is the nutritional 
intake. In particular, methionine intake plays a role in determining the fate 
of homocysteine, being remethylated to methionine or processed in the 
transsulphuration pathway (Selhub, 1999; Park et al., 1999).     
 
5. Effects of creatine on skeletal muscle 
 
Creatine has been extensively investigated in relation to skeletal muscle 
function in diverse exercise disciplines (Lemon, 2002; Rawson et al., 2003; 
Racette, 2003; Kreider, 2003; Paddon-Jones et al., 2004). 
 
The use of creatine in therapeutic conditions in patients with 
neuromuscular disorders will be briefly addressed here in relation to the 
presented manuscripts.  
Creatine has been studied in several neuromuscular disorders (Derave et 
al., 2003; Wyss et al., 2002). Three categories can be discriminated: (1) 
diseases related to creatine metabolism; (2) diseases with a disturbed 
creatine metabolism as a secondary symptom and (3) diseases without 
altered creatine metabolism.  
In diseases of the first category such as GAMT- or AGAT-deficiency, 
creatine concentrations are low in various tissues. Creatine 
supplementation can result in normalization of the creatine stores and 
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clinical improvement. A defect in the creatine transporter can also be 
classed in this group, though the effects of creatine supplements in this 
condition are only minimal due to the absence of an active uptake 
mechanism. (Stöckler et al., 1994; Bianchi et al., 2000;  Salomons et al., 
2001; Cecil et al., 2001) 
Gyrate atrophy due to a deficiency of the ornithine-aminotransferase, with 
inhibition of the creatine biosynthesis, together with mitochondrial 
cytopathies are classed in category 2. Creatine can improve muscular 
dysfunction of these patients, but not the loss of vision, associated with the 
disease (Heinanen et al., 1999; Sipilä et al., 1980; Sipilä et al., 1981;). 
The third category groups several neuromuscular disorders, where creatine 
metabolism is not primarily affected. Creatine is supplemented to increase 
the survival of neurons or muscle cells or to improve neuronal or muscular 
function, as creatine can facilitate energy transfer from the mitochondria. 
Contradictory and disappointing results have been obtained in this group of 
patients. 
In G93A mice, an animal model for amyotrophic lateral sclerosis, increased 
survival of these mice and improved neuromuscular control after creatine 
supplementation were described (Klivenyi et al., 1999; Zhang et al., 
2003). Using the same transgenic animal strain (G93A), other investigators 
could not demonstrate any effect of creatine on muscular performance, 
muscle contraction characteristics or metabolites (Derave et al., 2003). In 
humans, no benefit of creatine was demonstrated in amyotrophic lateral 
sclerosis, considering muscular function (Ellis et al., 2004; Shefner et al., 
2004; Groeneveld et al., 2003; Drory VE et al., 2002; Mazzini et al., 
2001). 
In Duchenne’s muscular dystrophy, in vitro evidence suggested improved 
myotube formation and survival (Pulido et al., 1998). In humans with 
Duchenne’s disease, creatine was found to increase the dominant hand 
isometric grip strength and lower excretion of N-terminal collagen 
telopeptides, indicative for lower bone resorption (Tarnopolsky et al., 
2004). 
In Kearns-Sayre (chronic progressive external ophtalmoplegia), a 
mitochondrial cytopathy, creatine supplementation did not improve skeletal 
muscle oxidative capacity (Kornblum, 2005). 
In 81 patients with various neuromuscular diseases (mitochondrial 
cytopathies, neuropathic disorders, dystrophies-congenital myopathies and 
inflammatory myopathies), creatine supplementation increased body 
weight, handgrip, dorsiflexion, and knee extensor strength (Tarnopolsky et 
al., 1999).  
In vitro studies identified creatine as an important neuroprotective factor 
for developing nigral dopaminergic neurons (Andres et al., 2005) 
In animals, creatine was found to attenuate the MPTP (1-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine)- neurotoxicity, a model for Huntington’s 
disease. Creatine protected against MPTP-induced loss of Nissl and tyrosine 
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hydroxylase immunostained neurons in the substantia nigra, indicative for 
attenuated dopamine depletion (Matthews et al., 1999). In the R6/2 mice, 
a transgenic animal model of Huntington’s disease, creatine increased 
survival, motor performance and decreased neuronal atrophy and 
huntingtin aggregates (Dedeoglu et al., 2003; Andreassen et al., 2001). In 
humans with Huntington’s disease, creatine did not improve functional, 
neuromuscular, and cognitive status. Creatine was supplemented at a dose 
of 5 g/d, sufficient to improve muscle function in healthy subjects 
(Verbessem et al., 2003). 
 
In aging, we assumed that creatine could enhance muscular performance 
comparable to the ergogenic effects of creatine in young subjects. Short-
term supplementation in older men slightly increased the isokinetic knee 
extension performance (Rawson (1) et al., 1999), whereas creatine 
supplementation of longer duration (1-2 months) did not improve muscular 
function (Rawson (2) et al., 1999; Bermon et al., 1998). Crusch (Crusch et 
al., 2001) demonstrated enhanced muscle strength, endurance and lean 
mass in addition to resistance training. The same authors (Candow et al., 
2004) however could not demonstrate an effect of creatine withdrawal 
during training on strength, endurance and changes in lean mass. Brose 
(Brose et al., 2003) demonstrated increased isometric knee extension 
strength, increased fat-free and total body mass in creatine supplemented 
subjects, compared to placebo treatment, in conjunction with strength 
exercise training. Gotshalk (Gotshalk et al., 2002) showed positive effects 
of creatine on isometric, dynamic and functional muscle function tests in a 
population of older men. In our study we could not demonstrate any effect 
of creatine on muscular performance in these elder men. As in other 
studies the increase in muscular creatine concentrations was dependent on 
the initial creatine concentration. A low initial concentration predisposes to 
a good responsiveness to creatine. In our study with older men, high 
muscular creatine concentrations were found, in contrast to younger 
subjects, possibly limiting the responsiveness to creatine treatment. The 
duration of creatine supplementation is also important in considering these 
results.  The effects of creatine, observed in short-term studies, may wear 
off in studies with longer duration. In senescence-accelerated mice 
(SAMP8), creatine supplementation was investigated in relation to 
contractile characteristics, creatine content and muscle morphology. In 
both soleus and extensor digitorum longus muscle, reduced 
phosphocreatine concentrations were observed with advancing age, 
without effect of creatine supplementation. In this animal model, creatine 
treatment did not influence the loss of muscle mass and contractility 
(Derave et al, 2005). An interesting aspect of creatine supplementation in 
elderly could be improvement of brain function. Creatine has been 
described to enhance brain performance in young vegetarians (Rae et al., 
2003). Preserving brain function during aging is important in maintaining 
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quality of life. Creatine was described to attenuate ischemic brain infarction 
in a mice-model (Zhu et al., 2004). This neuroprotective property needs 
futher research, but provides an interesting approach to keep fit at an 
older age. Reviewing the muscular creatine concentrations in relation to 
the duration, there is a marked decrease in muscular creatine 
concentrations after 12 weeks of supplementation, suggestive for 
habituation (Derave et al., 2003). The origin of this habituation process 
remains unknown, although downregulation of the creatine transporter is 
possible. (Guerrero-Ontiveros et al., 1998). Beneficial effects of creatine on 
muscular function in patients with neuromuscular disorders were also only 
observed in short-term studies, whereas long-term studies failed to 
demonstrate major effects of creatine in this group of diseases (Derave et 
al., 2003). 
  
In uraemia, specific alterations in skeletal muscle morphology have been 
described (Clyne et al., 1993; Campistol, 2002). The creatine metabolism 
could have been altered by the renal failure and the accumulation of 
uraemic retention products. Therefore we hypothesised that creatine 
supplementation could influence muscle metabolism in uraemia.  Promising 
findings were observed in our animal model of chronic uraemia considering 
the protective effect of creatine on MHC-expression in the skeletal muscle 
(Taes (2) et al., 2004). Extrapolation of our animal data to patients with 
renal failure creates the impression that creatine could be helpful in 
treating the muscular dysfunction, associated with uraemia. Similarly, in 
untrained young subjects, a higher proportion of MHC I was observed with 
creatine supplementation, compared to sedentary and trained control 
subjects (Willoughby et al., 2001). However, creatine treatment in older 
men together with exercise training did not influence the muscular 
performance of these subjects.  
 
Several remarks can be formulated on these opposing findings. Rats and 
humans differ in muscular composition. Especially, the M. soleus in the rat 
contains relatively more type I fibers, compared to humans (Pellegrino et 
al., 2003). This difference in muscular composition suggests that animal 
data could not be fully transposable to the human situation, also due to 
differences in contraction characteristics of single muscle fibers (Pellegrino 
et al., 2003). In this regard, biochemical effects of creatine on human 
MHC-expression could be smaller in aging men and without a measurable 
effect on contraction characteristics or muscular performance. Moreover 
creatine uptake can vary among species. In humans, intramuscular 
creatine concentrations increase more consistently compared to rodents or 
other animals. In horses, creatine uptake in muscle even seems absent 
after creatine loading (Schuback et al., 2000). In both rats, mice and 
guinea pigs, creatine supplementation was found to increase intramuscular 
creatine concentrations by about 30% (Ipsiroglu et al., 2001) 
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The effects of creatine on muscle function in dialysis have not been 
examined in large studies. Only Chang (Chang et al., 2002) reported in a 
small study, a decreased frequency of dialysis-associated muscle cramps, 
but muscular performance was not investigated. The absence of any 
beneficial effect of creatine on muscular performance in the aging men 
suggests that creatine could not prove useful in dialysis patients for 
increasing muscular performance. The muscular dysfunction in these 
patients is usually debilitating, with limited exercise tolerance and high 
fatigability. This finding, together with a multifactorial aetiology do not 
suggest a pronounced effect of creatine in this patient population. Also 
muscular creatine concentrations are not decreased in uraemia, limiting 
the responsiveness to creatine. Furthermore, these patients would only 
benefit from long-term creatine supplementation and with limited evidence 
available for long-term effect of creatine supplementation, this is less 
promising.  
 
 
6. Future perspectives 
 
Based on our data, the effect of creatine on muscular performance in aging 
men and by extrapolation in renal failure patients seems limited. As several 
publications with negative results on creatine and muscular function in 
humans with neuromuscular disorders have been published, it is to be 
expected that creatine will have only limited beneficial effect on muscular 
function in renal disease patients. 
In this regard, a more appealing substance to study in relation to muscular 
function in renal disease patients is vitamin D (Visser et al., 2003; Wanic-
Kossowska et al., 1996). Skeletal muscle has been identified as one of the 
non-classical target organs for vitamin D, by the presence of the vitamin D 
receptor (Bischoff-Ferrari et al., 2004). Treating elderly with vitamin D 
supplements reduced the number of falls and increased muscle strength 
(Kenny et al., 2003; Dhesi et al., 2004). The effects of vitamin D on 
skeletal muscle metabolism are still under investigation. The effect of 
vitamin D on muscle composition and contraction characteristics can prove 
interesting. Promoting physical exercise in renal failure patients could also 
help in limiting sarcopenia and increasing muscle strength.  
 
An intriguing aspect of creatine metabolism is the effect of increased 
creatine ingestion on guanidino compound concentrations in renal failure. 
Guanidino compounds are structurally and metabolically related to arginine 
and creatine and have been described as uraemic toxins. Creatine could 
influence the concentration of the guanidino compounds in uraemia by the 
arginine-sparing effect of creatine.  
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Creatine could also play a role in Advanced Glycation End-product (AGE) 
formation, due to structural analogy with arginine. Pentosidine is a well 
characterized AGE-product, formed by interaction of lysine, arginine and a 
reducing sugar. In vitro evidence points out towards creatine as a modifier 
in this reaction (Miyazaki et al., 2002). Creatine could interact in this 
mechanism by its amidinogroup, preventing intramolecular cross links 
between adjoining amino acids in proteins. In this regard, aminoguanidine 
is a well known inhibitor of AGE-formation (Heidland et al., 2001). 
Theoretically, creatine could have the same inhibiting properties on AGE-
formation.  
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Thirty spokes meet at a nave; 
Because of the hole we may use the wheel. 
Clay is moulded into a vessel; 
Because of the hollow we may use the cup. 
Walls are built around a hearth; 
Because of the doors we may use the house. 
Thus tools come from what exists, 
But use from what does not. 
Tao Te King 11/81  
Lao Tse 
 138
REFERENCES 
 
 
 
• Andreassen OA, Dedeoglu A, Ferrante RJ, Jenkins BG, Ferrante KL, Thomas M, 
Friedlich A, Browne SE, Schilling G, Borchelt DR, Hersch SM, Ross CA, Beal MF. 
Creatine increase survival and delays motor symptoms in a transgenic animal 
model of Huntington's disease. Neurobiol Dis 2001;8:479-491 
• Andres RH, Huber AW, Schlattner U, Perez-Bouza A, Krebs SH, Seiler RW, 
Wallimann T, Widmer HR.  Effects of creatine treatment on the survival of 
dopaminergic neurons in cultured fetal ventral mesencephalic tissue. 
Neuroscience 2005 May 9; [Epub ahead of print]  
• Baldwin KM, Haddad F. Effects of different activity and inactivity paradigms on 
myosin heavy chain gene expression in striated muscle. J Appl Physiol 
2001;90:345-357  
• Barrany M. ATPase activity of myosin correlated with speed of muscle 
shortening. J Gen Physiol 1967; 50: 197-218  
• Bayés B, Pastor CM,  Bonal J, Juncà J, Hernandez JM, Riutort N, Foraster A 
Romero R. Homocysteine, C-reactive protein, lipid peroxidation and mortality in 
haemodialysis patients. Nephrol Dial Transplant 2003; 18: 106-112 
• Bayes B, Pastor MC, Bonal J, Junca J, Romero R. Homocysteine and lipid 
peroxidation in haemodialysis: role of folinic acid and vitamin E. Nephrol Dial 
Transplant 2001;16:2172-2175 
• Bemben MG, Lamont HS.  Creatine supplementation and exercise performance: 
recent findings. Sports Med 2005;35:107-125 
• Benzi G. Is there a rationale for the use of creatine either as nutritional 
supplementation or drug administration in humans participating in a sport? 
Pharmacol Res 2000 ;41:255–264 
• Bermon S, Venembre P, Sachet C, Valour S, Dolis C. Effects of creatine 
monohydrate ingestion in sedentary and weight-trained older adults. Acta 
Physiol Scand 1998; 164: 147–155 
• Bessman SP, Fonyo A. The possible role of the mitochondrial bound creatine 
kinase in regulation of mitochondrial respiration. Biochem Biophys Res Commun 
1966;22:597-602 
• Bianchi MC, Tosetti M, Fornai F, Alessandri' MG, Cipriani P, De Vito G, Canapicchi 
R. Reversible brain creatine deficiency in two sisters with normal blood creatine 
level. Ann Neurol 2000;47:511–513 
• Bischoff-Ferrari HA, Borchers M, Gudat F, Durmuller U, Stahelin HB, Dick W. 
Vitamin D receptor expression in human muscle tissue decreases with age. J 
Bone Miner Res 2004;19:265-269  
• Bostom AG, Gohh RY, Beaulieu AJ, Nadeau MR, Hume AL, Jacques PF, Selhub J, 
Rosenberg IH. Treatment of hyperhomocysteinemia in renal transplant 
recipients. A randomized, placebo-controlled trial. Ann Intern Med 1997; 
127:1089-1092   
 139
• Brose A, Parise G, Tarnopolsky MA. Creatine supplementation enhances 
isometric strength and body composition improvements following strength 
exercise training in older adults. J Gerontol A Biol Sci Med Sci 2003;58:11-19 
• Campistol JM. Uremic myopathy. Kidney Int 2002;62:1901–1913 
• Candow DG, Chilibeck PD, Chad KE, et al. Effect of ceasing creatine 
supplementation while maintaining resistance training in older men. J Aging 
Phys Act 2004;12:219-23 
• Casey A, Greenhaff P.  Does dietary creatine supplementation play a role in 
skeletal muscle metabolism and performance? Am J Clin Nutr 2000;72: 607S–
617S 
• Cecil KM, Salomons GS, Ball WS,  Wong B,  Chuck G, Verhoeven NM,  Jakobs C, 
Degrauw TJ. Irreversible brain creatine deficiency with elevated serum and urine 
creatine: a creatine transporter defect? Ann Neurol 2001;49: 401–404 
• Chang CT, Wu CH, Yang CW, Huang JY, Wu MS. Creatine monohydrate 
treatment alleviates muscle cramps associated with haemodialysis. Nephrol Dial 
Transplant 2002;17:1978-1981 
• Chrusch M, Chilibeck P, Chad K, Davison KS, Burke D. Creatine supplementation 
combined with resistance training in older men. Med Sci Sports Exerc 
2001;33:2111–2117 
• Chrusch MJ, Chilibeck PD, Chad KE, Davison KS, Burke DG. Creatine 
supplementation combined with resistance training in older men. Med Sci Sports 
Exerc 2001;33:2111-2117   
• Clyne N, Esbjörnsson M, Jansson E, Jogestrand T, Lins LE, Pehrsson SK. Effects 
of renal failure on skeletal muscle. Nephron 1993;63:395–399 
• De Vriese AS, Verbeke F, Schrijvers BF, Lameire NH. Is folate a promising agent 
in the prevention and treatment of cardiovascular disease in patients with renal 
failure?  Kidney Int 2002;61:1199-1209 
• Dedeoglu A, Kubilus JK, Yang L, Ferrante KL, Hersch SM, Beal MF, Ferrante RJ. 
Creatine therapy provides neuroprotection after onset of clinical symptoms in 
Huntington's disease transgenic mice. J Neurochem 2003;85:1359-1367 
• Delanghe J, De Slypere JP, De Buyzere M, Robbrecht J, Wieme R, Vermeulen A. 
Normal reference values for creatine, creatinine, and carnitine are lower in 
vegetarians. Clin Chem 1989;35:1802-1803 
• Delanghe JR, De Buyzere ML, De Scheerder IK, Cluyse LP, Thierens HM. 
Characteristics of creatine release during acute myocardial infarction, unstable 
angina, and cardiac surgery. Clin Chem 1995;41:928-933 
• Demant T, Rhodes E.  Effects of creatine supplementation on exercise 
performance. Sports Med 1999;28: 49–60 
• Derave W, Eijnde BO, Hespel P. Creatine supplementation in health and disease: 
what is the evidence for long-term efficacy? Mol Cell Biochem 2003;244:49-55 
• Derave W, Eijnde BO, Ramaekers M, Hespel P.  No effects of lifelong creatine 
supplementation on sarcopenia in senescence-accelerated mice (SAMP8). Am J 
Physiol Endocrinol Metab. 2005 Feb 22; [Epub ahead of print]    
• Derave W, Eijnde BO, Verbessem P, Ramaekers M, Van Leemputte M, Richter 
EA, Hespel P. Combined creatine and protein supplementation in conjunction 
 140
with resistance training promotes muscle GLUT-4 content and glucose tolerance 
in humans. J Appl Physiol 2003;94:1910-1916 
• Derave W, Van Den Bosch L, Lemmens G, Eijnde BO, Robberecht W, Hespel P. 
Skeletal muscle properties in a transgenic mouse model for amyotrophic lateral 
sclerosis: effects of creatine treatment. Neurobiol Dis 2003;13:264-272  
• Dhesi JK, Jackson SH, Bearne LM, Moniz C, Hurley MV, Swift CG, Allain TJ. 
Vitamin D supplementation improves neuromuscular function in older people 
who fall. Age Ageing 2004;33:589-595 
• Drory VE, Gross D. No effect of creatine on respiratory distress in amyotrophic 
lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord 2002;3:43-
46 
• Edmunds JW, Jayapalan S, DiMarco NM, Saboorian MH, Aukema HM. Creatine 
supplementation increases renal disease progression in Han:SPRD-cy Rats. Am J 
Kidney Dis 2000; 37:73-78 
• Edstrom L, Hultman E, Sahlin K, Sjoholm H. The contents of high-energy 
phosphates in different fibre types in skeletal muscles from rat, guinea-pig and 
man. J Physiol 1982;332:47-58 
• Eijnde BO, Van Leemputte M, Goris M, Labarque V, Taes Y, Verbessem P, 
Vanhees L, Ramaekers M, Vanden Eynde B, Van Schuylenbergh R, Dom R, 
Richter EA, Hespel P. Effects of creatine supplementation and exercise training 
on fitness in men 55-75 yr old. J Appl Physiol 2003;95:818-828 
• Ellis AC, Rosenfeld J. The role of creatine in the management of amyotrophic 
lateral sclerosis and other neurodegenerative disorders. CNS DRUGS 2004;18: 
967-980 
• Engelhardt M, Neumann A, Berbalk A, Reuter I. Creatine supplementation in 
endurance sports. Med Sci Sports Exerc 1998;30: 1123–1129 
• Esposito C, He CJ, Striker GE, Zalups RK, Striker LJ. Nature and severity of the 
glomerular response to nephron reduction is strain-dependent in mice. Am J 
Pathol 1999;154:891-897 
• Francaux M, Demeure R, Goudemant J, Poortmans J. Effect of exogenous 
creatine supplementation on muscle PCr metabolism. Int J Sports Med 2000;21: 
139–145 
• Friedman AN, Bostom AG, Selhub J. The kidney and homocysteine metabolism. J 
Am Soc Nephrol 2001;12:2181-2189 
• Gagnon RF, Duguid WP. A reproducible model for chronic renal failure in the 
mouse. Urol Res 1983;11:11-14 
• Gotshalk LA, Volek JS, Staron RS, Denegar CR Hagerman FC, Kraemer WJ. 
Creatine supplementation improves muscular performance in older men. Med Sci 
Sports Exerc 2002;34:537-543 
• Graham A, Hatton R. Creatine: a review of efficacy and safety. J Am Pharm 
Assoc 1999;39: 803–810 
• Green, AL, Simpson EJ, Littlewood JJ, MacDonald IA, and Greenhaff PL. 
Carbohydrate ingestion augments creatine retention during creatine feeding in 
humans. Acta Physiol Scand 1996;158: 195-202 
 141
• Greenhaff P, Bodin K, Soderlund K, Hultman E. Effect of oral creatine 
supplementation on skeletal muscle phosphocreatine resynthesis. Am J Physiol 
1994;266: E725–E730 
• Greenhaff P, Casey A, Short A, Harris R, Soderlund K, Hultman E. Influence of 
oral creatine supplementation on muscle torque during repeated bouts of 
maximal voluntary exercise in man. Clin Sci 1993;84: 565–571 
• Groeneveld GJ, Beijer C, Veldink JH, Kalmijn S, Wokke JH, van den Berg LH. 
Few adverse effects of long-term creatine supplementation in a placebo-
controlled trial. Int J Sports Med 2005;26:307-313 
• Groeneveld GJ, Veldink JH, van der Tweel I, Kalmijn S, Beijer C, de Visser M, 
Wokke JH, Franssen H, van den Berg LH. A randomized sequential trial of 
creatine in amyotrophic lateral sclerosis. Ann Neurol 2003;53:437-445 
• Guerrero-Ontiveros M, Wallimann T. Creatine supplementation in health and 
disease. Effects of chronic creatine ingestion in vivo: down-regulation of the 
expression of creatine transporter isoforms in skeletal muscle. Mol Cell Biochem 
1998;184: 427–437 
• Guttormsen AB, Ueland PM, Svarstad E, Refsum H. Kinetic basis of 
hyperhomocysteinemia in patients with chronic renal failure. Kidney Int 1997; 
52:495-502 
• Harris R, Soderlund K, Hultman E. Elevation of creatine in resting and exercised 
muscle of normal subjects by creatine supplementation. Clin Sci 1992;83: 367–
374 
• Häussinger D, Roth E, Lang F, Gerok W. Cellular hydration state: an important 
determinant of protein catabolism in health and disease. Lancet 1993;341: 
1330–1332 
• Heidland A, Sebekova K, Schinzel R. Advanced glycation end products and the 
progressive course of renal disease. Am J Kidney Dis 2001;38:S100-S106 
• Heinänen K, Näntö-Salonen K, Komu M,  Erkintalo M, Alanen A, Heinonen OJ, 
Pulkki K, Nikoskelainen E,  Sipilä I, Simell O. Creatine corrects muscle 31P 
spectrum in gyrate atrophy with hyperornithinaemia. Eur J Clin Invest 
1999;29:1060–1065 
• Hespel P, Op't Eijnde B, Van Leemputte M, Urso B, Greenhaff PL, Labarque V, 
Dymarkowski S, Van Hecke P, and Richter EA. Oral creatine supplementation 
facilitates the rehabilitation of disuse atrophy and alters the expression of 
muscle myogenic factors in humans. J Physiol 2001;536: 625–633 
• Hoffer LJ. Homocysteine remethylation and trans-sulfuration. Metabolism. 
2004;53:1480-1483 
• Homocysteine Studies Collaboration. Homocysteine and Risk of Ischemic Heart 
Disease and Stroke.  A Meta-analysis.  JAMA 2002;288:2015-2022 
• House JD, Brosnan ME, Brosnan JT.  Renal uptake and excretion of 
homocysteine in rats with acute hyperhomocysteinemia. Kidney Int 
1998;54:1601-1607 
• Hultman E, Söderlund K, Timmons J, Cederblad G, Greenhaff PL. Muscle creatine 
loading in men. J Appl Physiol 1996;81:232-237 
 142
• Ingwall JS, Weiner CD, Morales MF, Davis E, and Stockdale FE. Specificity of 
creatine in the control of muscle protein synthesis. J Cell Biol 1974;62: 145–151 
• Ingwall JS. Creatine and the control of muscle-specific protein synthesis in 
cardiac and skeletal muscle. Circ Res 1976; 38: 115–122 
• Ipsiroglu OS, Stromberger C, Ilas J, Hoger H, Muhl A, Stockler-Ipsiroglu S. 
Changes of tissue creatine concentrations upon oral supplementation of 
creatine-monohydrate in various animal species. Life Sci 2001;69:1805-1815.   
• Ju JS, Smith JL, Oppelt PJ, Fisher JS. Creatine feeding increases GLUT4 
expression in rat skeletal muscle. Am J Physiol Endocrinol Metab 
2005;288:E347-E352  
• Kalantar-Zadeh K, Block G, Humphreys MH, McAllister CJ, Kopple JD. A low, 
rather than a high, total plasma homocysteine is an indicator of poor outcome in 
hemodialysis patients. J Am Soc Nephrol 2004;15:442-453 
• Kenny AM, Biskup B, Robbins B, Marcella G, Burleson JA. Effects of vitamin D 
supplementation on strength, physical function, and health perception in older, 
community-dwelling men. J Am Geriatr Soc 2003;51:1762-1767  
• Klerk M, Verhoef P, Clarke R, Blom HJ, Kok FJ, Schouten EG; MTHFR Studies 
Collaboration Group. MTHFR 677C[PI]T polymorphism and risk of coronary heart 
disease: a meta-analysis. JAMA 2002; 288:2023-2031 
• Klivenyi P, Ferrante RJ, Matthews RT, Bogdanov MB, Klein AM, Andreassen OA, 
Mueller G, Wermer M, Kaddurah-Daouk R, Beal MF. Neuroprotective effects of 
creatine in a transgenic animal model of amyotrophic lateral sclerosis. Nat Med 
1999;5:347-350 
• Kornblum C, Schroder R, Muller K, Vorgerd M, Eggers J, Bogdanow M, 
Papassotiropoulos A, Fabian K, Klockgether T, Zange J. Creatine has no 
beneficial effect on skeletal muscle energy metabolism in patients with single 
mitochondrial DNA deletions: a placebo-controlled, double-blind 31P-MRS 
crossover study. Eur J Neurol 2005;12:300-309 
• Kraemer W, Volek J. Creatine supplementation: its role in human performance. 
Clin Sports Med 1999;18: 651–666 
• Kreider RB, Ferreira M, Wilson M, Grindstaff P, Plisk S, Reinardy J, Cantler E, 
Almada AL. Effects of creatine supplementation on body composition, strength 
and sprint performance. Med Sci Sports Exerc 1998;30:73-82 
• Kreider RB. Effects of creatine supplementation on performance and training 
adaptations. Mol Cell Biochem 2003; 244:89-94 
• Kreider RB. Species-specific responses to creatine supplementation. Am J 
Physiol Regul Integr Comp Physiol 2003;285:R725-R726  
• Kreis R, Kamber M, Koster M, Felblinger J, Slotboom J, Hoppler H, Boesch C. 
Creatine supplementation — Part II: Invivo magnetic resonance spectroscopy. 
Med Sci Sports Exerc 1999;31: 1770–1777 
• Kren S, Hostetter TH.  The course of the remnant kidney model in mice. Kidney 
Int 1999;56:333-337 
•  Kühnle HF, Linsmeier P, Doerge L. Determination of glomerular filtration rate in 
rats. In: Gretz N, Strauch M, eds. Experimental and Genetic Rat Models of 
Chronic Uremic Failure. Karcher, Basel: 1993; 331–336  
 143
• Leemputte M, Vandenberghe K, Hespel P. Shortening of muscle relaxation time 
after creatine loading. J Appl Physiol 1999;86:840–844 
• Lemon PW. Dietary creatine supplementation and exercise performance: why 
inconsistent results? Can J Appl Physiol 2002;27:663-681 
• Louis M (1), Poortmans JR, Francaux M, Hultman E, Berre J, Boisseau N, Young 
VR, Smith K, Meier-Augenstein W, Babraj JA, Waddell T, and Rennie MJ. 
Creatine supplementation has no effect on human muscle protein turnover at 
rest in the postabsorptive or fed states. Am J Physiol Endocrinol Metab 
2003;284: E764–E770 
• Louis M (2) , Poortmans JR, Francaux M, Berre J, Boisseau N, Brassine E, 
Cuthbertson DJ, Smith K, Babraj JA, Waddell T, Rennie MJ. No effect of creatine 
supplementation on human myofibrillar and sarcoplasmic protein synthesis after 
resistance exercise. Am J Physiol Endocrinol Metab 2003;285:E1089-1094 
• Maganaris C, Maughan R. Creatine supplementation enhances maximum 
voluntary isometric formce and endurance capacity in resistance trained men. 
Acta Physiol Scand 1998;163:279-287 
• Matthews RT, Ferrante RJ, Klivenyi P, Yang L, Klein AM, Mueller G, Kaddurah-
Daouk R, Beal MF. Creatine and cyclocreatine attenuate MPTP neurotoxicity. Exp 
Neurol 1999;157:142-149 
• Maughan RJ. Nutritional ergogenic aids and exercise performance. Nutrition 
Research Reviews 1999;12:255-280 
• Mazzini L, Balzarini C, Colombo R, Mora G, Pastore I, De Ambrogio R, Caligari M. 
Effects of creatine supplementation on exercise performance and muscular 
strength in amyotrophic lateral sclerosis: preliminary results. J Neurol Sci 
2001;191:139-144 
• McGregor DO, Dellow WJ, Robson RA, Lever M, George PM, Chambers ST. 
Betaine supplementation decreases post-methionine hyperhomocysteinemia in 
chronic renal failure. Kidney Int 2002;61:1040-1046 
• Mendel RW, Blegen M, Cheatham C, Antonio J, Ziegenfuss T. Effects of creatine 
on thermoregulatory responses while exercising in the heat. Nutrition 
2005;21:301-307   
• Mesa JL, Ruiz JR, Gonzalez-Gross MM, Gutierrez Sainz A, Castillo Garzon MJ. 
Oral creatine supplementation and skeletal muscle metabolism in physical 
exercise. Sports Med. 2002;32:903-944 
• Meyer RA, Sweeney HL, Kushmerick MJ. A simple analysis of the 
"phosphocreatine shuttle". Am J Physiol 1984;246:C365-C377 
• Mitch WE. Insights into the abnormalities of chronic renal disease attributed to 
malnutrition. J Am Soc Nephrol 2002;13:S22–S27 
• Miyazaki K, Nagai R, Horiuchi S. Creatine plays a direct role as a protein 
modifier in the formation of a novel advanced glycation end product. J Biochem 
(Tokyo) 2002;132:543-550 
• Moat SJ, Doshi SN, Lang D, McDowell IFW, Lewis MJ, Goodfellow J. Treatment of 
coronary heart disease with folic acid: is there a future? Am J Physiol Heart Circ 
Physiol 2004; 287: H1 - H7 
 144
• Mudd SH, Ebert MH, Scriver CR. Labile methyl group balances in the human: the 
role of sarcosine. Metabolism 1980;29:707-739 
• Mudd SH, Poole JR. Labile methyl balance for normal humans on various dietary 
regimes. Metabolism 1975;24:721-735 
• O'Bryan T, Weiher H, Rennke HG, Kren S, Hostetter TH. Course of renal injury in 
the Mpv17-deficient transgenic mouse. J Am Soc Nephrol 2000;11:1067-1074 
• Op 't Eijnde B (1), Richter EA, Henquin JC, Kiens B, Hespel P. Effect of creatine 
supplementation on creatine and glycogen content in rat skeletal muscle. Acta 
Physiol Scand 2001;171:169-176  
• Op 't Eijnde B (2), Urso B, Richter EA, Greenhaff PL, Hespel P. Effect of oral 
creatine supplementation on human muscle GLUT4 protein content after 
immobilization. Diabetes 2001;50:18-23 
• Paddon-Jones D, Borsheim E, Wolfe RR. Potential ergogenic effects of arginine 
and creatine supplementation. J Nutr 2004;134:2888S-2894S 
• Park EI, Garrow TA. Interaction between Dietary Methionine and Methyl Donor 
Intake on Rat Liver Betaine-homocysteine Methyltransferase Gene Expression 
and Organization of the Human Gene.  J Biol Chem 1999; 274: 7816-7824 
• Paulsen M, Ferguson-Smith AC. DNA methylation in genomic imprinting, 
development, and disease. J Pathol 2005;195:97-110   
• Pellegrino MA, Canepari M, Rossi R, D'Antona G, Reggiani C, Bottinelli R. 
Orthologous myosin isoforms and scaling of shortening velocity with body size in 
mouse, rat, rabbit and human muscles. J Physiol 2003;546:677-689 
• Perna AF, Ingrosso D, Castaldo P, Galletti P, De Santo NG. Homocysteine and 
transmethylations in uremia. Kidney Int 2001;59:S230-S233 
• Perna AF, Ingrosso D, Lombardi C, Cesare CM, Acantora F, Satta E, De Santo 
NG. Homocysteine in uremia. Am J Kidney Dis 2003;41:S123-S126 
• Persky AM,  Brazeau GA. Clinical Pharmacology of the Dietary Supplement 
Creatine Monohydrate. Pharmacol Rev 2001 ;53: 161-176 
• Pette D, Peuker H, Staron RS. The impact of biochemical methods for single 
muscle fibre analysis. Acta Physiol Scand 1999;166:261-277  
• Pette D, Staron RS. Cellular and molecular diversities of mammalian skeletal 
muscle fibers. Rev Physiol Biochem Pharmacol 1990; 116: 1-76  
• Pette D, Staron RS. Myosin isoforms, muscle fiber types, and transitions. 
Microsc Res Tech 2000;50:500-509  
• Peyrebrune MC, Nevill ME, Donaldson FJ, Cosford DJ. The effects of oral creatine 
supplementation on performance in single and repeated sprint swimming. J 
Sports Sci 1998;16:271-279 
• Pline KA, Smith CL. The effect of creatine intake on renal function. Ann 
Pharmacother 2005;39:1093-1096 
• Poortmans J, Auguier H, Renaut V, Durussel A, Saugy M, Brisson G. Effect of 
short-term creatine supplementation on renal responses in man. Eur J Appl 
Physiol 1997;76: 566–567 
• Poortmans J, Francaux M.  Long-term creatine supplementation does not impair 
renal function in healthy athletes. Med Sci Sports Exerc 1999;31:1108–1110 
 145
• Poortmans JR, Francaux M: Adverse effects of creatine supplementation. Fact or 
Fiction ? Sports Med 2000;30:155-170 
• Preen D, Dawson B, Goodman C, Lawrence S, Beilby J, Ching S.  Effect of 
creatine loading on long-term sprint exercise performance and metabolism. Med 
Sci Sports Exerc 2001;33: 814–821 
• Preen DB, Dawson BT, Goodman C, Beilby J, Ching S. Comparison of erythrocyte 
and skeletal muscle creatine accumulation following creatine loading. Int J Sport 
Nutr Exerc Metab 2005;15:84-93   
• Pritchard NR, Kalra PA. Renal dysfunction accompanying oral creatine 
supplements. Lancet 1998;351:1252-1253 
• Pulido SM, Passaquin AC, Leijendekker WJ, Challet C, Wallimann T, Ruegg UT. 
Creatine supplementation improves intracellular Ca2+ handling and survival in 
mdx skeletal muscle cells. FEBS Lett 1998;439:357-362  
• Racette SB. Creatine supplementation and athletic performance. J Orthop Sports 
Phys Ther 2003; 33:615-621 
• Rae C, Digney AL, McEwan SR, Bates TC. Oral creatine monohydrate 
supplementation improves brain performance: a double-blind, placebo-
controlled, cross-over trial. Proc Biol Sci 2003;270:2147-2150    
• Rawson E (1), Clarkson P. Acute creatine supplementation in older men. Int J 
Sports Med 1999;20: 71–75. 
• Rawson E (2), Wehnert M, Clarkson P. Effects of 30 days of creatine ingestion in 
older men. Eur J Appl Physiol 1999;80: 139–144 
• Rawson ES, Volek JS. Effects of creatine supplementation and resistance 
training on muscle strength and weightlifting performance. J Strength Cond Res 
2003;17:822-831 
• Refsum H, Helland S, Ueland PM. Radioenzymic determination of homocysteine 
in plasma and urine. Clin Chem 1985; 31:624-628 
• Refsum H, Ueland PM,  Nygård O, Vollset SE. Homocysteine and cardiovascular 
disease. Annu Rev Med 1998;49:31-62   
• Ridker PM, Shih J, Cook TJ, Clearfield M, Downs JR, Pradhan AD, Weis SE, Gotto 
AM Jr; Air Force/Texas Coronary Atherosclerosis Prevention Study 
(AFCAPS/TexCAPS) Investigators. Plasma homocysteine concentration, statin 
therapy, and the risk of first acute coronary events. Circulation 2002; 105: 
1776–1779 
• Ritz E, Schoemig M, Massry SG. Uremic myopathy. In Massry S, Glassock R 
(eds): Textbook of Nephrology. Philadelphia, William & Wilkins, 2001, pp 1426–
1429 
• Robinson SJ. Acute quadriceps compartment syndrome and rhabdomyolysis in a 
weight lifter using high-dose creatine supplementation. J Am Board Fam Pract 
2000;13:134-137 
• Robinson TM, Sewell DA, Hultman E, Greenhaff PL. Role of submaximal exercise 
in promoting creatine and glycogen accumulation in human skeletal muscle. J 
Appl Physiol 1999;87:598-604 
• Sahlin K. Intracellular pH and energy metabolism in skeletal muscle of man. 
With special reference to exercise. Acta Physiol Scand (Suppl) 1978;455:1-56 
 146
• Saks VA, Ventura-Clapier R, Aliev MK. Metabolic control and metabolic capacity: 
two aspects of creatine kinase functioning in the cells. Biochim Biophys Acta 
1996 13;1274:81-88 
• Salomons GS, Van Dooren SJG, Verhoeven NM, Cecil KM, Ball WS, Degrauw TJ,  
Jakobs C. X-linked creatine-transporter gene (SLC6A8) defect: a new creatine-
deficiency syndrome. Am J Hum Genet 2001;68:1497–1500 
• Schiaffino S, Reggiani C. Molecular diversity of myofibrillar proteins: gene 
regulation and functional significance. Physiol Rev 1996;76:371-423  
• Schiaffino S, Reggiani C. Myosin isoforms in mammalian skeletal muscle. J Appl 
Physiol. 1994;77:493-501  
• Schilling  B, Stone MH, Utter A, Kearney J, Johnson M, Coglianese  R, Smith L, 
O'Bryant  H, Fry A, Starks M, Keith R, Stone ME. Creatine supplementation and 
health variables: a retrospective study. Med Sci Sports Exerc 2001;33: 183–188 
• Schmidt G, Stamminger G, Daniel A, Gross J, Syllm-Rapoport I, Lun A, Zoellner 
K. Evaluation of indicators of erythropoiesis stimulated by recombinant human 
erythropoietin in renal anemia. Biomed Biochim Acta. 1990;49:S275-279 
• Schuback K, Essen-Gustavsson B, Persson SG. Effect of creatine 
supplementation on muscle metabolic response to a maximal treadmill exercise 
test in Standard bred horses. Equine Vet J 2000;32:533-540  
• Selhub J. Homocysteine metabolism. Annu Rev Nutr 1999;19:217-246 
• Shefner JM, Cudkowicz ME, Schoenfeld D, Conrad T, Taft J, Chilton M, Urbinelli 
L, Qureshi M, Zhang H, Pestronk A, Caress J, Donofrio P, Sorenson E, Bradley 
W, Lomen-Hoerth C, Pioro E, Rezania K, Ross M, Pascuzzi R, Heiman-Patterson 
T, Tandan R, Mitsumoto H, Rothstein J, Smith-Palmer T, MacDonald D, Burke D; 
NEALS Consortium.  A clinical trial of creatine in ALS. Neurology 2004;63:1656-
1661 
• Sheppard H, Raichada S, Kouri K, Stenson-Bar-Maor L, Branch J. Use of creatine 
and other supplements by members of civilian and military health clubs: a 
cross-sectional survey. Int J Sport Nutr Ex Metab 2000;10: 245–259 
• Sipilä I, Rapola J, Simell O, Vannas A.  Supplementary creatine as a treatment 
for gyrate atrophy of the choroid and retina. N Engl J Med 1981;304:867-870 
• Sipilä I, Simell O, Arjomaa P. Gyrate atrophy of the choroid and retina with 
hyperornithinemia. Deficient formation of guanidinoacetic acid from arginine. J 
Clin Invest 1980;66:684-687   
• Splaver A, Lamas GA, Hennekens CH. Homocysteine and cardiovascular disease: 
biological mechanisms, observational epidemiology, and the need for 
randomized trials. Am Heart J 2004;148:34-40 
• Stead LM, Au KP, Jacobs RL, Brosnan ME, Brosnan JT. Methylation demand and 
homocysteine metabolism: effects of dietary provision of creatine and 
guanidinoacetate. Am J Physiol Endocrinol Metab 2001;281:E1095-100 
• Steenge GR, Verhoef P, Greenhaff PL: The effect of creatine and resistance 
training on plasma homocysteine concentrations in healthy volunteers. Arch 
Intern Med 2001;161:1455-1456 
 147
• Stöckler S, Holzbach U, Hanefeld F, Marquardt I, Helms G, Requart M, Hänicke 
W, Frahm J. Creatine deficiency in the brain: a new, treatable inborn error of 
metabolism. Pediatr Res 1994;36:409–413 
• Suliman ME, Anderstam B, Lindholm B, Bergstrom J.  Total, free, and protein-
bound sulphur amino acids in uraemic patients. Nephrol Dial Transplant 
1997;12:2332-2338   
• Suliman ME, Barany P, Kalantar-Zadeh K, Lindholm B, Stenvinkel P. 
Homocysteine in uraemia--a puzzling and conflicting story. Nephrol Dial 
Transplant 2005;20:16-21 
• Taes YE (2), Delanghe JR, De Vriese AS, Rombaut R, Van Camp J, Lameire NH. 
Creatine supplementation decreases homocysteine in an animal model of 
uremia. Kidney Int  2003;64:1331-1337 
• Taes YE (2), Speeckaert M, Bauwens E, De Buyzere MR, Libbrecht J, Lameire 
NH, Delanghe JR. Effect of dietary creatine on skeletal muscle myosin heavy 
chain isoform expression in an animal model of uremia. Nephron Exp Nephrol 
2004;96:e103-e110   
• Taes YE, De Vriese AS.  Analytical and biochemical aspects associated with 
supraphysiological creatine intake. Clin Chim Acta 2005;351:217-219 
• Taes YE, Delanghe JR, Wuyts B, van de Voorde J, Lameire NH.  Creatine 
supplementation does not affect kidney function in an animal model with pre-
existing renal failure. Nephrol Dial Transplant 2003;18:258-264  
• Taes YEC (1), Delanghe JR, De Bacquer D, Langlois M, Stevens L, Geerolf I, 
Lameire N, De Vriese AS.. Creatine supplementation does not decrease total 
plasma homocysteine in chronic hemodialysis patients. Kidney Int 2004; 
66:2422-2428 
• Tarnopolsky M, Martin J. Creatine monohydrate increases strength in patients 
with neuromuscular disease. Neurology 1999;52:854-857 
• Tarnopolsky MA, Mahoney DJ, Vajsar J, Rodriguez C, Doherty TJ, Roy BD, Biggar 
D. Creatine monohydrate enhances strength and body composition in Duchenne 
muscular dystrophy. Neurology 2004;62:1771-1777 
• Terjung R, Clarkson P, Eichner E, Greenhaff P, Hespel P, Israel R, Kraemer W, 
Meyer R, Spriet L, Tarnopolsky M, Wagenmakers A, Williams M. American 
College of Sports Medicine roundtable. The physiological and health effects of 
oral creatine supplementation. Med Sci Sports Exerc 2000;32: 706–717 
• Terzi F, Burtin M, Friedlander G. Using Transgenic Mice to Analyze the 
Mechanisms of Progression of Chronic Renal Failure. J Am Soc Nephrol 2000; 
11: 144S – 148 
• Thambyrajah J, Landray MJ, McGlynn FJ, Jones HJ, Wheeler DC, Townend JN. 
Does folic acid decrease plasma homocysteine and improve endothelial function 
in patients with predialysis renal failure? Circulation 2000;102:871-875 
• Thambyrajah J, Townend JN. Homocysteine and atherothrombosis--mechanisms 
for injury. Eur Heart J 2000;21:967-974 
• Thomason DB, Baldwin KM, Herrick RE. Myosin isoenzyme distribution in rodent 
hindlimb skeletal muscle. J Appl Physiol 1986;60:1923-1931  
 148
• Van Guldener C , Kulik W, Berger R, Dijkstra DA, Jakobs C, Reijngoud DJ, 
Donker AJ, Stehouwer CD, De Meer K. Homocysteine and methionine 
metabolism in ESRD: a stable isotope study. Kidney Int 1999; 56:1064-1071 
• Van Guldener C, Donker AJ, Jakobs C, Teerlink T, de Meer K, Stehouwer CD. No 
net renal extraction of homocysteine in fasting humans. Kidney Int 
1998;54:166-169  
• Van Guldener C, Lambert J, Ter Wee PM, Donker AJ, Stehouwer CD. Carotid 
artery stiffness in patients with end-stage renal disease: no effect of long-term 
homocysteine-lowering therapy. Clin Nephrol 2000;53:33-41 
• Van Liew JB, Zamlauski-Tucker MJ, Feld LG. Endogenous creatinine clearance in 
the rat: strain variation. Life Sci. 1993;53:1015-1021 
• Van Loon LJ, Murphy R, Oosterlaar AM, Cameron-Smith D, Hargreaves M, 
Wagenmakers AJ, Snow R. Creatine supplementation increases glycogen storage 
but not GLUT-4 expression in human skeletal muscle. Clin Sci (Lond) 
2004;106:99-106  
• Vandenberghe K, Goris M, Van Hecke P, Van Leemputte M, Van Gerven D, 
Hespel P. Long-term creatine is beneficial to muscle performance during 
resistance training. J Appl Physiol 1997;83:2055-2083 
• Verbessem P, Lemiere J, Eijnde BO, Swinnen S, Vanhees L, Van Leemputte M, 
Hespel P, Dom R. Creatine supplementation in Huntington's disease: a placebo-
controlled pilot trial. Neurology 2003;61:925-930.  
• Visser M, Deeg DJ, Lips P; Longitudinal Aging Study Amsterdam. Low vitamin D 
and high parathyroid hormone levels as determinants of loss of muscle strength 
and muscle mass (sarcopenia): the Longitudinal Aging Study Amsterdam. J Clin 
Endocrinol Metab. 2003;88:5766-5772   
• Volek J, Duncan N, Mazzetti S, Staron R, Putukian M, Gomez A, Person D, Fink 
W, Kraemer W. Performance and muscle fiber adaptations to creatine 
supplementation and heavy resistance training. Med Sci Sports Exerc 
1999;31:1147-1156 
• Volek JS, Mazzetti SA, Farquhar WB, Barnes  B, Gómez A.  Kraemer W. 
Physiological responses to short-term exercise in the heat after creatine loading. 
Med Sci Sports Exerc 2001;33:1101–1108 
• Wald DS, Bishop L, Wald NJ, Law M, Hennessy E, Weir D, McPartlin J, Scott J. 
Randomized trial of folic acid supplementation and serum homocysteine levels. 
Arch Intern Med 2001;161:695–700 
• Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence 
on causality from a meta-analysis. BMJ  2002;325:1202-1206 
• Walker JB. Creatine: biosynthesis, regulation and function. Adv Enzymol Relat 
Areas Mol Biol 1979;50:177-242 
• Wallimann T, Wyss M, Brdiczka D, Nicolay K, Eppenberger HM. Intracellular 
compartmentation, structure and function of creatine kinase isoenzymes in 
tissues with high and fluctuating energy demands: the 'phosphocreatine circuit' 
for cellular energy homeostasis. Biochem J 1992;281:21-40 
• Walsh B, Tonkonogi M, Söderlund K, Hultman E, Saks V, Sahlin K. The role of 
phosphorylcreatine and creatine in the regulation of mitochondrial respiration in 
human skeletal muscle. J Physiol (Lond) 2001;537: 971-978 
 149
• Wanic-Kossowska M, Grzegorzewska A, Plotast H, Bombicki K. Does calcitriol 
therapy improve muscle function in uremic patients. Perit Dial Int. 
1996;16:S305-308   
• Weber JA, Van Zanten AP. Interferences in current methods for measurements 
of creatinine. Clin Chem 1991; 37:695–700 
• Williams M, Branch J. Creatine supplementation and exercise performance: an 
update. J Am Coll Nutr 1998;17: 216–234 
• Willoughby DS, Rosene J. Effects of oral creatine and resistance training on 
myosin heavy chain expression. Med Sci Sports Exerc. 2001;33:1674-1681 
• Wyss M, Kaddurah Daouk R. Creatine and creatinine metabolism. Physiol Rev 
2000;80:1107-1213 
• Wyss M, Schulze A: Health implications of creatine: can oral creatine 
supplementation protect against neurological and atherosclerotic disease? 
Neuroscience 2002;112:243-60 
• Zhang W, Narayanan M, Friedlander RM. Additive neuroprotective effects of 
minocycline with creatine in a mouse model of ALS. Ann Neurol 2003;53:267-
270 
• Zhu S, Li M, Figueroa BE, Liu A, Stavrovskaya IG, Pasinelli P, Beal MF, Brown RH 
Jr, Kristal BS, Ferrante RJ, Friedlander RM. Prophylactic creatine administration 
mediates neuroprotection in cerebral ischemia in mice. J Neurosci 
2004;24:5909-5912 
• Ziegenfuss T, Gales D, Felix S, Straehle S, Klemash K, Konrath D, Lemon P. 
Performance benefits following a five day creatine loading procedure persist for 
at least four weeks. Med Sci Sports Exerc 1998;30: S265 
 
 150
SAMENVATTING 
 
 
 
In dit proefschrift werd het effect van creatinesupplementatie bij nierfalen 
en veroudering bestudeerd. Drie aspecten met betrekking tot het 
creatinemetabolisme werden in het bijzonder bestudeerd bij uremie.  
 
Ten eerste werd de veiligheid van creatinesupplementatie bij verminderde 
nierfunctie nagegaan. In een uremisch diermodel werden geen effecten 
van creatine vastgesteld op de glomerulaire filtratie, bepaald door middel 
van inuline- en creatinineklaring, en op eiwitexcretie. Enkel een verhoogde 
serum creatinineconcentratie werd vastgesteld. Creatine vertoonde 
eveneens een analytische interferentie met de creatininebepaling volgens 
Jaffé. Hogere creatinineconcentraties na inname van creatine zijn een 
weerspiegeling van een hogere creatine-creatinine conversie, samen met 
een hogere meetwaarde door interferentie.  
 
Ten tweede werd het effect van creatinesupplementatie op de plasma 
homocysteïneconcentraties bij uremie onderzocht. Verhoogde plasma 
homocysteïneconcentraties zijn geassocieerd met verhoogde 
cardiovasculaire morbiditeit en mortaliteit, vooral bij patiënten met 
nierlijden. Foliumzuur supplementatie is de standaard behandeling. Het is 
echter slechts ten dele effectief en 80 % van de patiënten met nierlijden 
houden verhoogde plasma homocysteïneconcentraties. De endogene 
synthese van creatine is gekoppeld aan de vorming van homocysteïne. 
Deze synthese geschiedt in twee stappen. Vooreerst wordt 
guanidinoacetaat gevormd uit glycine en arginine. Dit guanidinoacetaat 
wordt vervolgens gemethyleerd tot creatine. Deze methylatie geschiedt 
door methyldonatie van S-adenosylmethionine met vorming van S-
adenosylhomocysteïne en vervolgens homocysteïne. Quantitatief betekent 
dit dat ongeveer 70% van alle in vivo methylaties, met methionine-
homocysteïne cycli gebeuren omwille van creatinesynthese.  
In het uremisch diermodel werd een significante verlaging (22%; p<0.05) 
van de plasma homocysteïneconcentraties vastgesteld bij de 
creatinegesupplementeerde uremische dieren, vergeleken met de 
uremische controle dieet dieren. De plasma homocysteïne concentraties 
correleerden omgekeerd met de plasma creatine concentraties. Plasma 
folaat en de hepatische tetrahydrofolaatconcentraties waren hoger in de 
uremische gesupplementeerde  dieren. In een tweede experiment werd 
creatine als mogelijke behandeling voor hyperhomocysteinemie onderzocht 
in patiënten met terminaal nierfalen. Deze studie onderzocht bij 49 
dialysepatiënten, reeds behandeld met foliumzuur, vitamine B12 en B6-
preparaten, het effect van creatinesupplementatie op plasma 
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homocysteïneconcentraties in een placebo-gecontroleerde en overkruiste 
studie. In tegenstelling met de bevindingen in het diermodel werd bij deze 
dialysepatiënten geen effect van creatine op de plasma 
homocysteïneconcentraties vastgesteld. De creatineconcentraties na 
behandeling met creatine waren duidelijk toegenomen, wijzend op een 
adequate opname van het creatinepreparaat. In tegenstelling tot de 
proefdieren werden de dialysepatiënten reeds behandeld met 
suprafysiologische folaat, vitamine B6 en B12 preparaten. Het effect van 
creatine op het homocysteïnemetabolisme kan hierdoor  geminimaliseerd 
zijn. Er werden geen negatieve effecten van creatinesupplementatie 
vastgesteld op de KT/V of andere parameters.     
 
Het derde aspect betrof het inspanningsbevorderend effect van creatine. 
Creatine wordt als inspanningsbevorderend voedingssupplement gebruikt 
in verscheidene sportdisciplines. Recent werd het gebruik van creatine als 
therapeuticum bij patiënten met neuromusculaire aandoeningen ter 
verbetering van de spierfunctie onderzocht. De rationale is dat creatine 
inwerkt op de energiehuishouding van de cel en neuronale dood en 
spierdysfunctie kan verminderen.  
In een cohorte van 46 oudere mannen (55-75 j) werd het effect van 
training, samen met creatinesupplementatie onderzocht. Na 6 maanden 
creatine supplementatie was er geen verschil in totale creatineconcentratie 
tussen placebo- en creatinegroepen, en evenmin verschillen in statische of 
dynamische krachtsontwikkeling van de knie-extensoren of 
cardiorespiratoire uithouding. Creatinesupplementatie heeft aldus geen 
invloed op de fysieke fitheid van deze cohorte oudere mannen. 
Het effect van creatine op de myosine-isovormexpressie (myosin heavy 
chain (MHC)) werd nagegaan in een uremisch diermodel. In de uremische 
groepen werd  een slow-to-fast MHC-transitie in zowel de M. soleus 
(verhoogd MHC IIb-gehalte) als in de M. extensor digitorum longus (hoger 
MHC IIb-gehalte, ten koste van MHC IIx). Creatinesupplementatie in de 
uremische groep, resulteerde in een lagere MHC IIb-expressie en een 
hogere MHC I expressie in de M. soleus. Dit werd niet vastgesteld in de M. 
extensor digitorum longus. Deze resultaten tonen een gewijzigde MHC-
verhouding in de skeletspier bij uremie. Deze biochemische veranderingen 
zijn mogelijks geassocieerd met de gedaalde inspanningscapaciteit bij 
uremie. Creatinesupplementatie kan binnen dit diermodel de slow-to-fast 
overgang remmen. 
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SUMMARY 
 
 
 
This thesis addresses the effects of creatine supplementation in renal 
failure and aging. Three aspects of creatine metabolism were studied in 
detail with regards to renal failure. 
 
First, the safety of creatine supplementation in conditions with diminished 
renal function was investigated. No effects were observed on glomerular 
filtration, assessed by inulin and creatine clearance rates and on protein 
excretion. An apparent increase in serum creatinine concentrations was 
observed after creatine ingestion, together with an analytical interference 
of creatine on creatinine determinations by the Jafffé method. Higher 
creatinine concentrations after creatine ingestion are to be attributed to a 
higher creatine-creatinine conversion, together with an analytical 
interference. 
 
Secondly, the effect of creatine supplementation on plasma homocysteine 
concentrations was investigated. As homocysteine is described as an 
important cardiovascular risk factor in renal failure patients, and folic acid 
treatment is only partially effective, we investigated creatine as a possible 
homocysteine lowering substance. Endogenous creatine synthesis is linked 
to the formation of homocysteine. Creatine is formed by methylation of 
guanidinoacetic acid  through methyl donation from S-adenosylmethionine 
with eventually formation of homocysteine. Quantitatively this methylation 
process contributes to about 70% of all the methylation reactions in vivo. 
In the uraemic animal model we observed a significant decrease in plasma 
homocysteine concentrations (22%; p<0.05) in creatine supplemented 
uraemic animals compared to control diet animals, and plasma 
homocysteine concentrations correlated inversely with plasma creatine 
concentrations. Plasma folate and hepatic tetrahydrofolate concentrations 
were higher in uraemic creatine supplemented animals. In a second 
experiment we investigated the use of creatine as a homocysteine-lowering 
substance in dialysis patients. Forty-nine patients on chronic hemodialysis, 
already treated with folic acid, vitamin B6 and B12 supplements were 
studied in a placebo-controlled cross-over study. In contrast to the findings 
in our animal model, we observed no effect of creatine on plasma 
homocysteine concentrations. Creatine concentrations were significantly 
increased after creatine supplementation, indicative for adequate uptake of 
creatine. In contrast to the animals, the patients were already treated with 
supraphysiological folic acid, vitamin B6 and B12 supplements, possibly 
masking the effect of creatine on homocysteine. No negative effects of 
creatine on KT/V or other parameters were observed. 
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The third aspect concerned the ergogenic properties of creatine. Creatine is 
widely used as a performance enhancing substance in several sports. 
Recently, the use of creatine has been investigated to improve muscular 
function in patients with neuromuscular disorders. Creatine could improve 
cellular energy metabolism, neuronal death and muscle dysfunction. 
In a cohort of 46 older men (55-75y) the effect of exercise training, 
together with creatine supplementation was investigated. After 6 months 
(and 1 year (n=20)) of creatine supplementation, no difference was 
observed in muscular total creatine concentrations, nor in static or dynamic 
knee extensor force or cardiorespiratory endurance markers. In this cohort 
of aging man, creatine does not influence beneficially fitness. 
In the uraemic animal model, the effect of creatine on the myosin heavy 
chain (MHC)-expression was studied. In the uraemic group, a slow-to-fast 
transition was observed in both M. soleus (increased MHC IIb) and in M. 
extensor digitorum longus (increased MHC IIb at the expense of MHCIIx). 
Creatine supplementation in the uraemic group resulted in a proportionally 
lower MHC IIb and higher MHC I-expression. This effect was not observed 
in the M. extensor digitorum longus. The results in this animal model show 
a muscle wasting with a slow-to-fast transition in uraemia. Creatine halted 
the slow-to-fast transition in the M. soleus. 
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